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Angiogenesis is the growth of new blood vessels from existing vasculature; it 
requires the breakdown of existing blood vessel walls followed by the migration and 
proliferation of endothelial cells to form the new vessels. It is a complex process that 
is regulated by many pro- and anti-angiogenic factors and the roles of some of these 
factors are still unclear. Angiogenesis is a key feature of many pathological 
conditions including cancer, polycystic ovary syndrome and endometriosis so is an 
area of great research interest. There are several methods currently available for the 
study of angiogenesis, both in vitro and in vivo, and whilst all of these methods have 
enhanced understanding of angiogenesis, they also have limitations.  
 
The ovary is an excellent model for the study of angiogenesis as it undergoes intense 
vascular morphogenesis in a cyclical manner. The female reproductive system is 
unique as no other healthy adult tissue undergoes spontaneous angiogenesis. The 
tissues in the ovary undergo constant remodelling during both folliculogenesis and 
the formation and regression of the corpus luteum. Blood vessels are recruited from 
the ovarian stroma at the preantral stage to form vascular sheaths, in the thecal layer, 
which surround the developing follicle and supply nutrients, hormones and allow 
gaseous exchange. As follicular development progresses to the antral stage, when 
gonadotrophin-dependence is established, increased angiogenesis is essential to 
sustain development of the rapidly expanding follicle. Previous research into ovarian 
angiogenesis has focussed on the corpus luteum but the mechanisms of the regulation 
of angiogenesis during folliculogenesis need further elucidation. The work in this 
thesis aims to develop and utilise an in vitro angiogenesis assay using the culture of 
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intact preantral and early antral follicles to provide a new approach to the study of 
follicular angiogenesis. During the course of this thesis this assay was utilised to 
investigate the effect of various factors on follicular angiogenesis and ovarian 
function.  
 
The role of the putative anti-angiogenic factor thrombospondin-1 (TSP-1) in the 
regulation of physiological angiogenesis was investigated using the in vitro 
angiogenesis assay developed during the course of this thesis and the role of TSP-1 
in normal ovarian function was investigated using the culture of isolated granulosa 
cells. The results suggest that TSP-1 is able to inhibit angiogenesis and that it has an 
extravascular role in the ovary, in vitro. These findings were extended to an in vivo 
angiogenesis model where follicular angiogenesis was assessed by quantitative 
immunohistochemistry for bromodeoxyuridine and the endothelial cell marker 
CD31. The extravascular role for TSP-1 was also further investigated in vivo and was 
assessed by quantitative immunohistochemistry for activated caspase-3. The results 
confirmed the findings of the in vitro study, indicating that TSP-1 has anti-
angiogenic action and acts to clear non-dominant follicles from the ovary through the 
induction of atresia. 
 
Vascular endothelial growth factor (VEGF) is the main factor involved in stimulating 
angiogenesis and many advances have been made into elucidating the role, and the 
mechanisms of action, of VEGF on angiogenesis. Angiopoietin-1 (Ang-1) is 
considered to be one of the main factors acting in concert with VEGF to stabilise 
new blood vessels and its role in angiogenesis has been the subject of much 
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discussion and controversy. This thesis investigates the effects of Ang-1 on follicular 
angiogenesis and development, using the in vitro angiogenesis assay, granulosa cell 
culture and RNA knockdown experiments. The results have shown that Ang-1 can 
induce follicular angiogenesis at high doses and that at low doses stimulates pro-
survival pathways and inhibits apoptotic mediators. 
 
This thesis describes a novel in vitro culture system for the study of angiogenesis in 
ovarian follicles. Using this system the effects of various factors on follicular 
angiogenesis and on follicle development and survival have been investigated. 
Investigations into the mechanisms of action of these factors have also been 
performed. These studies have improved understanding of the regulation of follicular 
angiogenesis and have indicated extravascular roles for angiogenic factors in the 
ovary. Since angiogenesis is a key feature of many pathological conditions, the 
ability to manipulate angiogenesis and to investigate and quantify the effects of pro- 
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1.1 General introduction 
The function of the ovary is to produce fertilisable oocytes and although many 
follicles begin development only a few will complete the process to become 
dominant, preovulatory follicles. Follicles are avascular at the primordial stage of 
development and as a blood supply is necessary for follicle development to occur, 
angiogenesis must take place to allow the developing follicles to be supplied with 
gases, nutrients and hormones. Blood vessels are recruited from the ovarian stroma at 
the preantral stage to form vascular sheaths in the thecal layer, which surround the 
developing follicle. These new vessels begin to circulate blood to and from the 
follicle, allowing the exchange of nutrients, hormones and gases (Geva and Jaffe, 
2000). 
 
Angiogenesis is the growth of new blood vessels from existing vasculature and it 
involves the breakdown of existing blood vessels, followed by endothelial cell 
migration and proliferation and then the stabilisation of the new blood vessels 
(Folkman and Klagsbrun, 1987). Physiological angiogenesis is rare in the healthy 
adult, except in the female reproductive system where angiogenesis occurs in a 
cyclical manner, during follicle development and the formation of the corpus luteum. 
The majority of angiogenic factors principally act on endothelial cells. However, 
many of these factors and their receptors are expressed on non-vascular cells so it has 
been suggested that they may have extravascular effects (Jimenez et al., 2000, 
Greenaway et al., 2004, Greenaway et al., 2007, Parborell et al., 2008).  
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This chapter reviews the current understanding of the factors involved in follicular 
angiogenesis and ovarian follicle development. First the process of follicle 
development and ovulation is discussed, followed by the regulation of angiogenesis, 
the clinical relevance of manipulating angiogenesis and the potential extravascular 
roles of angiogenic factors within the ovary. This chapter serves as an introduction to 
the following experimental chapters that report studies on the regulation and 
inhibition of angiogenesis in the ovarian follicle in vitro and in vivo and on the 
actions of these factors in non-vascular cells.  
                                                                                                                               
1.2 Folliculogenesis 
Folliculogenesis is the growth of ovarian follicles from the primordial stage to the 
preovulatory stage of development and is regulated by many endocrine, paracrine 
and autocrine factors. There are approximately 300,000 to 400,000 primordial 
follicles present in the human, at birth, (Forabosco et al., 1991, Gougeon et al., 1994, 
Oktem and Oktay, 2008) but only around 400 will develop into dominant, 
preovulatory follicles and go on to ovulate (Hillier, 1994) until the cessation of 
ovulation is reached at the menopause. Follicle development is gonadotrophin-
independent at the primordial stage. Follicles become increasingly dependent on 
gonadotrophins as folliculogenesis progresses and preovulatory follicle development 
is completely dependent on gonadotrophins (Zeleznik and Hillier, 1996). As only a 
fraction of follicles that begin development will eventually ovulate, the rest of these 
follicles will be cleared from the ovary by follicular atresia. 
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1.2.1 Primordial Follicle recruitment 
Follicles are the functional parts of the ovary and as primordial follicles generate all 
dominant follicles, they are considered the fundamental reproductive units of the 
ovary. Each primordial follicle consist of a small primary oocyte in meiotic arrest 
which is surrounded by a single layer of flattened granulosa cells (Sherwood, 2006). 
 
Folliculogenesis begins with the recruitment of quiescent primordial follicles to 
begin development, and this process is not fully understood. This process has been 
investigated in many different species including humans, mice, sheep and pigs and 
this introduction focuses on women where possible, which references to other 
species as necessary. The initiation of follicle development involves the interaction 
of many factors including the surrounding follicles, endocrine factors and factors 
produced by the primordial follicles themselves (Lenton et al., 1984, Gougeon et al., 
1994, Spears et al., 1996, Spears et al., 2002). Previous studies have suggested that 
the oocyte may be responsible for controlling the regulation of follicle recruitment 
(Lenton et al., 1984, Brankin et al., 2003, Hunter et al., 2005). The initiation of 
primordial follicle development is regulated by the members of the transforming 
growth factor (TGF)-β superfamily, which include growth-differentiation factors 
(GDF), activins, inhibins, anti-Müllerian hormone (AMH) and the bone morphogenic 
factors (BMPs), and are expressed by oocytes and granulosa cells (Fukuda et al., 
2000, Oktem and Oktay, 2008). Platelet-derived growth factor (PDGF), basic 
fibroblast growth factor (bFGF), leukaemia inhibitory factor (LIF), kit ligand and 
Foxo3a (Forkhead box O3) have also been implicated in regulating the initiation of 
primordial follicle development (Driancourt et al., 2000, Nilsson et al., 2001, Nilsson 
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et al., 2002, Smitz and Cortvrindt, 2002, Nilsson and Skinner, 2004, Castrillon et al., 
2003). This autocrine and paracrine regulation of the recruitment of primordial 
follicles involves communication between the oocyte and its surrounding flattened 
granulosa cells but it is thought that the oocyte itself is largely in control of the 
regulation of follicle recruitment (Lenton et al., 1984, Vanderhyden et al., 1992, 
Eppig, 2001, Gilchrist et al., 2006, Matzuk et al., 2002, Orisaka et al., 2009). PDGF 
and bFGF positively regulate follicle activation and increase secretion of kit ligand 
by pre-granulosa cells. This increase in kit ligand stimulates oocyte growth and 
therefore promotes the activation of primordial follicles (Tsafriri and Dekel, 1994, 
Sawetawan et al., 1996). The PI3K pathway, and especially Foxo3a, has been shown 
to play an important role in regulating the initiation of follicle development 
(Castrillon et al., 2003). Foxo3a is expressed most highly in the oocytes of 
primordial follicles and is swiftly down-regulated in the oocytes of larger follicle, 
supporting the suggestion that Foxo3a is a crucial suppressor of follicle activation 
and oocyte growth (Liu et al., 2007, Reddy et al., 2010). A pivotal study by 
Castrillon et al (Castrillon et al., 2003) with Foxo3a
-/-
 mice showed that the absence 
of Foxo3a leads to over-abundant activation of primordial follicles, resulting in 
premature ovarian failure and infertility. Foxo3a has been shown to act as an 
inhibitor of follicle activation and the down-regulation of Foxo3a in oocytes has been 
suggested to be essential for the initiation of oocyte growth (Castrillon et al., 2003, 
Liu et al., 2007, Adhikari and Liu, 2009). Therefore Foxo3a is thought to be essential 
in negatively regulating the activation of follicle development. 
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Along with promoting their own activation, primordial follicles release an inhibitory 
signal that negatively regulates the activation of other primordial follicles (Gougeon 
and Chainy, 1987, Gougeon et al., 1994). AMH is a dimeric glycoprotein that is 
produced by granulosa cells of developing follicles (Rajpert-De Meyts et al., 1999, 
McGee et al., 2001, Durlinger et al., 2002, Drummond, 2005) and it negatively 
regulates the recruitment of adjacent follicles (Young and Jaffe, 1976, McNatty et 
al., 1979). AMH also decreases the sensitivity of larger follicles to follicle 
stimulating hormone (FSH) which reduces the recruitment of follicles (Durlinger et 
al., 2001, Hillier, 2009). 
 
1.2.2 Gonadotrophin production 
The synthesis and release of pituitary gonadotrophins is controlled by the binding of 
gonadotrophin-releasing hormone (GnRH) to its receptor on anterior pituitary 
gonadotrope cells and the activation of protein kinase C (PKC). The gonadotrophins 
FSH and luteinising hormone (LH) are heterodimeric polypeptides that are made up 
of a common α-subunit and a unique β-subunit that confers biological specificity. 
GnRH is released in a pulsatile manner from the GnRH neurones in the 
hypothalamus (Clarke, 1996). After it is released by the hypothalamus, GnRH travels 
to the anterior pituitary, binds to the GnRH receptor and stimulates gonadotrophin 
synthesis and release. Binding of GnRH to its receptor triggers a rapid increase in 
intracellular calcium levels and activation of PKC, both of which may lead to 
enhanced synthesis of gonadotrophin subunits. In addition, gonadal hormones, such 
as oestrogen, progesterone and inhibin, can regulate the action of GnRH (Clarke, 
1996). 
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Figure 1.1 The hypothalamic-pituitary axis  
GnRH from the hypothalamus stimulates the secretion of pituitary gonadotrophins, LH and 
FSH, which directly regulate ovarian function. Ovaries exert negative feedback on the 
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1.2.3 Follicle development 
Follicle development begins with the transition of primordial follicles to primary 
follicles. The flattened, epithelial-like granulosa cells that surround the primordial 
follicle expand and become cuboidal in appearance and as the follicle gains a single 
layer of cuboidal granulosa cells it becomes a primary follicle. At this stage follicles 
begin to express the FSH receptor on their granulosa cells and oocyte growth and 
differentiation is initiated (Hillier et al., 1980). The initial stages of follicle growth 
are independent of gonadotrophins; however FSH is required for the development of 
follicles to the preantral stage (Maruo et al., 1993). 
 
Once primordial follicles are recruited into the growing follicle pool the paracrine 
regulation of oocytes and granulosa cells become important for follicle development 
(Gilchrist et al., 2006). The development of follicles from the primary to the 
preantral stage is dependent on paracrine signalling by members of the TGFβ 
superfamily. Activins, along with GDF-9, BMP-15 and BMP-6, are known to 
increase granulosa cell proliferation and to modulate the sensitivity of granulosa cells 
to FSH (Hillier, 2009). TGFβ can also induce expression of the FSH and LH 
receptors and increase production of inhibin (Knight and Glister, 2006, Hillier, 
2009). Inhibins stimulate the production of androgens in thecal cells and are 
important in regulating the LH-dependent stages of follicle development (Hillier, 
2009). Small antral follicles produce more activin than inhibin whereas larger 
follicles produce more inhibin (Knight and Glister, 2006). The increased levels of 
inhibin expression in larger follicles results in increased androgen production, thus 
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sustaining a high level of estradiol secretion and suppressed FSH production (Knight 
and Glister, 2001, Spears et al., 2002, Knight and Glister, 2003).  
 
In addition to the paracrine regulation of follicle development, the members of the 
TGFβ superfamily also regulate follicle development through autocrine signalling. 
For example GDF-9, which is produced by the oocyte, can act on the oocyte through 
autocrine actions to regulate its own development, and when GDF-9 is absent it 
results in abnormal oocyte growth, giving evidence for autocrine actions of GDF-9 
on the oocyte (Dong et al., 1996). An autocrine role for inhibin has been suggested as 
it is produced by granulosa cells and the binding site for inhibin-α is present on 
granulosa cells (Findlay, 1993). It has also been suggested that inhibin can inhibit 
estradiol production in rat granulosa cells and that it may inhibit FSH-induced 
aromatase activity in granulosa cells by autocrine action. Another member of the 
TGFβ superfamily, activin, could also have an autocrine role in granulosa cells as the 
β-subunit has been shown to be expressed on granulosa cells. Activin promotes 
granulosa cell proliferation and can up-regulate the expression of LH receptors on 
granulosa cells (Chedrese et al., 2009).  
 
The gonadotrophins and members of the TGFβ superfamily are vitally important in 
regulating follicular development, often by endocrine, autocrine and paracrine 
signalling. In addition to this, these molecules are involved in the regulation of 
granulosa cell survival. Several of these factors, including GDF-9 and activin have 
been shown to stimulate the pro-survival PI3K/Akt pathway (Wang and Tsang, 
2007) which is also stimulated by several angiogenic factors, through either 
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autocrine or paracrine signalling. Several angiogenic factors, such as 
thrombospondin-1 (TSP-1) (Lawler et al., 1998, Hugo and Daniel, 2009), can 
regulate members of the TGFβ superfamily, suggesting that they have the potential to 
influence granulosa cell function. Therefore the effect of angiogenic factors on 
granulosa cell function will be investigated during the course of this thesis.  
 
1.2.4 Antral follicle development 
As the preantral stage of development progresses the oocyte increases in size and 
develops its zona pellucida. Granulosa cells proliferate and accumulate to form 
multiple layers around the oocyte. Cells are then recruited from the ovarian stroma to 
form the two layers of the theca; the theca interna that can differentiate into 
interstitial cells, and the theca externa that can differentiate into smooth muscle cells 
(Fortune and Eppig, 1979, Gougeon, 1996, Braw-Tal and Yossefi, 1997, Lundy et 
al., 1999, Smitz and Cortvrindt, 2002).  A distinct thecal layer is evident at different 
stages of folliculogenesis in different species.  In rodents, it can be seen as early as 
the late primary/early preantral stage of follicle development (Fortune and Eppig, 
1979), but cannot be seen in the primate, bovine or ovine follicle until the mid or late 
preantral stage of follicular development (Gougeon, 1996, Braw-Tal and Yossefi, 
1997, Lundy et al., 1999). The development of the thecal layer is accompanied by the 
initiation of angiogenesis in the preantral follicles which allows blood to circulate 
and to bring nutrients and gonadotrophins to, and waste and secretory products from, 
the developing follicles.  
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The transition of follicles from the preantral to the antral stage is characterised by the 
development of a fluid filled cavity on one side of the oocyte that contains follicular 
fluid(Hillier, 1991). The antrum begins to form after 6-7 layers of granulosa cells 
have surrounded the follicle and granulosa cells surrounding the oocyte form the 
cumulus layer (Gougeon, 1996). At this stage of follicular development the early 
antral follicles are responsive to FSH but not to LH and LH receptors are not present 
on granulosa cells (Zeleznik et al., 1981, Smitz and Cortvrindt, 2002). Antral 
follicles are present at all stages of the human ovarian cycle, due to primordial 
follicles continuously entering the pool of developing follicles, but only early antral 
follicles with sufficient FSH receptors will be selected for dominance and potentially 
go on to ovulate as the maturation of early antral follicles is regulated by FSH (Baker 
and Spears, 1999). FSH binds to the FSH receptors expressed on granulosa cells, 
which activates adenylyl cyclase and cAMP-dependent protein kinases, leading to 
the expression or inhibition of various genes involved in cell development (Richards, 
1994). Tonic stimulation by FSH is sufficient to maintain the development of early 
antral follicles, however cyclic levels of FSH are required for further follicular 
development.  
 
1.2.5 Selection of dominant follicle(s) 
Follicular development progresses as the level of FSH expression increases and 
antral follicles enter preovulatory development, following the withdrawal of the 
negative feedback action of the estradiol, progesterone and inhibin produced by the 
corpus luteum of the previous cycle (Goodman and Hodgen, 1983, Baird et al., 
1984). In humans and other mono-ovulatory species only one follicle is commonly 
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selected for dominance whereas in other species, multiple follicles are selected for 
dominance which is reflected in the multiple births of multi-ovulatory species. It is 
thought that sensitivity to FSH is one of the determining factors in follicle dominance 
(Zeleznik and Kubik, 1986)  as larger, more dominant follicles have greater levels of 
FSH receptor expression on the granulosa cells whilst less mature follicles have 
fewer FSH receptors. To continue to develop, follicles need a ‘threshold’ level of 
FSH stimulation and follicles that do not get this level of FSH stimulation are not 
chosen to begin preovulatory development. In addition, FSH stimulates the synthesis 
of inhibin by granulosa cells (Findlay, 1993), which suppresses secretion of FSH by 
the pituitary (Groome et al., 1995). As FSH is required for follicle development to 
progress, this decline in the concentration of FSH prevents the further development 
of other antral follicles and they undergo atresia (Baker et al., 2001). 
 
Once follicles enter preovulatory development they begin to produce oestrogen and 
the follicle(s) that produce the highest levels of oestrogen are selected for dominance 
(Goodman et al., 1977, Zeleznik et al., 1981). The production of oestrogen by the 
dominant follicle suppresses FSH secretion by negative feedback at the 
hypothalamic-pituitary axis (Spears et al., 2002). In the follicular phase of the cycle 
the plasma FSH level rises and P450arom, which is responsible for oestrogen 
synthesis, is increasingly expressed in the granulosa cell layer of the dominant 
follicle(s). Both granulosa and thecal cells, regulated by FSH and LH, are crucial to 
oestrogen synthesis. LH stimulates the production of testosterone and 
androstenedione by thecal cells, but thecal cells cannot aromatise C19 androgens to 
oestrogens (Hillier et al., 1981). Granulosa cells lack the P450C17 enzymes that are 
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required to metabolise steroids to androgens but, in contrast to thecal cells, they are 
stimulated by FSH to acquire the aromatase enzymes that convert androgens to 
oestrogens. The thecal layer is highly vascularised so is directly supplied with 
steroids, and thecal cells contain the steroidogenic enzymes necessary to synthesise 
androgens from acetate and cholesterol. The vasculature in the thecal layer is well 
developed in preovulatory follicles so the granulosa cells in preovulatory follicles are 
well placed to respond to changes in the level of circulating LH, which is important 
in the maintenance of follicular dominance.  
 
It is thought that the presence of LH receptors on granulosa cells of the dominant 
follicle(s) protect it from the decline in FSH levels (Yong et al., 1992, Baker and 
Spears, 1999), as both FSH and LH act via the stimulation of adenylyl cyclase and an 
increase in intracellular cAMP (Gonzalez-Robayna et al., 2000). The number of 
follicles that secrete enough oestrogen to become dominant in a cycle varies from 
species to species (Goodman et al., 1977, Zeleznik et al., 1981) and they are selected 
from a cohort of healthy antral follicles in the ovaries (Gougeon and Lefevre, 1983). 
 
Ovulation is the culmination of follicular development and is triggered by the LH 
surge from the anterior pituitary (van den Hurk and Zhao, 2005). This LH surge is 
triggered by the high levels of estradiol produced by the dominant follicle(s). The LH 
surge reactivates maturation of the oocyte and also stimulates steroidogenic cells to 
induce an inflammatory response which prepares the preovulatory follicle for rupture 
(Espey, 1980). After the LH surge occurs, the follicle wall ruptures and the oocyte is 
released from the follicle (Balasch and Fabregues, 2002). An area of the preovulatory 
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follicle wall weakens as ovulation approaches and at ovulation the apex of the 
follicle ruptures, releasing the cumulus-oocyte complex. After ovulation the 
granulosa cells in the preovulatory follicle undergo luteinisation and the corpus 
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Figure 1.2 Diagram of follicular development 
Diagram illustrating the stages of follicular growth, ovulation, and corpora lutea formation 
and maturation. Blood vessels, shown in red, appear within follicles at the preantral stage. 
They are confined to the thecal layer by the presence of a basement membrane. At ovulation, 
the basement membrane breaks down and, in association with intense angiogenesis, the 
blood vessels invade the resulting corpora lutea. (Adapted from Fraser 2009). 
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1.2.6  Follicular atresia 
Although many follicles are recruited to begin development only a few ever develop 
to the preovulatory stage and go on to ovulate. In fact, 99% of all follicles undergo 
atresia and die. The majority of follicular atresia occurs during foetal development 
and it is controlled by a balance of pro-survival factors and pro-apoptotic factors 
(Shikone et al., 1996), including gonadotrophins and members of the TGFβ 
superfamily (Gosden and Spears, 1997). Follicular atresia begins in the granulosa 
cells before progressing to the thecal cells. In fact, the apoptosis of granulosa cells is 
one of the main ways that follicles are cleared from the ovary. There are many 
factors involved in regulating follicular atresia including the caspase cascade, the 
Bcl-2 family and mitogen-activated protein kinases (MAPK) signalling (Markstrom 
et al., 2002). The Bcl-2 family consists of both pro-apoptotic and anti-apoptotic 
factors. The pro-apoptotic members of the Bcl-2 family such as Bax stimulate 
cytochrome C which then goes on to trigger the caspase cascade, which is a well 
known inducer of apoptosis. Additionally, the MAPKs play an important role in 
regulating apoptosis and they include the extracellular signal-regulated kinases 
(ERKs) and the p38 MAPKs (Robinson and Cobb, 1997), which have anti- and pro-
apoptotic functions, respectively. This demonstrates that the regulation of follicular 
atresia is complex and involves the interaction of several signalling pathways. 
 
1.3 Angiogenesis in the ovary 
There are two main methods of blood vessel development and they are 
vasculogenesis and angiogenesis. Vasculogenesis is the formation of blood vessels 
during embryogenesis by endothelial progenitors such as angioblasts. These 
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endothelial progenitors migrate, sometimes to distant sites, differentiate into 
endothelial cells and then form the vascular plexus (Risau, 1997, Carmeliet, 2004). 
Once the vascular plexus has been formed new vasculature develops by the process 
of angiogenesis, which is the growth of new blood vessels by proliferation and 
migration of pre-existing blood vessels. Pivotal research into the field of 
angiogenesis first suggested that angiogenic inhibitors could be used to treat cancer 
and other diseases dependent on aberrant angiogenesis (Folkman et al., 1971). This 
crucial research was followed by studies showing that tumours are only able to grow 
when they are able to attract blood vessels from the existing vasculature surrounding 
the tumour (Gimbrone et al., 1972). 
 
Angiogenesis is a complex process that requires the breakdown of existing blood 
vessel walls followed by the migration and proliferation of endothelial cells to form 
the new vessels. For this to occur the extracellular matrix needs to be degraded and 
proteinases of the matrix metalloproteinase (MMP) family degrade basement 
membrane collagens, thus allowing endothelial cells to migrate and proliferate 
(Bendeck, 2004). These new vessels are comprised of endothelial cells and one or 
more enveloping layers of supporting cells, usually pericytes or smooth muscle cells 
(Chantrain et al., 2006). These surrounding pericytes are first found at the advancing 
tips of endothelial sprouts and once the new vessels are formed these pericytes then 
extend along the length of the blood vessels and stabilise them (Bergers and Song, 
2005, Hall, 2006, Robinson et al., 2009, Raza et al., 2010). 
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In the healthy adult the endothelial cells of established vessels are quiescent but the 
migration and proliferation of endothelial cells is required for angiogenesis to occur. 
The proliferation of endothelial cells is stimulated through the binding of vascular 
endothelial growth factor (VEGF) to its receptors VEGFR1 and VEGFR2, and 
occurs in the endothelial cells behind the quiescent tip of the extending blood vessel 
(Klagsbrun and D'Amore, 1991). The process of angiogenesis is complete when the 
endothelial cells stop dividing and start to adhere to each other to form new blood 
vessels. Pericytes are then recruited to surround and stabilise the new blood vessels, 
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Figure 1.3 Diagram of angiogenesis.  
Follicle release pro-angiogenic factors such as VEGF when they reach the preantral stage 
of development and they travel to nearby blood vessels and bind to their receptors (A). This 
stimulates the breakdown of the existing blood vessel wall and the endothelial cells and 
pericytes from this vessel proliferate and migrate towards the follicle (B), and form new 
blood vessels in the theca of the developing follicle (C). 
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1.3.1 Physiological angiogenesis  
Vasculogenesis and angiogenesis are essential processes during embryonic and foetal 
development when organ development is occurring. However, they are rare in the 
healthy adult as there is very little physiological vessel growth and remodelling, 
except during wound healing and in the female reproductive system, where 
angiogenesis occurs in a cyclical manner. 
 
Angiogenesis is a pivotal event in both bone and organ formation during 
embryogenesis (Gerber et al., 1999) and VEGF mediated angiogenesis has been 
shown to be critical for both of these processes. In fact, the inhibition of VEGF can 
cause abnormal organ development and tissue hypoxia in neonatal life. Although 
physiological angiogenesis is rare in the healthy adult, the female reproductive 
system undergoes serial angiogenesis and vessel regression during both follicle 
development and the establishment and regression of the corpus luteum. 
1.3.1.1  Follicular angiogenesis 
Primordial and primary follicles do not have their own blood supply so angiogenesis 
is required for follicular growth and development (Robinson et al., 2009). As 
follicles reach the preantral stage of development endothelial cells are recruited from 
the ovarian stroma to form vascular sheaths within the thecal layer. These vascular 
sheaths consist of two concentric networks of blood vessels located in the theca 
interna and the theca externa (Findlay, 1986, Hunter et al., 2004). The network of 
arterioles and venules in the theca externa send branches into the theca interna to 
form the inner capillary plexus. These capillaries are located immediately outside the 
basement membrane that separates the granulosa and thecal layers and they do not 
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penetrate the granulosa cell layer until after ovulation has occurred (Findlay, 1986, 
Reynolds et al., 1992, Gordon et al., 1995, Augustin, 2000, Jaffe, 2000, Fraser, 
2006). 
 
This cyclical angiogenesis is tightly regulated by a variety of pro- and anti-
angiogenic factors, including VEGF which is considered to be the key factor 
involved in the stimulation of angiogenesis (Tamanini and De Ambrogi, 2004). 
VEGF and its receptors have been localized in the ovary, especially in endothelial 
cells (Phillips et al., 1990, Shweiki et al., 1993, Hunter et al., 2004), and have been 
shown to be stimulated by FSH and LH (Garrido et al., 1993, Christenson and 
Stouffer, 1997, Hazzard et al., 1999), suggesting that the expression of VEGF could 
be hormonally regulated. Additionally, it has been shown that the inhibition of 
gonadotrophin secretion by a GnRH antagonist results in decreased VEGF 
expression, further supporting the suggestion that VEGF could be hormonally 
regulated (Taylor et al., 2004). Various studies have highlighted the role of VEGF in 
ovarian physiology by demonstrating its essential role in follicular development, as 
well as its impact upon angiogenesis (Geva and Jaffe, 2000, Danforth et al., 2003, 
Zimmermann et al., 2003, Fraser and Wulff, 2003, Fraser et al., 2005a, Fraser et al., 
2006, Abramovich et al., 2006, Taylor et al., 2007).  
 
1.3.2 Pathological angiogenesis 
Although angiogenesis is rare in the healthy adult it is a common feature of many 
pathological conditions, including coronary artery disease and tumour growth. In 
addition, in the reproductive system aberrant angiogenesis is involved in 
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endometriosis, polycystic ovary syndrome (PCOS), ovarian hyperstimulation 
syndrome (OHSS) and pre-eclampsia (Smith, 1998, Geva and Jaffe, 2000, Folkman, 
2001). 
 
Tumours cannot grow larger than 1-2mm
3
 in size without developing their own 
blood supply (Folkman et al., 1971, McDougall et al., 2006) as oxygen and nutrients 
from the surrounding vasculature cannot penetrate tissues larger than this. Therefore, 
angiogenesis is a crucial process in tumour growth. Tumours secrete various pro-
angiogenic factors, such as VEGF, which stimulate the growth of new blood vessels 
towards the tumour, allowing them to be supplied with nutrients and gases. 
 
In ovarian conditions that involve aberrant angiogenesis the expression of VEGF is 
often altered when compared to its physiological regulation. In women with PCOS 
the expression of VEGF is up-regulated (Agrawal et al., 1998a, Agrawal et al., 
1998b) and it has been found to be present in the ascetic fluid from women with 
OHSS and with ovarian cancer (Gordon et al., 1995), suggesting that VEGF is a key 
factor involved in stimulating pathological, as well as physiological, angiogenesis. 
 
1.3.3 Angiogenic growth factors 
Angiogenesis is a complex process that requires a careful balance between pro- and 
anti-angiogenic factors. There are many factors involved in the stimulation of 
angiogenesis but VEGF is considered to be the key factor involved in inducing 
angiogenesis (Ferrara, 2004). However, the angiopoietins (Ang-1 and Ang-2), bFGF, 
hypoxia-inducible factor-1α (HIF1α), tumour necrosis factor-α (TNFα) and TGFβ 
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have also been shown to be involved in the positive regulation of angiogenesis 
(Folkman and Shing, 1992, Yancopoulos et al., 2000). 
 
Hypoxia is an inducer of angiogenesis and it results increased levels of HIF1α by 
inhibiting the degradation of HIF1α and by stimulating the expression of HIF1α 
(Boonyaprakob et al., 2005). As the expression of HIF1α increases, VEGF 
production is stimulated, resulting in the induction of angiogenesis (Berra et al., 
2000, Mukhopadhyay and Datta, 2004, Liao and Johnson, 2007, Fong, 2009). In vivo 
lack of oxygen increases hypoxia which results in the stimulation of HIF1α and 
therefore increases angiogenesis. However, several studies have indicated that 
treatment with anti-angiogenic factors can inhibit the expression and/or activity of 
HIF1α (Semenza, 2000, Mabjeesh et al., 2003, Ricker et al., 2004, Dunn et al., 2009, 
Ban et al., 2010, Semenza, 2010). The inhibition of HIF1α by RNA interference 
reduces the level of angiogenesis, showing that HIF1α plays an important role in 
stimulating angiogenesis (Kim et al., 2010). As HIF1α plays an important role in 
promoting angiogenesis it was hypothesised that anti-angiogenic compounds could 
be inhibiting HIF1α as a mechanism of angiogenesis inhibition. The use of the in 
vitro system would allow the elucidation of the potential mechanisms of anti-
angiogenesis via the interaction with HIF1α. 
1.3.3.1  Vascular endothelial growth factor (VEGF) 
VEGF was originally identified as vascular permeability factor (VPF) due to its 
ability to stimulate vascular leakage and induce fenestrations in the endothelial cells 
of capillaries (Senger et al., 1983) however, it was later shown that a factor, named 
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VEGF, could stimulate angiogenesis (Ferrara and Henzel, 1989, Connolly et al., 
1989). The discovery that the DNA sequences encoding both VEGF and VPF were 
identical (Keck et al., 1989, Leung et al., 1989) lead to the realisation that both VPF 
and VEGF were the same factor, and it was henceforth referred to as VEGF. 
 
VEGF is part of a family of heparin-binding dimeric glycoproteins that include 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth factor. The 
VEGF that was initially discovered was termed VEGF-A and is the member of the 
family that is commonly referred to as VEGF. VEGF has various isoforms that result 
from alternative splicing of the VEGF gene and they are VEGF121, VEGF145, 
VEGF165, VEGF183, VEGF189 and VEGF206 (Bates and Jones, 2003, Ferrara, 2004, 
Tammela et al., 2005). VEGF165 and VEGF121 are the predominant isoforms in the 
human ovary (Fujimoto et al., 1998, Otani et al., 1999, Ferrara, 2004). VEGF binds 
to the receptors VEGFR1 and VEGFR2 and the exons encoding the binding domains 
for these receptors, exons 3 and 4 respectively, are present in all of the VEGF 
isoforms (Keyt et al., 1996). In addition, there have been recent reports of additional 
splicing to produce other VEGF isoforms that have either slightly (VEGFxxx) or very 
(VEGFxxxb) different properties to the common VEGF isoforms (Bates and Jones, 
2003). Although VEGF plays an important role in stimulating angiogenesis, recent 
studies have suggested that the VEGFxxxb isoforms have anti-angiogenic activity 
(Glass et al., 2006). 
 
All of the members of the VEGF family bind to cell surface receptors (VEGFRs) 
which activate an intracellular kinase domain and trigger a cellular response. VEGF 
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exerts its effects mainly through binding to VEGFR1 (Flt-1) and VEGFR2 
(KDR/Flk-1) although it can also bind to neuropilin-1 and -2 (Ferrara and Keyt, 
1997, Bates and Jones, 2003, Ferrara, 2004, Tammela et al., 2005, Pandya et al., 
2006). 
 
VEGFR1 and VEGFR2 have seven immunoglobulin (Ig)-like regions in the 
extracellular domain, a single-transmembrane region and a consensus tyrosine kinase 
sequence with a kinase-insert domain (Tammela et al., 2005). Although they are 
structurally similar, VEGFR1 and VEGFR2 have different signalling and biological 
properties and bind to VEGF with different, but high, affinities (de Vries et al., 
1992). VEGFR2 has been shown to bind VEGF with lower affinity than VEGFR1, 
however, studies have shown that it is the key receptor involved in triggering 
angiogenesis and vascular permeability (Tammela et al., 2005, Guo et al., 2010). The 
role of VEGFR1 is less clear but it is thought to mediate cell migration and vascular 
permeability. In addition there is good evidence that it acts as a decoy receptor to 
negatively regulate the activity of VEGF by binding to it and sequestering it (Park et 
al., 1994).  
 
The expression of VEGF mRNA and protein is up-regulated by many cytokines and 
growth factors including epidermal growth factor (EGF), TGFα and TGFβ, bFGF, 
interleukin (IL)-1 and IL-6 and insulin-like growth factor-1 (IGF-1) (Warren et al., 
1996, Ferrara and Davis-Smyth, 1997). VEGF expression is also stimulated by the 
gonadotrophins FSH and LH (Christenson and Stouffer, 1997) and studies using a 
GnRH antagonist have shown that the blockage of gonadotrophin secretion resulted 
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in decreased VEGF expression and inhibited angiogenesis in dominant follicles 
(Taylor et al., 2004). The production of VEGF is also regulated by hypoxia. Hypoxia 
blocks the degradation of HIF1α and the increased activity of HIF1α induces 
expression of VEGF and therefore increased angiogenesis (Duncan et al., 2008). 
Stimulation of VEGFR1 by VEGF results in the autophosphorylation of the receptor 
and promotion of cell migration (Fong et al., 1995). VEGF stimulation of VEGFR2 
leads to autophosphorylation of the receptor, activation of the MAP kinase cascade 
and stimulation of endothelial cell proliferation (Fong et al., 1995).  
 
VEGF plays a crucial role in angiogenesis and studies in knockout mice have shown 
that the inactivation of VEGF results in embryonic lethality, confirming the essential 
role of VEGF in the induction of angiogenesis (Carmeliet et al., 1996, Ferrara et al., 
1996). Many studies have investigated the effect of inhibiting or neutralising VEGF 
on angiogenesis and have shown that vessels do not develop without VEGF being 
expressed. Furthermore, studies in the ovary have shown that when VEGF is 
inhibited follicles do not undergo follicle development and ovulation is blocked, 
showing the vital role VEGF has in both ovarian angiogenesis and ovarian function 
(Wulff et al., 2001a, Wulff et al., 2001b, Fraser et al., 2005a, Fraser et al., 2005b, 
Fraser et al., 2006, Taylor et al., 2007). In addition, the observation that VEGF is up-
regulated in many pathological conditions (Krasnow et al., 1996, Agrawal et al., 
1998b) has led to the proposed use of anti-VEGF treatments, such as Bevacizumab 
and Aflibercept (VEGF Trap), to inhibit pathological angiogenesis (Strawn et al., 
1996, Presta et al., 1997, Taylor et al., 2007). 
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1.3.3.2 Angiopoietins 
The angiopoietins are considered to be the most important class of proteins that act in 
concert with VEGF to produce and maintain stable blood vessels (Maisonpierre et 
al., 1997). The angiopoietins are cytokine glycoproteins that act in a competitive 
manner via the tyrosine kinase receptor Tie-2 (Maisonpierre et al., 1997). There are 
four known angiopoietins; Ang-1, Ang-2, Ang-3 and Ang-4; with the best 
characterised being Ang-1 and Ang-2. All four bind to the receptor Tie-2 however, 
Tie-1 is an orphan tyrosine kinase receptor that does not appear to bind to any of the 
angiopoietins (Partanen et al., 1992, Kontos et al., 2002).  
 
Ang-1 and Tie-2 are widely expressed, including in the ovarian follicle of the rodent, 
bovine and primate, however expression of Ang-1 and its receptor varies from 
species to species (Maisonpierre et al., 1997, Wulff et al., 2001a, Hayashi et al., 
2003, Abramovich et al., 2009). In the marmoset in situ hybridisation has shown that 
Tie-2 is expressed in the vasculature of the thecal layer of antral follicles but is also 
expressed in granulosa cells of primordial, primary and preantral follicles (Wulff et 
al., 2001a). Ang-1 and Tie-2 mRNA has been shown by RT-PCR to be expressed in 
the thecal layer of bovine follicles but granulosa cells express mRNA for Ang-1 only 
(Hayashi et al., 2003). Recently it has been shown by immunohistochemistry and 
western blotting that Ang-1 and Tie-2 expression is confined to the endothelial cells 
in the thecal layer of rat follicles and is not present in granulosa cells at any stage of 
follicular development (Abramovich et al., 2009). Overall, it is generally thought that 
the expression of Tie-2 is confined to endothelial cells. Ang-1 is primarily involved 
in supporting and stabilising newly developed blood vessels (Thurston, 2002). In 
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addition, Koblizek et al showed that Ang-1 can stimulate capillary sprouting and that 
after treatment with soluble Tie-2 receptor domains, this sprouting was inhibited 
(Koblizek et al., 1998), supporting the evidence for Ang-1 regulating angiogenesis 
through interaction with Tie-2. The pattern of expression of both Ang-1 and Tie-2 in 
the ovary suggests that Ang-1/Tie-2 signalling may play a role in regulating the 
cyclical angiogenesis that occurs in the female reproductive system. 
 
Ang-2 has considerable sequence homology to Ang-1 and the balance between the 
expression of Ang-1 and Ang-2 during angiogenesis is important.  The expression of 
Ang-2 has been localised to the ovary, placenta and uterus (Maisonpierre et al., 
1997). Studies have shown that the over-expression of Ang-2 can disrupt blood 
vessel formation in the embryo, much like in Tie-2 and Ang-1 knockout mice, 
indicating that Ang-2 also plays an important role in the regulation of angiogenesis. 
Ang-2 can both aid the development of new blood vessels and aid vascular 
regression, dependent on the circumstances, through antagonism of the Tie-2 
receptor (Maisonpierre et al., 1997, Asahara et al., 1998, Witzenbichler et al., 1998). 
Ang-2, when acting with VEGF, can stimulate angiogenesis by interfering with 
endothelial cell-pericyte interactions and aiding the degradation of the extracellular 
matrix, thus allowing the endothelial cells to migrate from the existing blood vessels. 
In the absence of VEGF, Ang-2 inhibits angiogenesis, induces vessel regression and 
stimulates endothelial cell death (Maisonpierre et al., 1997). Ang-2 also reduces the 
effect of Ang-1 by competing for receptor binding. Little is known about the actions 
of Ang-3 and Ang-4 but they can both positively and negatively influence 
angiogenesis, dependent on the conditions (Lee et al., 2004, Kim et al., 2007). 
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1.3.4 Anti-angiogenic factors 
Angiogenesis is regulated by a careful balance of pro- and anti-angiogenic factors 
(Ferrara, 2004, Tamanini and De Ambrogi, 2004, Greenaway et al., 2007). 
Endogenous angiogenesis inhibitors play an important role in regulating both 
physiological angiogenesis and pathological angiogenesis and many angiogenesis 
inhibitors have been described. They include interferons, platelet factor 4, TNFα, 
thrombospondin-1, TGFβ and angiostatic steroids (Klagsbrun and D'Amore, 1991). 
Endogenous angiogenesis inhibitors, such as angiostatin, arresten and endostatin, are 
often generated from larger molecules, that are not themselves inhibitors of 
angiogenesis, and they are released from these larger molecules to maintain normal 
blood vessel development (Ribatti, 2009). 
 
Synthetic compounds have been developed that have anti-angiogenic activity and 
they have potential use as therapeutics in pathological angiogenesis. Exogenous 
angiogenesis inhibitors have been identified through the use of cell culture assays 
(Ingber et al., 1990) and there are now numerous synthetic compounds available to 
inhibit angiogenesis, including antibodies to VEGF (Kim et al., 1993, Fraser et al., 
2000, Dickson et al., 2001) and inhibitors of VEGF such as Aflibercept (Wulff et al., 
2001a, Wulff et al., 2001b, Wulff et al., 2002, Fraser et al., 2006). The development 
of angiogenesis inhibitors is an area of great clinical interest as angiogenesis plays an 
important role in many pathological conditions.  
1.3.4.1  Thrombospondin-1 (TSP-1) 
The members of the thrombospondin family are large extracellular matrix 
glycoproteins that are secreted by many cell types and can act as autocrine factors. 
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There are five members of the TSP family and they are TSP-1 and TSP-2 which are 
trimers, and TSP-3, TSP-4 and TSP-5 which are pentamers (Bonnefoy et al., 2008). 
The members of the TSP family have a high degree of homology but are 
differentially expressed and have different promoters, suggesting that they are likely 
to have different functions. TSP-1 and TSP-2 are the best described members of the 
TSP family and TSP-1 has been widely studied since its discovery. 
 
TSP-1 can bind to a variety of receptors and therefore has a wide range of effects due 
to the different signalling pathways that it activates (Lawler, 2002). Although TSP-1 
activates a variety of receptors its main function is as an endogenous angiogenesis 
inhibitor with anti-cell migration properties (Tamanini and De Ambrogi, 2004, 
Ferrara, 2004, Greenaway et al., 2007). The anti-angiogenic activity of TSP-1 has 
been isolated to a smaller sequence within TSP-1 known as thrombospondin type 1 
repeats (TSRs) (Zhang and Lawler, 2007). Three TSRs are found in TSP-1 and TSP-
2 but they are not found in TSP-3, TSP-4 and TSP-5. The regulation of the anti-
angiogenic effect of TSP-1 is complex and both direct and indirect effects on 
endothelial cells are involved. TSP-1 acts indirectly on inflammatory cells and 
myofibroblasts and also directly inhibits the migration of endothelial cells and 
induces their apoptosis (Lawler, 2002). TSP-1 inhibits angiogenesis both in vitro and 
in vivo and studies have shown that treatment with TSP-1 renders endothelial cells 
unable to respond to many pro-angiogenic factors (Lawler, 2002, Folkman, 2004). 
Several studies have used knock-out mice to show that the absence of TSP-1 leads to 
increased vascularisation (Lawler et al., 1998, Lawler et al., 2001, Wang et al., 2003, 
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Sund et al., 2005, Greenaway et al., 2007), providing the first evidence for a role of 
TSP-1 in vivo as an inhibitor of angiogenesis. 
 
The anti-angiogenic effects of TSP-1 are mediated through binding to the cell surface 
receptors CD36 and CD47 (integrin-associated protein) (Dawson et al., 1997, 
Lawler, 2002). CD36 is expressed on many cell types including endothelial cells and 
platelets. CD36 interacts with TSP-1 but can also bind low-density lipoproteins and 
collagens I and V (Asch et al., 1987, Tandon et al., 1989, Kehrel et al., 1993). During 
platelet activation CD36 is dephosphorylated which blocks collagen binding and 
allows TSP-1 to bind to the receptor (Bonnefoy et al., 2008). In addition, studies with 
monoclonal antibodies against CD36 demonstrated that the expression of TSP-1 on 
platelets is also inhibited. Studies in CD36 deficient mice have confirmed the 
importance of this receptor in TSP-1 signalling but it is not the sole receptor for TSP-
1 (Lawler, 2002, Bonnefoy et al., 2008). Integrin-associated protein (IAP) or CD47 is 
present on the surface of many cell types and interacts with integrins and 
heterotrimeric G proteins (Gao et al., 1996, Chung et al., 1997, Wang and Frazier, 
1998, Frazier et al., 1999). CD47 is a member of the immunoglobulin receptor 
superfamily and it has been shown that TSP-1 signalling via CD47 inhibits nitric 
oxide (NO) signalling (Isenberg et al., 2009). As NO signalling promotes endothelial 
cell health and inhibits the activation of inflammatory cells, signalling via CD47 
could be involved in the stimulation of endothelial cell apoptosis by TSP-1. This is 
supported by evidence that animals without TSP-1 or CD47 show enhanced tissue 
survival in hypoxic conditions (Isenberg et al., 2009). 
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In the ovary, TSP-1 is most highly expressed during the preantral and early antral 
stages of follicular development (Petrik et al., 2002, Greenaway et al., 2005), and 
studies in rat, bovine and marmoset models have demonstrated a decrease in both 
TSP-1 and CD36 expression as follicular development progresses  (Petrik et al., 
2002, Greenaway et al., 2005, Thomas et al., 2008), leading to the suggestion that 
TSP-1 acts to limit any overgrowth of the vasculature that develops in response to 
the high levels of pro-angiogenic factors expressed at these stages. In addition, TSP-
1 is often produced at a rate that is inversely proportional to the production of VEGF 
and it has been shown to bind to VEGF and inhibit its action (Greenaway et al., 
2007), suggesting that the anti-angiogenic action of TSP-1 could, at least in part, be 
regulated through interaction with VEGF.   
 
A previous descriptive study has made the interesting observation that TSP-1 mRNA 
and protein is up-regulated during follicular atresia in vivo (Thomas et al., 2008), 
suggesting that TSP-1 may be involved in the cessation of angiogenesis in follicles 
undergoing atresia. Alternatively, TSP-1 may be an autocrine/paracrine factor acting 
on granulosa and/or endothelial cells to promote follicular atresia, as the CD36 
receptor for TSP-1 is present in both cell types (Thomas et al., 2008). 
1.3.4.2 2-methoxyestradiol (2-ME) 
2-methoxyestradiol (2-ME) is a naturally occurring derivative of 17β-estradiol 
(Shang et al., 2001) and it has been shown to have anti-tumour and anti-angiogenic 
activity (Fotsis et al., 1994, Pribluda et al., 2000, Ricker et al., 2004). It is 
synthesised by hydroxylation of estradiol at the 2-position and the subsequent O-
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methylation by catechol-o-methyltransferase (Pribluda et al., 2000, Dahut et al., 
2006). Although 2-ME is an oestrogen derivative it has low binding affinity for 
oestrogen receptors α and β, and its anti-proliferative action is not mediated through 
an oestrogen-mediated pathway (LaVallee et al., 2002).  
 
As the ovary produces high levels of oestrogen it is likely that 2-ME is produced in 
the ovary. A previous study has shown that 2-ME is present in porcine follicular 
fluid, with concentration increasing a folliculogenesis progresses (Basini et al., 
2007). As 2-ME is present in ovarian follicles it is likely that 2-ME plays a role in 
regulating follicular angiogenesis. In addition, several studies have shown that 2-ME 
can induce apoptosis (Pribluda et al., 2000) suggesting that the anti-proliferative 
activity of 2-ME is likely to be due to the initiation of apoptosis and that 2-ME could 
have an extravascular role in the ovary. 2-ME has been demonstrated to directly 
inhibit the proliferation of endothelial cells and tumour cells and can indirectly 
reduce angiogenesis through the inhibition of HIF1α protein expression, as well as 
inhibiting its translocation to the nucleus (Mabjeesh et al., 2003, Ricker et al., 2004, 
Lu et al., 2010). As 2-ME has previously been shown to inhibit the activity of HIF1α 
it is possible that the anti-proliferative action of 2-ME could be due to negative 
regulation of the cytoprotective activity of VEGF via the inhibition of HIF1α. 2-ME 
has also been shown to activate the caspase cascade (Mooberry, 2003a, Mooberry, 
2003b), induce p38 activation (LaVallee et al., 2003, Shimada et al., 2003) and 
inhibit Akt (Lin et al., 2007). Therefore it is possible that 2-ME negatively regulates 
proliferation due to the stimulation of pro-apoptotic mediators and/or the suppression 
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of pro-survival pathways, but the mechanisms of these extravascular effects remain 
unclear.  
 
1.3.5 Extravascular action of angiogenic factors 
This chapter has discussed the roles of various pro- and anti-angiogenic factors in 
regulating angiogenesis. However, some of these factors have been suggested to have 
extravascular roles within the ovary, including VEGF, TSP-1 and Ang-1 (Jimenez et 
al., 2000, Greenaway et al., 2004, Greenaway et al., 2007, Parborell et al., 2008). 
Many of the factors and their receptors are expressed on granulosa cells, as well as 
on endothelial cells, and can stimulate non-angiogenic pathways, but the mechanisms 
of these extravascular effects remain unclear. 
 
In addition to its pro-angiogenic effect, VEGF has been shown to have a 
cytoprotective effect in the bovine ovary. VEGF interacts with VEGFR2 to reduce 
apoptosis and to stimulate the expression of pro-survival mediators in endothelial and 
granulosa cells (Gerber et al., 1999, Greenaway et al., 2004). Moreover, treatment 
with inhibitors of VEGF, such as Aflibercept, results in an increase in follicular 
atresia suggesting that VEGF plays an important extravascular role in follicular 
development (Greenaway et al., 2004, Abramovich et al., 2006). It is possible that 
the inhibition of angiogenesis alone would be sufficient to induce follicular atresia as 
the reduced blood supply would prevent delivery of hormones, nutrients and gases, 
resulting in increased apoptosis. However, it is thought that VEGF exerts its 
cytoprotective effect by directly inhibiting apoptosis in granulosa cells as it blocks 
the release of CAD from the CAD:ICAD complex which, when released, causes 
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fragmentation of DNA (Kosaka et al., 2007). Furthermore, it has been shown that the 
inhibition of VEGF can inhibit granulosa cell proliferation (Doyle et al., 2010) and 
migration, suggesting that VEGF could play an important role in regulating 
granulosa cell function and/or survival. 
 
Treatment of rat ovaries in vivo with an antibody to Ang-1 results in the promotion of 
follicular atresia (Parborell et al., 2008), suggesting that Ang-1 could have a role in 
cell survival. The expression pattern of Ang-1 and Tie-2 suggests that they could be 
regulating cell survival via autocrine/paracrine signalling. The anti-apoptotic activity 
of Ang-1 is thought to be mediated by the phosphatidylinositol 3’-kinase (PI3K)/Akt 
signalling pathway, downstream of the Tie-2 receptor (Augustin et al., 2009). This 
signalling pathway is a key mediator of cell survival so stimulation of this pathway 
would induce a pro-survival effect. Furthermore, Kim et al. (Kim et al., 2000) 
demonstrated that Ang-1 induces PI3K-dependent phosphorylation of Akt, resulting 
in decreased apoptosis in serum deprived human umbilical vein endothelial cells 
(HUVECs). Previous studies have investigated the effects of both Ang-1 and Ang-2 
on ovarian function in vivo and have shown that the addition of Ang-1 has little 
detrimental effect on ovarian function but that treatment with Ang-2 resulted in 
deterioration of the mature, preovulatory follicle(s) and inhibited ovulation (Xu and 
Stouffer, 2005).  Additionally, in the rat ovary the expression of Ang-2 mRNA is 
increased in follicles undergoing atresia (Maisonpierre et al., 1997). These results 
suggest that Ang-2 could have a role in regulating follicle survival and that Ang/Tie 
signalling is important for promoting follicle health. 
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Since CD36 is expressed in granulosa cells, it is possible that TSP-1 may be acting 
directly on these cells in an autocrine fashion to promote follicular atresia via an 
apoptotic mechanism (Thomas et al., 2008). Induction of apoptosis by TSP-1 
requires the sequential activation of the CD36 receptor, p59fyn, caspase-like 
proteases and p38 mitogen-activated protein kinases (MAPK) (Jimenez et al., 2000). 
It has been suggested that TSP-1 could have an extravascular role in regulating 
follicular apoptosis (Jimenez et al., 2000, Nor et al., 2000, Greenaway et al., 2007). 
Additionally studies have suggested that TSP-1 can interact with the survival 
mediators ERK and MAPK (Wilson et al., 1999, Sengupta et al., 2004, Tan et al., 
2009), which supports the suggestion that TSP-1 could play a role in follicle survival. 
Using a granulosa cell line, Greenaway and colleagues showed that TSP-1 treatment 
decreased VEGF levels and rendered cells more susceptible to TNF-α-induced 
apoptosis (Greenaway et al., 2007). TSP-1 acts mainly via the receptor CD36 and 
since CD36 receptors are present on granulosa cells, it is likely that the promotion of 
follicular apoptosis by TSP-1 is due to a direct effect on the granulosa cells. 
 
Treatment with 2-ME increases the stimulation of activated caspase-3, one of the 
main molecules involved in the induction of apoptosis, so it is likely that 2-ME also 
regulates the expression of other pro- or anti-apoptotic mediators. It was anticipated 
that 2-ME could have an effect on the expression of pERK and/or p38 (LaVallee et 
al., 2003, Mooberry, 2003a, Mooberry, 2003b, Shimada et al., 2003, Lin et al., 2007) 
as they are key factors involved in anti- and pro-apoptotic pathways. 
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 Although the main role of these factors is in regulating angiogenesis, they have been 
shown to act on non-vascular cells and have extravascular actions within the ovary. 
Therefore the role of angiogenic factors in normal ovarian function will be 
investigated in this thesis. As many of the factors either stimulate or inhibit pro-
survival mediators, the expression of pERK, p38 and FOXO1 will be investigated 
following treatment with the different angiogenic factors. Akt signalling leads to 
inactivation of the forkhead transcription factor, FOXO1 which blocks cell division 
and promotes apoptosis (Augustin et al., 2009) and has been shown to be expressed 
on granulosa cells of growing follicles (Bastie et al., 2005). The expression of 
FOXO1 is regulated by the gonadotrophins; FSH and estradiol increases the 
expression of FOXO1, whereas LH decreases its expression (Liu et al., 2009). 
FOXO1 is also involved in regulating FSH-mediated granulosa cell proliferation and 
differentiation, suggesting that FOXO1 may play a critical role in granulosa cell 
function. Therefore, alteration in the expression of these molecules could indicate an 
extravascular role for the angiogenic factors in follicle survival and development. 
 
1.3.6 Manipulation of angiogenesis 
There are many models available to investigate angiogenesis, including both in vitro 
and in vivo systems. In vitro angiogenesis assays allow the analysis of the isolated 
processes of angiogenesis to be carried out, enable the identification of the direct 
effect of compounds on endothelial cell function, are more easily quantified and are 
generally less expensive to perform than in vivo assays. However, in vivo assays are 
more representative of physiological angiogenesis and give a whole system view of 
the effect of compounds on angiogenesis. Therefore, both in vitro and in vivo assays 
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are important for angiogenesis research despite their various advantages and 
disadvantages. 
1.3.6.1  In vitro assays 
In vitro angiogenesis assays have several critical advantages over in vivo 
angiogenesis assays and they are frequently used in research due to their ease of 
manipulation and quantification. There are several in vitro systems commonly used 
and they include assays designed to investigate one specific process in angiogenesis 
and also those designed to investigate the angiogenic process as a whole.  
 
Angiogenesis begins with the degradation of the extracellular matrix and this 
involves the action of proteases such as the MMPs (Davis and Senger, 2005). To 
study the process of matrix degradation, matrix invasion or zymogen assays are used. 
This technique is relatively inexpensive and provides information about MMP 
activity. However, it is time consuming and is not suitable for large-scale screening.  
 
After basement membrane degradation occurs endothelial cells migrate from the 
existing blood vessels into the surrounding tissue. This process is investigated using 
a variety of assays, including scratch wound assays, transwell or Boyden assays and 
migration assays (Staton et al., 2004, Goodwin, 2007). These assays are designed to 
allow quantification of the rate at which endothelial cells migrate into an area lacking 
endothelial cells. Whilst these assays have advantages they also have limitations. 
Scratch wound assays allow multiple quantifications to be carried out at different 
time points and can easily be adapted for large-scale screening, however, they can be 
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difficult to quantify and are highly variable (Auerbach et al., 2003, Goodwin, 2007). 
Migration assays are inexpensive to perform and allow the differentiation between 
chemokinesis and directed cell migration but are variable and difficult to quantify. 
Transwell assays are the easiest of the migration assays to quantify and are sensitive 
and highly reproducible, but the membranes used in this assay are expensive 
(Goodwin, 2007). There are also assays available for the investigation of endothelial 
cell proliferation and survival but they tend to be used in conjunction with other 
angiogenesis assays.  
 
Despite the availability of assays for the individual processes that make up 
angiogenesis, the main in vitro angiogenesis assays currently used to investigate 
angiogenesis, excepting human umbilical vein endothelial cell (HUVEC) assays 
(Nehls and Drenckhahn, 1995a, Nehls and Drenckhahn, 1995b, Nakatsu and Hughes, 
2008), tend to be organ culture assays including the rat aortic ring assay, the chick 
aortic arch assay and the mouse metatarsal assay (Auerbach et al., 2000, Auerbach et 
al., 2003, Staton et al., 2004, Goodwin, 2007), and whilst all of these methods have 
enhanced the understanding of angiogenesis, and of the mechanisms involved in it, 
they also have limitations.  
 
Angiogenesis is primarily microvascular event so the use of large vessels, such as in 
the rat aortic ring assay, the chick aortic arch assay and HUVEC assays is not truly 
representative of in vivo angiogenesis. The use of tissues that have been obtained 
from growing embryos is also not representative of physiological angiogenesis as the 
cells are undergoing rapid cell division and proliferation, before explantation. 
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Therefore the vessel outgrowth seen is not representative of the stimulation of 
angiogenesis from non-proliferative endothelial cells (Staton et al., 2004, Goodwin, 
2007). In addition, these assays are time consuming – often taking up to 2 weeks to 
provide results (Auerbach et al., 2000, Auerbach et al., 2003, Staton et al., 2004, 
Goodwin, 2007) and many of these assays are limited by variability of the tissues 
used, making it necessary to use large numbers to achieve significance. HUVEC 
assays (Kubota and Tamauchi, 1988, Donovan et al., 2001, Auerbach et al., 2003) 
have proven useful in defining the mechanisms involved in the individual stages of 
angiogenesis, as they are ideal for focussing on one stage of angiogenesis. Moreover, 
they are much more rapid than other in vitro assays and are easily reproducible. 
However, HUVEC assays share many of the limitations of the other in vitro assays 
and are not suited to the study of the complete angiogenic process. 
1.3.6.2  In vivo assays 
There are several in vivo angiogenesis models used in current research and whilst 
they are more representative of the stimulation of angiogenesis under normal in vivo 
conditions, they are limited by numerous challenges due to the complexity of the 
system used and the need to reduce the use of live animals in scientific research. The 
most commonly used in vivo models are the Matrigel plug assay, the corneal assay, 
the chick chorio-allantoic membrane (CAM) assay and chamber assays including the 
rabbit ear chamber, dorsal skinfold chamber and cranial window chamber (Auerbach 
et al., 2000, Akhtar et al., 2002, Auerbach et al., 2003, Staton et al., 2004).  
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In the Matrigel plug assay, Matrigel (or other gels such as collagen or fibrin) which 
is liquid at 4
o
C, allows the injection of cells or test compounds into test animals, 
where it then solidifies into a plug as Matrigel is solid at body temperature 
(Auerbach et al., 2000, Akhtar et al., 2002, Staton et al., 2004). Blood vessels then 
grow into the Matrigel plug, allowing the quantification of angiogenesis as all the 
vessels present in the plug are newly formed (Auerbach et al., 2003). This assay is 
easy to perform but has high levels of variability due to the difficulties in forming 
identical plugs and is time consuming to quantify. The corneal assay was originally 
developed for use in the rabbit but is now used in a variety of species including rats, 
guinea pigs and mice (Auerbach et al., 2000, Auerbach et al., 2003). This assay is 
reliable and can be monitored by direct observation however; the surgery is 
technically demanding and expensive to perform. The CAM assay is easy to carry 
out but uses an embryonic model so is not representative of physiological 
angiogenesis (Klagsbrun and D'Amore, 1991, Auerbach et al., 2000, Auerbach et al., 
2003, Staton et al., 2004). Chamber assays enable the determination of blood vessel 
growth over an extended time period which reduces the number of animals used and 
are considered a ‘gold standard’ angiogenesis assay but they are all highly invasive 
and technically difficult to perform (Auerbach et al., 2000). They are also expensive 
to carry out and can have reduced visualisation due to the thickness of the skin 
(Staton et al., 2004). 
 
There are also ovarian models available for the in vivo investigation of angiogenesis 
and the marmoset is a well established model that has been investigated in great 
detail (Fraser et al., 2000, Fraser et al., 2006, Fraser and Duncan, 2009). The 
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marmoset has advantages over other non-human primate models (Fraser et al., 1999) 
as they have high fecundity which allows sufficient animals to be bred in captivity 
without the need for wild-caught animals, and they are easy to handle and reach 
sexual maturity quickly (Torii et al., 1996), making them a useful model for 
reproductive research. They are small in size so only small amounts of compounds 
are needed to carry out investigations in this species and the ovarian cycle can be 
easily manipulated. The effects of test compounds on ovarian angiogenesis can be 
investigated by employing the well established method of using 
immunohistochemical markers such as bromodeoxyuridine (BrdU) and CD31, to 
enable the identification of actively proliferating endothelial cells (Wulff et al., 
2001a, Wulff et al., 2001b, Fraser et al., 2006, Taylor et al., 2007). This method has 
been thoroughly investigated and analysed, and it allows the effect on angiogenesis 
and cellular proliferation to be easily determined. Effects on angiogenesis can also be 
determined through hormone assays (Smith et al., 1990) and through colour Doppler 
ultrasonography (Fraser, 2006, Einspanier et al., 2006), allowing results to be 
determined non-invasively as well as through more traditional methods. The 
marmoset model has many advantages over other angiogenesis assays as it utilises 
and manipulates the natural angiogenic properties of the ovary and the angiogenesis 
that occurs is both natural and physiological. 
 
Overall, the assays currently available for angiogenesis each have their own 
limitations and the development of a novel in vitro angiogenesis assay, that would be 
representative of in vivo angiogenesis, that would be easily reproducible and that 
would provide a method for mechanistic studies would be a valuable tool in 
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angiogenesis research. The ovarian follicle is potentially an excellent tissue to utilise 
for the development of an angiogenesis assay as the tissue is already primed to 
undergo angiogenesis and the endothelial cells in the thecal layer are ready to sprout. 
In addition, the angiogenesis in follicles is easy to measure in vivo allowing the same 
system to be interrogated in vivo as well as in vitro. 
1.3.6.3 Development of anti-angiogenic agents 
The development of anti-angiogenic agents has become a focus of cancer therapy 
and several compounds have been developed (Kerbel and Folkman, 2002). These 
compounds have a variety of actions including inhibiting the action of pro-
angiogenic factors and inhibiting endothelial cell proliferation, migration and 
survival (Hagedorn and Bikfalvi, 2000, Kerbel, 2001).  
 
Some of these compounds have shown promise in the therapeutic inhibition of 
angiogenesis, such as antibodies to VEGF and VEGFR2, whilst others have proved 
disappointing (O'Reilly, 1997, O'Reilly et al., 1997, Coussens et al., 2002, Marshall, 
2002). Ferrara and colleagues demonstrated that antibodies to VEGF slowed tumour 
growth in the mouse model (Kim et al., 1993), and a variety of therapeutic strategies 
aimed at blocking VEGF or its receptor signalling are currently being developed for 
the treatment of neoplastic diseases (Alvarez et al., 2010, Delli Carpini et al., 2010, 
Korpanty et al., 2010, Tol and Punt, 2010). VEGF/VEGFR blockade by monoclonal 
antibodies and inhibition of receptor signalling by tyrosine kinase inhibitors are, to 
date, the most studied approaches. Bevacizumab (rhuMAb VEGF, Avastin
TM
, 
Genentech Inc, South San Francisco, CA, USA), a humanised monoclonal antibody 
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directed at VEGF, is the most advanced in clinical development (Ferrara, 2004). 
Bevacizumab was approved for use in metastatic cancer by the US Food and Drug 
Administration in 2004 (Huang et al., 2009) and has now been approved for use in a 
variety of cancers (Mancuso and Sternberg, 2006, Bossung and Harbeck, 2010, 
Chamberlain, 2010, Summers et al., 2010). In addition, Aflibercept (Regeneron
 
Pharmaceuticals), a recombinant chimeric protein comprising
 
portions of the 
extracellular domains of the human VEGFR1 and 2 expressed in sequence with the 
Fc portion of human Ig (Holash et al., 2002), is currently in clinical trials and has 
shown promising results (Dixon et al., 2009, Tew et al., 2009, Twardowski et al., 
2010). 
 
A correlation between down-regulation of TSP-1 and tumour angiogenesis and 
invasiveness (Rodriguez-Manzaneque et al., 2001, Miyanaga et al., 2002, Tanaka et 
al., 2002, Ren et al., 2006), has led to the proposed use of TSP-1 as a therapeutic 
inhibitor of angiogenesis (Weinstat-Saslow and Steeg, 1994, Streit et al., 1999, 
Greenaway et al., 2009). The anti-angiogenic activity of TSP-1 has been mimicked 
by many synthetic compounds and they are usually designed to mimic the activity of 
the TSR region. A much smaller heptapeptide sequence within TSR-1, GVITRIR, 
has been mimicked by the modified nonapeptide, ABT-510: Ac-Sar-GV-DalloIle-T-
Nva-IRP-ethylamide, which has been shown to be active anti-angiogenically in 
slowing tumour growth in preclinical models (Anderson et al., 2007, Yang et al., 
2007) and shown to reduce VEGF production in a model of ovarian cancer 
(Greenaway et al., 2009). It has also been demonstrated to be efficacious in the 
treatment of spontaneously occurring cancer in companion dogs (Rusk et al., 2006), 
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and has been in clinical trials, mainly as monotherapy (Hoekstra et al., 2005, 
Gietema et al., 2006, Hoekstra et al., 2006, Markovic et al., 2007).  
 
However, the potency of ABT-510 in human clinical trials was found to be 
insufficient so a second generation mimetic of the anti-angiogenic activity of TSP-1 
has been developed. The thrombospondin mimetic peptide-A-428898 (ABT-898) 
(Abbott Laboratories, N. Chicago, IL, USA) is a substituted octapeptide, Ac-GV-
DalloIle-SQIRP-ethylamide, with greatly increased potency over that of ABT-510 as 
well as slower clearance in primates. ABT-898 is thus expected to have greater 
efficacy than the other available TSP-1-mimetic peptides. Overall, much work is 
being carried out in developing angiogenesis inhibitors as future therapeutics and the 
development of potent therapeutics with few side effects would have great clinical 
benefit. 
1.4 Clinical Relevance of follicular angiogenesis research 
The physiological angiogenesis that occurs in the female reproductive tract is highly 
organised and is tightly regulated by a balance of pro- and anti-angiogenic factors. 
However, pathological angiogenesis results from an imbalance of these factors and 
this can result in severe clinical conditions. Understanding the mechanisms involved 
in regulating physiological angiogenesis will highlight the importance of each factor 
involved in this process and could lead to the development of new therapeutics. 
Novel treatments that can target aberrant ovarian angiogenesis would have a wide 
range of clinical applications, in conditions such as PCOS, and could benefit many 
people. Moreover, the elucidation of the role of endogenous and exogenous 
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angiogenesis inhibitors could indicate lead compounds for further investigation and 
clinical trials.  
 
In addition, utilising the natural angiogenic properties of the ovarian follicle allows 
investigation into the role of angiogenic factors in non-vascular cells and could 
enable the elucidation of their potential extravascular effects within the ovary. The 
promotion of follicle and oocyte health is a crucial for healthy follicle development 
and the discovery of novel factors that could promote follicle health may help to 
improve culture systems for follicular development. This could result in 
improvements to in vitro maturation (IVM) techniques, facilitating the development 
of novel treatments for infertility. 
 
1.5 Aims of the thesis 
The aims of this thesis were: 
 To develop a novel in vitro angiogenesis assay that allows the quantification 
and manipulation of follicular angiogenesis.  
 
 To elucidate the role of angiogenic factors on follicular angiogenesis.  
 
 To use an in vitro angiogenesis assay to investigate the effects of the 
angiogenic factors on the health of ovarian follicles to determine potential 
roles for these factors in ovarian function. 
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 To translate factors of interest from in vitro studies to an in vivo marmoset 
monkey model. 
 
This thesis hypothesised that factors involved in regulating angiogenesis may have 
extravascular roles within the ovary and that an in vitro assay utilizing the angiogenic 
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2 Chapter 2 Materials and Methods 
2.1 Materials and suppliers 
Unless otherwise stated all reagents were supplied by Sigma-Aldrich Company Ltd 
(Poole, Dorset, UK). 
 
2.2 Experimental models 
Two main experimental models were used for the investigation of follicular 
angiogenesis, an in vitro rodent model and an in vivo marmoset model. There are 
several animal species used in scientific research but rats and mice are the most 
commonly used. Rodents are easy to handle and have a short ovulatory cycle and 
gestation, which allows many litters to be produced in a short time period. In 
addition, they are multi-ovulatory species and as such have high numbers of follicles 
at all stages of development in the pre-pubertal ovary, making them ideal for the 
study of follicular angiogenesis. These high numbers of different classes of follicle 
allow experiments with high n numbers to be carried out whilst minimising the 
number of animals used.  
 
There are several non-human primate models available for scientific research and 
although none of them are ideal for research relating to the human, the marmoset has 
some advantages over other non-human primate models (Fraser et al., 1999). 
Marmosets have high fecundity, are easy to handle and reach sexual maturity quickly 
(Torii et al., 1996) making them a useful model for reproductive research. In 
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addition, the ability to synchronise the ovarian cycle through the induction of 
luteolysis after injection of prostaglandin enables the study of precise stages in the 
ovarian cycle (Summers et al., 1985, Duncan et al., 1998, Gilchrist et al., 2001).  
 
2.2.1 The rodent ovulatory cycle 
The rat (Rattus norvegicus) was the animal model used for the follicle culture and 
granulosa cell experiments during the course of this thesis. In rats the ovarian cycle 
starts immediately after the opening of the vaginal orifice. Rats can initially have 
some irregular cycles (Goldman et al., 2007) but will then settle into a regular 
ovarian cycle lasting approximately 4-5 days, typically with several ovulations per 
cycle (Conn MP and S, 1997). 
  
2.2.2 The marmoset ovulatory cycle 
The marmoset monkey (Callithrix jacchus) was the animal model used for the in vivo 
investigations of follicular angiogenesis. In marmosets the ovarian cycle starts at 
approximately 14 to 18 months of age (McAnulty, 1994). The ovarian cycle lasts for 
approximately 28 days, typically with two or three ovulations per cycle (Harding et 
al., 1982, Hearn, 1983). The follicular phase lasts for approximately 9 to 10 days and 
it has been demonstrated that it takes 10.7 days on average for the growth of follicles 
to reach the ovulatory stage after the sudden termination of the corpus luteum with 
administration of a PGF2 analogue (Summers et al., 1985). Marmosets have a luteal 
phase of approximately 20 days (Harding et al., 1982). In most cycles, 2 or 3 
dominant follicles grow at similar rates with ovulation occurring at up to 12-hour 
intervals (Torii et al., 1996). 
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2.3 Rodent Tissue 
2.3.1  Rodent husbandry 
All rodents were housed in the Animal House, Chancellors Building, Edinburgh. 
Staff at the centre were responsible for the care and maintenance of the animals. 
Animals were housed under temperature controlled conditions on a 12h light/12h 
darkness cycle and fed rodent chow ad libitum. Handling and treatment of animals 
were according to the Animals (Scientific Procedures) Act, 1986. 
 
2.3.2 Collection of tissue 
Animals were killed by asphyxiation with CO2 and their ovaries were removed 
immediately using manual dissection. Follicles were then manually isolated from the 
ovaries under a laminar flow hood.  
 
2.3.3 Treatment regimes 
Administration of treatments was undertaken after isolation of primary tissues. The 
treatment was added to the medium and tissues were cultured in this medium or in 
control medium. Specific details of the dose, timing and duration of treatment can be 
found in the relevant experimental chapters (Chapters 3, 4, 5, 6 and 7).  
 
2.4 Follicle culture  
2.4.1 Classification of follicle stage  
Follicles were classified as primordial (an oocyte surrounded by a single flat layer of 
follicular epithelial cells); primary (an oocyte surrounded by a single layer of 
cuboidal granulosa cells); early preantral (an oocyte surrounded by two to four 
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granulosa cell layers); preantral (an oocyte surrounded by more than four granulosa 
cell layers, no antrum formation); antral (follicles containing an antrum that are 
approximately 400µm in diameter in the rat and less than 2000μm in diameter in the 
marmoset); and dominant (follicles greater than 600µm in diameter in the rat and 
greater than 2000μm in diameter in the marmoset). Follicles that had a transparent 
appearance, an intact basement membrane, even granulosa cell layers, normal 
morphology and less than 10% pyknosis in the granulosa cells were classified as 
healthy. Follicles that had greater than 10% pyknosis in the granulosa cells, which is 
one of the first morphological signs of atresia (Durlinger et al., 2000), were classified 
as atretic. 
 
2.4.2 Follicle isolation 
Follicles were isolated from the ovaries of 21-day-old Wistar rats (Charles River 
Laboratories, Tranent, UK) under a laminar flow hood using 27-gauge needles in 
serum-free endothelial basal medium (EBM)-2 medium (Lonza, Wokingham, UK) 
supplemented with bovine serum albumin (BSA) (0.1%), L-glutamine (3mM), 
penicillin (100 IU/ml), streptomycin (0.1mg/ml), transferrin (2.5µg/ml), selenium 
(4ng/ml), insulin (10ng/ml) and L-ascorbic acid, sodium salt (50µg/ml). Healthy 
looking preantral/ early antral follicles (170-350 µm), characterized by a transparent 
appearance, intact basement membrane and even granulosa cell layer were selected 
for culture, for all experiments. Follicles at these stages were selected as they have 
undergone recruitment of endothelial cells to the thecal layer and have the highest 
angiogenic potential.  
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2.4.3 Follicle culture 
For all experiments, preantral/early antral follicles were cultured individually in flat-
bottomed 12-well plates (Corning Inc., Corning, NY, USA), embedded in the centre 
of a 20µl droplet of  growth-factor reduced Matrigel (BD Biosciences, Bedford, UK).  
Tissue engineering technologies have recently been applied to the culture of ovarian 
follicles (Xu et al., 2006) and have shown that a three-dimensional culture system 
yields favourable results (Pangas et al., 2003). Matrigel is a solubilised basement 
membrane preparation extracted from Engelbreth-Holm-Swarm mouse sarcoma, a 
tumour rich in extracellular matrix (ECM) proteins and its main components are 
structural proteins such as lamanin and collagen. Matrigel polymerises to produce a 
biologically active matrix material resembling the mammalian cellular basement 
membrane which allows cells to behave as they do in vivo. It provides a three-
dimensional mechanical support for the follicles as they increase in size, allowing 
them to maintain an in vivo-like morphology. This is highly useful in various studies 
including in vitro and in vivo angiogenesis assays as it provides a physiologically 
relevant environment for cell morphology, biochemical function, migration or 
invasion; thus allowing vascular outgrowths to develop in an in vivo-like manner. 
Follicles were incubated for 6 days in a sterile humidified air atmosphere with 5% 
CO2 at 37°C in 600µl serum-free EBM-2 medium supplemented as described in 
2.4.2, and culture medium was refreshed every 48h.  
 
For standard immunohistochemical (IHC) analysis follicles were fixed in 4% neutral 
buffered formalin (NBF) for 24h before being embedded in paraffin wax. The wax 
blocks were serial sectioned, and 5μm tissue sections were placed onto BDH 
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SuperFrost slides (Merck Co., Inc., Poole, UK). Sectioned follicles were stained for 
haematoxylin and eosin (H&E), activated caspase-3 and Tie-2. For wholemount 
immunohistochemical analysis follicles were fixed in 4% NBF for 2h and then 




2.4.4 Quantification of angiogenesis 
To assess the impact of the treatments on angiogenic sprouting, follicles were 
examined and photographed directly in the 12-well plates under an inverted light 
microscope (Axiovert 200), at x10 magnification, with Axiovision image capturing 
software (Carl Zeiss Ltd, Welwyn Garden City, Hertfordshire, UK) on days 0 and 6 of 
the culture period. The total area of angiogenic sprouting for each follicle was 
determined using Image Pro Plus software (Media Cybernetics, Bethesda, MD). This 
software allows an area of interest to be drawn around the outgrowths (but excluding 
the follicle), and the sprouts are then highlighted by the software as it allows the 
selection of light areas against a dark background. The sum of the area of all sprouts 
was then calculated by the software. The mean area of angiogenic sprouting for each 
treatment was then compared to the control.   
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Figure 2.1 Quantification of angiogenesis 
Diagram illustrates the method of quantifying angiogenesis in the cultured follicles. First the 
follicle is photographed (A) and then Image Pro-Plus software is used to highlight and 
measure the area of the sprouts. An area of interest is drawn around the outgrowths, 
excluding the follicle (B) and then the option to highlight light areas against a dark 
background is chosen. This highlights the sprouts (C) and then the software measures the 
area that is highlighted. Area of interest is shown in green and highlighted are to be 
measured is shown in red. Scale bars represent 200µm. 
 
 
2.5 Tissue fixation, processing and sectioning 
Tissue fixation was needed to stop autolysis, putrefaction, bacterial attack and other 
undesirable cellular changes. It also keeps the tissue in as close a state as possible to 
its in vivo form. Ovaries were fixed in 4% NBF for 24 h and then transferred to a 
70% alcohol (C2H5OH) solution until processed into paraffin wax. Processing and 
paraffin wax embedding was carried out by the Unit histology laboratory staff. 
Tissue was dehydrated through a series of graded alcohols before saturation in 
paraffin wax. This process was carried out using a 17.5 h automated cycle on a Leica 
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TP-1050 processor (Leica UK Limited, Milton Keynes, UK). The tissue was then 
embedded onto plastic cassettes for sectioning. 
 
All tissues were serial sectioned at a thickness of 5µm on to electrostatically charged 
slides (Merck Co). The electrostatic charging improved the binding of the tissue to 
the slides. Sections were cut using a hand-operated microtome (Leica UK Ltd) with 
disposable blades. Sections were floated onto water at 45
o
C, then transferred onto 
slides and dried overnight. 
 
2.6  Haematoxylin and eosin staining 
H&E staining is used to visualise the tissue for morphometric analysis. 
Haematoxylin is a purple nuclear stain and eosin is a red cytoplasmic stain. These 
stains were prepared by Histology staff. For this thesis Harris’s mercury free 
haematoxylin (VWR International Ltd, Hunter Boulevard, Leicestershire, UK) was 
used and the eosin Y (Richard-Allan, Richland, MI, USA) was prepared by making a 
1% solution in distilled water. Sections were dewaxed in two 5min washes of xylene 
before being taken through graded (100%, 90%, 70%) alcohols and finally taken into 
water. Once dewaxed, slides were stained in haematoxylin for 5min, washed in 
water, washed in acid alcohol for 20 seconds, washed in water, washed in Scott’s tap 
water for 30 seconds, washed in water, stained in eosin for 20 seconds and finally 
washed in water. The slides are then taken through graded (70%, 80%, 95%, 100%) 
alcohols, washed in xylene and then mounted using Pertex (Cell Path, Hemel 
Hempstead, UK). 
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2.7  Immunohistochemistry  
Immunohistochemistry is a method used to localise a specific protein within a cell or 
on the surface of a cell using an antibody raised to an epitope of the protein of 
interest. This is a useful technique, as it allows a protein to be localised to a specific 
cell type and often a specific cellular location. The immunohistochemical process 
involves building up layers of antibodies to increase the available binding sites for 
the antibody and detection system. Quantification of immunohistochemical staining 
is possible and is generally based on parameters such as: number of positive cells in a 
population; the area of staining in a given tissue or structure (in this case the ovarian 
follicle); or a combination of the two. The advent of image analysis systems and 
software has increased the efficiency and accuracy of quantification of 
immunohistochemistry. For all immunohistochemistry negative controls were 
performed by omitting the primary antibody. 
 
2.7.1 Antigen retrieval  
Some antigenic epitopes can be masked during fixation and paraffin wax embedding. 
Therefore, antigen retrieval by heat treatment (Shi et al., 1991) is necessary to expose 
those antigens. Slides were dewaxed in xylene, rehydrated through a series of 
alcohols, and exposed to 0.01M citrate buffer, pH 6, in a Tefal Clypso pressure 
cooker (Tefal, Essex, UK). Two litres of citrate buffer were heated to boiling point in 
the pressure cooker and once boiling, racks containing the dewaxed and rehydrated 
slides were placed into the buffer. The lid was sealed and the slides were heated at 
high pressure for 5min, starting when full pressure was reached. After pressure was 
released, the slides remained in the hot buffer for a further 20min before they were 
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cooled with water and transferred to 0.05M Tris buffered saline (TBS, pH 7.4) for 
5min. 
 
2.7.2 Blocking non-specific background 
The main cause of non-specific background staining is non-immunological binding 
of the specific immune sera by hydrophobic and electrostatic forces to certain sites 
within tissue sections (Kraehenbuhl and Jamieson, 1974). As it is usually the first 
immune serum that gives rise to the highest non-specific background staining these 
sites are blocked prior to the application of the primary antibody with 
immunoglobulins that will not react or interfere with the primary specific antiserum.   
This is achieved by incubating the sections in normal whole serum from the species 
in which the secondary antibody was raised. For example, when mouse BrdU was 
localised using rabbit anti-mouse as a secondary antibody, blocking was performed 
using normal rabbit serum. All slides were treated with the relevant blocking serum 
diluted 1:5 in TBS with 20% BSA for 30min at room temperature. Details for each 
specific antigen are given in Table 1. 
 
2.7.3 Immunohistochemical procedure 
Immunohistochemical procedures were performed using an automated incubation 
method, the Sequenza System (Shandon Scientific, Runcorn, Cheshire, UK). A 
Sequenza works by capillary action and reduces the volumes of reagents required. 
Each section was retained within its own Sequenza cassette, which prevents 
cross-contamination and antibody-antigen complexes are prevented from 
precipitating onto sections, which would give rise to unwanted background staining. 
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Unbound antibody was washed from each section before the proceeding step in each 
protocol. Detection systems vary according to antibody, details are given in Table 1.  
Table 1 Antibodies and reagents used in immunohistochemistry protocols. 
Table outline information about the antibodies and detection methods used for IHC 
performed in this thesis. The majority of the IHC methods had been optimised previously as 
they are routinely used in our group. However, the protocol for the Tie-2 IHC had to be 
optimised. The antibody was tested at a range of concentrations and a variety of detection 
methods and times were tested. It was found that using the antibody at 1:100 and detecting 
with DAB for 4min gave the best results so these were the condition used. 
 
 
Secondary antibodies also varied according to antibody and slides incubated with 
non-biotinylated secondary antibodies were subsequently incubated with a tertiary 
alkaline phosphatase-antialkaline phosphatase (APAAP) antibody complex (Cordell 
et al., 1984).  The secondary antibody was applied in excess so that one of its two 






















































Goat anti rabbit 
peroxidase 
labelled polymer 









Streptavidin-HRP DAB Yes Yes 
Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
60 
Chapter 2 Materials and Methods 
complex, illustrated in Figure 2.2. The APAAP was added, diluted in the appropriate 
serum block for 40min, before slides were washed in and then transferred to TBS. 
The APAAP detection method can be used with a variety of substrates giving rise to 
a variety of colours. The two used in this thesis were nitroblue tetrazolium (NBT), 
which forms a deep blue/black stain (McGadey, 1970), and fast red used with 
naphthol AS-MX phosphate sodium, which gives a bright red stain. 
 
 
Figure 2.2 Illustration of the APAAP detection system 
Diagram showing a primary antibody binding to the specific antigen. The secondary 
antibody binds to the primary antibody and also to the APAAP complex. Staining can then 
be detected using either NBT or fast red. 
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2.7.4 Specific immunohistochemistry techniques in the rodent 
2.7.4.1  Caspase-3 (apoptotic cells) 
Although other techniques for the detection of apoptosis, such as TdT-mediated 
dUTP-biotin nick end labelling (TUNEL), are useful, they often have issues with 
specificity and interpretation of the results (Allen et al., 1997). Therefore, the 
development of antibodies to more generally distributed apoptotic markers, such as 
activated caspase-3, are preferred for the detection of apoptosis (Barrett et al., 2001). 
The caspases are a family of cysteine proteases that are essential for apoptosis 
(Thornberry and Lazebnik, 1998). There are two types of apoptotic caspases, initiator 
caspases (caspases 2, 8, 9, 10 and 12) and effector caspases (caspases 3, 6 and 7) 
(Thornberry and Lazebnik, 1998, Lavrik et al., 2005). The initiator caspases are 
closely coupled to pro-apoptotic signals such as FasL (Fas ligand), tumour necrosis 
factor (TNF) and DNA damage. Caspases are synthesised as inactive pro-caspases 
and are converted to active caspases by cleavage at specific aspartate residues or by 
autocatalysis due to either the removal of inhibitors or the binding of co-factors 
(Cohen, 1997). These activated initiator caspases then activate the effector caspases 
which have many downstream effects that result in programmed cell death, including 
the inactivation of cytoprotective proteins such as the ICAD/CAD complex and Bcl-
2 (Thornberry and Lazebnik, 1998). The caspases have different roles within the 
apoptotic cascade and caspase-3 is one of the predominant caspases that is activated 
in cells undergoing programmed cell death (Faleiro et al., 1997).  A diagram of the 
apoptotic cascade is provided in Figure 2.3. 
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Figure 2.3 Schematic overview of the apoptotic process. 
There are several factors involved in regulating the ‘decision to die’. In granulosa cells 
examples of survival factors include the gonadotrophins FSH and LH, the steroids 
progesterone (P4) and estrogen (E2), and other factors including growth hormone, insulin-
like growth factor I (IGF-I), bFGF and insulin. Pro- and anti-apoptotic signals interact in 
the mitochondria and when pro-apoptotic activity is greater than anti-apoptotic activity 
molecules are released. These molecules activate the caspase cascade and apoptosis occurs. 
In addition, apoptosis can be induced via DNA damage and activation of the death receptor 
pathway, as shown on the diagram. GPCR – G-protein coupled receptor, DISC – Death-
inducing signalling Complex, FADD – Fas-associated protein with death domain, CAD – 
Caspase-activated DNase, ICAD – Inhibitor of CAD, APAF-1 – Apoptotic protease 
activating factor-1.(Figure adapted from (Markstrom et al., 2002) 
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For the purposes of this thesis, a polyclonal antibody to cleaved (activated) caspase-3 
(Asp175; New England Biolabs, Hitchen, UK) was used to determine the localization 
and changes in the number of dying cells and a peroxidase labelled polymer was 
used with 3,3’ diaminobenzidine (DAB) was used for immunohistochemical 
visualisation. DAB yields a crisp, insoluble, dark brown reaction product (Graham 
and Karnovsky, 1966), a diagram illustrating this technique is provided in Figure 2.4. 
As endogenous peroxidase in animal tissues can react with DAB and cause a blurring 
of the resulting stain, slides were treated with saturating amounts of hydrogen 
peroxide to irreversibly inactivate these endogenous peroxidases.  
 
Therefore, immediately after antigen retrieval, endogenous peroxidase activity was 
quenched by a 5min incubation in peroxidase block (EnVision HRP kit, Dako), and 
then the slides were washed three times with TBS for 5min and then blocked in 
normal goat serum (NGS, diluted 1:5 in TBS containing 5% BSA), for 30min. The 
sections were incubated overnight at 4°C with activated caspase-3 antibody (1:100 in 
NGS). Slides were washed in TBS and incubated with labelled polymer-horse radish 
peroxidase (HRP) as secondary antibody (rabbit EnVison kit) for 30min. Slides were 
washed and transferred to TBS before the tissue sections were dried around and DAB 
substrate added. Staining was produced after approximately 5min. Reactions were 
stopped in tap water and sections were counterstained in haematoxylin for 
approximately 10 seconds before being dehydrated through graded alcohols, cleared 
and mounted using Pertex. 
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Figure 2.4 Illustration of EnVision DAB/Chromagen immunohistochemical detection. 
Diagram showing a primary antibody binding to its specific antigen. The secondary antibody 
that binds to the primary is biotinylated to allow binding of the tertiary complex. Coloured 
substrates are then used for visualisation of detection, e.g. DAB. 
 
2.7.4.2  Tie-2 
To determine the localisation of Tie-2 in the animal models used in this thesis, IHC 
was performed. Immediately after antigen retrieval, endogenous peroxidase activity 
was quenched by a 30min incubation in peroxidase block (30ml 30% H2O2 and 
270ml methanol), the slides were washed three times with TBS for 5min and then 
blocked in NGS, for 30min. The slides were blocked with streptavidin for 15min 
followed by three TBS washes, blocked with biotin for 15min followed by three TBS 
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washes and then the sections were incubated overnight at 4°C with an antibody to 
Tie-2 (1:100 in NGS, sc-324 Santa Cruz Biotechnology, Heidelberg, Germany). 
Slides were washed three times in TBS-Tween and incubated with goat anti-rabbit 
biotinylated secondary antibody (1:500 in NGS). Following three TBS-Tween 
washes, slides were incubated in streptavidin labelled polymer-HRP as tertiary 
antibody (1:1000 in TBS) for 30min. Slides were washed and transferred to TBS 
before the tissue sections were dried around and DAB substrate added. Staining was 
produced after approximately 5min. Reactions were stopped in tap water and 
sections were counterstained in haematoxylin for approximately 10 seconds before 
being dehydrated through graded alcohols, cleared and mounted using Pertex. 
 
2.8 Wholemount Immunohistochemistry 
To confirm the endothelial nature of the angiogenic sprouting, a sample of follicles 
was analyzed by wholemount IHC for incorporation of various endothelial cell 
markers. Negative controls were performed for all immunohistochemistry by 
omitting the primary antibody. 
 
2.8.1 Immunohistochemical procedure 
Follicles were fixed for 2h in 4% NBF and permeabilised in dH2O overnight at 4
0
C. 
Follicles were washed in between each treatment step in tris-buffered saline-Tween 
(TBS-Tween) for 5min 3-5 times and all incubations were carried out at room 
temperature unless stated otherwise. 
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2.8.1.1  Dil-Ac-LDL 
1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate (Dil-Ac-LDL) 
(20µg/ml, Serotec, Oxford, UK) is a fluorescent-labelled acetylated low-density 
lipoprotein is taken up by macrophages and endothelial cells via the “scavenger” 
metabolic pathway (Voyta et al., 1984). To confirm the endothelial nature of the 
angiogenic sprouting Dil-Ac-LDL was added to the culture medium on day 4, and 
outgrowths were assessed for uptake of the molecule on day 6 via confocal 
fluorescence microscopy at 568nm. 
2.8.1.2  CD31  
Platelet-endothelial cell adhesion molecule (PECAM-1/CD31) is a commonly used 
endothelial cell marker (Ilan et al., 2000) and is a 130-kDa glycoprotein belonging to 
the Ig superfamily of cell adhesion molecules. CD31 expression is restricted to cells 
of the vascular system platelets, monocytes, neutrophils, selected T cells, and 
endothelial cells (Newman, 1997, Newman, 1999). It has previously been shown that 
CD31 knockout mice suffer from prolonged bleeding times after surgical insult, 
which is at least in part due to disrupted endothelial-platelet interactions (Mahooti et 
al., 2000). In addition to the role of CD31 in endothelial cell adhesion, there is 
growing evidence that CD31 is able to transduce signals that suppress endothelial 
cell apoptosis (Noble et al., 1999, Newman and Newman, 2003). 
 
For CD31 IHC endogenous peroxidase activity was quenched with hydrogen 
peroxidase at 1% in phosphate-buffered saline (PBS) for 30min, then blocked in 
NGS for 30min, and then incubated with an antibody to CD31 (1:300 in NGS, 
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550300 BD Biosciences Pharmingen, Oxford, UK) overnight at 4
0
C. Follicles were 
incubated with goat anti-mouse peroxidase with Fab fragments (1:500 in NGS) and 
kept in the dark before incubating with Tyramide TSA-Plus Cy3 System (1:50, 
Perkin Elmer Life Sciences, Beaconsfield, UK) for 10min. After washing, labelling 
was detected using confocal fluorescence microscopy at 568nm (red channel to show 
CD31 stained cells). 
2.8.1.3  CD34  
CD34 is a cell surface glycoprotein and acts as a cell adhesion factor. It is expressed 
on both endothelial progenitor cells and endothelial cells and is therefore a marker 
for endothelial cells (Muller et al., 2002, Pusztaszeri et al., 2006). For CD34 IHC 
follicles were blocked in normal donkey serum (NDS, diluted 1:5 in TBS containing 
5% BSA) for 1h, and then incubated with an antibody to CD34 (1:100 in NDS, sc-
7045 Santa Cruz) overnight at 4
0
C. After washing, follicles were incubated with 
donkey anti-goat-AlexaFluor555 (1:200 in PBS) for 1h and then labelling was 
detected using confocal fluorescence microscopy at 546nm (red channel to show 
CD34 stained cells). 
2.8.1.4  αSMA  
Alpha–smooth muscle actin (αSMA) is a differentiation
 
marker of smooth muscle 
cells and is also present in myofibroblasts and pericytes. αSMA expressing cells have 
important roles in angiogenesis as myofibroblasts induce wound contraction during 
normal wound healing (Grinnell, 1994, Powell et al., 1999, Tomasek et al., 2002). In 
addition, pericytes are recruited to developing blood vessels during angiogenesis to 
support and stabilise the new vessels. Therefore, the expression of αSMA by new 
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blood vessels is an indicator of blood vessel maturity. For αSMA IHC follicles were 
blocked in NGS and then incubated with an antibody to αSMA primary antibody 
(1:500 in NGS, A2547 Sigma Aldrich) at 4
0
C overnight. After washing, follicles 
were incubated with goat anti-mouse-AlexaFluor488 (1:200 in PBS) for 1h and then 
labelling was detected using confocal fluorescence microscopy at 488nm (green 
channel to show αSMA labelled cells). 
2.8.1.5  CD31/αSMA Dual 
For the CD31/αSMA dual IHC the method for CD31 IHC was followed as above. 
After Tyramide staining follicles were incubated with the αSMA primary antibody 
(1:500 in NGS) at 4
0
C overnight. After washing, follicles were incubated with goat 
anti-mouse-AlexaFluor488 (1:200 in PBS) for 1h and then labelling was detected 
using confocal fluorescence microscopy at 488nm (green channel to show αSMA 
labelled cells) and 568nm (red channel to show CD31 stained cells) simultaneously. 
2.8.1.6  TdT-mediated dUTP-biotin nick end labelling (TUNEL) 
To provide another method for investigation of the effect of TSP-1 on apoptosis, 
whole follicles from control and TSP-1 treatment groups were subjected to TUNEL 
analysis in order to detect proportions of apoptotic cells. At the end of the culture 
period, follicles were transferred to 24-well culture plates (Corning Inc.) and then 
washed (10 min, PBS, 37
o
C). Cultured follicles were permeabilised and prefixed (40 
min; 0.5% Triton-X100, 0.25% paraformaldehyde in PBS at 37
o
C), and then fixed 
(30 min; 4% paraformaldehyde in PBS at room temperature), washed in PBS (2x 10 
min) and stored (0.02% NaN3 in PBS, 48
o
C). Follicles were washed and equilibrated 
to room temperature with PBS (20 min; 2x 10 min). Samples were then incubated 
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with proteinase K (Roche, Welwyn Garden City, Hertfordshire, UK) (30 min, 17.1 
µg ml
-1
 in PBS, 37
o
C), refixed at room temperature (20 min, 3% paraformaldehyde 
in PBS) and washed (20 min, 0.01% Triton-X100 in PBS; 2x 10 min PBS). A 
preincubation with TdT buffer (10 min, 30 mmol Tris–HCl l
-1
, pH 7.2, 140 mmol 
sodium cacodylate l
-1
, 1 mmol cobalt chloride l
-1
) was carried out before incubation 
with TUNEL reaction mixture (2.5 h, 37
o
C in the dark) from an in situ cell death 
detection kit, Fluorescein (Roche), which was prepared according to the 
manufacturer’s instructions. Still in the dark, follicles were washed in PBS (2x 10 
min) and incubated with propidium iodide (1 h, 2.5 µg ml
-1
, room temperature) in 
bovine pancreatic RNase A (Roche). Samples were washed (20 min, 0.01% Triton-
X100 in PBS; 2x 10 min PBS) and stored in PBS at 4
o
C in the dark.  
 
2.8.2 Detection of Wholemount immunohistochemistry 
Follicle sections were analysed using the Leica TCSNT 710 confocal system (Leica 
Microsystems, Milton Keynes), equipped with a number of standard objective lenses. 
The pinhole size was 1 Airy unit. A z-stack was taken through the centre of each 
follicle using the first/last method and a plan-neofluor x10/ 0.3-n.a. objective lens. 
The acquisition parameters and number of slices to be taken were determined using 
the Nyquist calculator on the CALM website. Simultaneous scans at 488nm (the 
green channel) and 546nm (the red channel) were taken and then the z-stacks were 
converted into three dimensional projections using the Zen software. 
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2.9 Granulosa cell culture 
21-day-old female Wistar rats (Charles River Laboratories) were used as described 
above. Two animals were used for each experiment and experiments were done in 
triplicate. Animals were killed by asphyxiation with CO2 and the ovaries removed. 
 
2.9.1 Isolation of granulosa cells 
Granulosa cells were isolated by puncturing follicles with a 27-gauge needle and 
gently expelling the cells into culture medium. Pooled cells were centrifuged, re-
suspended in fresh M199 medium (Gibco, Invitrogen Life Technologies, Inc.), 
Paisley, UK) containing 0.1% BSA, 2 mmol L-glutamine, 50µg/ml streptomycin and 
50 IU/ml penicillin and their viability assessed by counting a Trypan blue-stained 
preparation in a haemocytometer. Cell viability was 30-40%.  
 
2.9.2 Culture of granulosa cells 
To measure caspase activity tissue culture grade 96-well plastic plates (Corning Inc.) 
were precoated with 0.1ml donor calf serum (Lonza) and washed twice with PBS 
(0.1ml) before inoculating with 0.1ml medium containing 1 x 10
5
 cells/ml. Following 
overnight preincubation in a sterile humidified air atmosphere with 5 % CO2 at 37°C, 
prewarmed medium containing varying doses of the compound of interest was added 
to triplicate wells and the incubation continued for 48h. 
 
To measure expression of various factors by qRT-PCR tissue culture grade 6-well 
plastic plates (Corning Inc.) were precoated with 0.5ml donor calf serum (Lonza) and 
washed twice with PBS (0.5 ml) before inoculating with 1.5ml medium containing 3 
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x 10
5
 cells/ml. Following overnight preincubation in a sterile humidified air 
atmosphere with 5 % CO2 at 37°C, 1.5ml prewarmed medium containing varying 
doses of the compound of interest was added to triplicate wells and the incubation 
continued for 48h. 
 
To measure expression of various factors by western blotting, tissue culture grade 6-
well plastic plates (Corning Inc.) were precoated with 0.5ml donor calf serum 
(Lonza) and washed twice with PBS (0.5ml) before inoculating with 1.5ml medium 
containing 3 x 10
5
 cells/ml. Following overnight preincubation in a sterile humidified 
air atmosphere with 5 % CO2 at 37°C, 1.5ml prewarmed medium containing varying 
doses of the compound of interest was added to triplicate wells and the incubation 
continued for 96h with medium refreshed every 48h. 
 
2.9.3 Caspase-3/7 assay 
To measure caspase-3 and -7 activities in isolated granulosa cells, the Caspase-Glo 
3/7 assay was
 
performed according to the manufacturer’s instructions
 
(Promega UK 
Ltd., Southampton, UK).  
 
Treatments were carried out in triplicate and experiments were repeated three times.
 
As serum can generate a background caspase activity signal,
 
two additional wells 
contained cell culture medium and carrier
 
solution without any cells. To ensure 
reagent activity and signal detection were working effectively an additional two 
wells contained 50ng/ml TNFα, which was used as a positive control. 
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After 48h, the granulosa cells were allowed to equilibrate to room temperature and 
100µl of blank, negative control cells, positive control cells or treated cells were 
added to each well of a white-walled 96-well plate (Corning Inc.). Caspase-Glo 3/7 
reagent was added directly to the
 
cells in culture medium in a 1:1 ratio. The well 
contents were
 
then mixed for 30secs and incubated at room temperature for up to 3h.
 
This resulted in cell lysis, followed by caspase cleavage of
 
the substrate and 
generation of a glow-type luminescent signal,
 
produced by luciferase. Luminescence 
was measured using a FLUOstar
 
OPTIMA microplate reader (BMG Labtech Ltd., 
Aylesbury, UK).
 
Luminescence was directly proportional to the amount of caspase
 
activity present. The value for the no cell control was subtracted
 
from the 
experimental values. The experiment was repeated
 





2.9.4 RNA extraction and cDNA synthesis 
At the end of the culture period, RNA was extracted for analysis, using the RNeasy 
micro-kit (Qiagen, West Sussex, UK), following the manufacturer’s instructions. 
Cells were lysed in 350µl RLT buffer, collected in a Safe-Lock tube (Eppendorf 
Eppendorf UK Limited, Cambridge, UK) and vortexed. A volume of 350µl of 70% 
ethanol was added to the lysate and mixed well by pipetting. The sample was then 
transferred to an RNeasy MinElute spin column and centrifuged at ≥8000 x g for 
15secs. A volume of 350µl wash buffer RW1 was added to the spin column and 
centrifuged for 15secs at ≥8000 x g. On-column digestion of DNA was then 
performed by addition of DNase1 (Qiagen) which was incubated at room 
temperature for 15min. DNase1 was then removed by a further wash with wash 
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buffer RW1. Subsequently 500µl of buffer RPE containing ethanol, to wash the 
RNA, was added to the column and centrifuged at ≥8000 x g for 15secs. A volume of 
500µl of 80% ethanol was added to the spin column and centrifuged for 2min at 
≥8000 x g to wash the spin column membrane. The spin column was then dried by 
centrifugation at full speed for 5min with the spin column lids open. This longer 
centrifuge ensured all residual ethanol was removed from the columns as residual 
ethanol can interfere with downstream reactions. The RNA, which had remained 
stuck to the column throughout, was eluted in 14µl of RNase-free water and 
centrifuged for 1min at ≥8000 x g. The eluate was collected in new microcentrifuge 
tubes. 
2.9.4.1  cDNA Synthesis 
The concentration of the RNA was determined prior to cDNA synthesis using the 
Nanodrop 1000 (Thermo Scientific, Loughborough, UK). This machine 
automatically calculates the concentration (A260) and quality (A260/280) of RNA. RNA 
was reverse-transcribed using the Vilo cDNA synthesis kit (Invitrogen) in a reaction 
mixture (total vol. 20µl) containing 4µl 5x Vilo Reaction Mix, 0.25µl 10x 
Superscript Enzyme Mix, 100ng/µl RNA and topped up to 20µl with RNase free 
H2O. The cDNA was then amplified in a cyclic process of DNA denaturation, 
specific primer annealing and primer extension using the Peltier Thermal Cycler-200 
DNA Engine Cycler (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) under the 
conditions 25°C for 10 min, 42°C for 60min and 85°C for 5min. This results in the 
primer specified cDNA fragment being exponentially increased. Genomic DNA 
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contamination was excluded in each PCR using a control for each sample that was 
generated in the absence of reverse transcriptase. 
 
2.9.5 Taqman quantitative RT-PCR 
2.9.5.1  Principle of Taqman reaction 
Taqman quantitative RT-PCR was used to accurately quantify mRNA of genes of 
interest. Taqman probes have the fluorophore FAM attached to the 5’ end and a 
quencher dye (TAMRA for Universal Probe library probes, Non-fluorescent for 
Assay-On-Demand probes) attached to the 3’ end. The 18S probe used in this thesis 
used the VIC fluorophore to distinguish it from the gene of interest. After annealing 
to the gene of interest Taq polymerase extends the primer 5’ to 3’ and displaces 
FAM. This leads to a separation between the fluorophore and the quencher, leading 
to an increase in fluorescence which can be measured. As the PCR reaction is 
exponential, the original amount of cDNA in the sample, and therefore RNA, can be 
quantified by measuring the amount of fluorescence (Figure 2.5). 
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Figure 2.5 Principle of Taqman reaction 
A: Specific primers and probe anneal to the gene of interest. Taq polymerase begins to 
extend the primers from 5’ to 3’ 
B: Taq polymerase extends the primer to displace the fluorophore FAM (F) from the 
TAMRA quencher (Q). This results in an increase in fluorescence which can be measured 
and which increases as the PCR reaction continues exponentially. 
 
2.9.5.2  Taqman reaction 
Expression of Tie-2, Ang-2 and 18S rRNA mRNA was measured in cDNA samples 
from granulosa cells cultured in the presence or absence of test compounds, in 
triplicate. Negative controls included RT- samples and nuclease-free water. 
 
Expression was measured using an ABI 7900HT Real-Time PCR System (Applied 
Biosystems, Warrington, UK). Oligonucleotide primers for PCR were designed to 
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amplify Tie-2 using the Universal Probe library (Roche) and custom ordered from 
MWG (Eurofins MWG Operon, Ebersberg, Germany) – forward primer 
GCAAATGTCCAAAGAAGAATG, reverse primer 
TGAACAGCTGGTTCTTCTCTCA. The corresponding probe, according to the 
Universal Probe library was ordered from Roche (Probe #97). Primers were designed 
with the following features: 
 No multiple repeats of a nucleotide, particularly guanosine 
 A melting temperature of 58-60°C that was equal between the forward and 
reverse primers 
 Primers that were intron spanning, to avoid amplifying genomic sequences 
 Primers that were as close together as possible, without overlapping and that 
were 50-150bp in length 
 Primers that amplified segments of the sequence that displayed low 
homology with other genes in the same family 
 
PCR for Ang-2 was performed using Assays on Demand Gene Expression Products 
(Agpt2; TaqMan assay ID: Rn01756774_m1) (Applied Biosystems).  
 
For the PCR for Tie-2, 1.5µl cDNA was amplified in a reaction mixture (total vol, 
15µl) containing 7.5µl 2x Express Mastermix (Invitrogen), 0.1125µl 18S 
primer/probe mix (Invitrogen), 0.15µl each of forward and reverse primers (MWG), 
0.15 of the target probe (probe 97 – Roche Universal Probe Library) and 5.4375µl 
double distilled H2O. This mix was added in triplicate to a 96-well MicroAmp fast 
optical reaction PCR plate (Applied Biosystems). Reactions were incubated for 5min 
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at 45°C followed by 5 min at 95°C, followed by PCR cycling for 40 cycles of 15sec 
at 95°C and 1min at 60°C. 
 
For the PCR for Ang-2, 1.5µl cDNA was amplified in a reaction mixture (total vol, 
15µl) containing 7.5µl 2x Express Mastermix, 0.225µl 18S primer/probe mix, 0.75µl 
of the 20x Assay-on-demand primer probe mix and 5.025µl double distilled H2O. 
This mix was added in triplicate to a 96-well MicroAmp fast optical reaction PCR 
plate. Reactions were incubated for 5min at 45°C followed by 5 min at 95°C, 
followed by PCR cycling for 40 cycles of 15sec at 95°C and 1min at 60°C. 
 
To determine change in specific gene expression in the follicles, the levels of 
expression of specific mRNAs in each sample were quantified using the 2
– Ct
 
method. To ensure the integrity of these results and to account for possible variation 
due to differing amounts of RNA and pipetting errors, an endogenous housekeeping 
gene, 18S, was used as an internal standard to ensure that the genes of interest were 
not regulated under any of the culture conditions tested. This gene has been 
identified as an appropriate housekeeping gene for use in quantitative PCR studies 
(Thellin et al., 1999, Schmittgen and Zakrajsek, 2000).  
 
First the expression of the gene of interest is normalised to that of the housekeeping 
gene by subtraction of the threshold cycle (Ct; the cycle number at which the gene is 
termed Ct. This assumes that the primers and probes of 18S and those of the gene 
of interest are working at similar efficiencies (see 2.9.5.3). To determine change in 
specific gene expression in the follicles, the levels of expression of specific mRNAs 
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in each sample were quantified using the 2
– Ct
 method. This is derived from the 
equation describing exponential amplification of PCR: 
Xn = X0(1 + Ex)
Ct,x
 
Where Xn is the number of templates at cycle X, X0 is the number of template copies 
at initiation, Ex is the efficiency of target amplification and n is the number of cycles. 
 
As the Ct of the control sample is subtracted against itself, its final value after 
applying 2
– Ct
 is 1. Therefore, all other samples are expressed as a percentage 
increase relative to this. 
2.9.5.3  Primer and probe validation 
Increasing dilutions (from 1:10 to 1:1000) of cDNA were used to generate standard 
curves, for Tie-2, Ang-2 and 18S, of the number of cycles needed to yield a 
fluorescent signal above background against the log of relative concentration. The 
resulting slope of the curve is a measure of the efficiency of the PCR reaction 
(Hartley et al., 2002). The slopes of the standard curves are indicative of the 
efficiency of the PCR reaction and were all close to -3.3 (equivalent to 100% PCR 





2.9.6 Protein extraction 
At the end of the culture period (when granulosa cells were above 50% confluent), 
protein was extracted for analysis. Medium was removed from cells and 120μl of 
lysis buffer (1ml glycerol, 50μl 1M HEPES pH7.4, 40μl 0.5M EDTA pH8.0, 100μl 
NP40, 0.146g NaCl, 300μl PMSF, 300Ml NaVO4, 30μl Leupeptin, made up to 10ml 
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with dH2O) was added at 4
o
C to each well of a 6-well plate. Cells were scraped off 
the plates and transferred to a chilled 1.5ml eppendorf and then centrifuged at 
≥10,000 x g for 10min at 4
o
C. A volume of 100μl of supernatant was removed and 
mixed with 100μl 2xLSB (40ml 10% SDS, 12.5ml 1M Tris pH6.8, 5ml glycerol, 
3.75ml dH2O, a small amount of bromophenol blue powder and just before use 
7μl/ml β-mercaptoethanol was added) to give the cytoplasmic fraction of the cell 
extract. To get the nuclear fraction 100μl of lysis buffer was added at 4
o
C to pellet 
and centrifuged at ≥10,000 x g for 10min at 4
o
C. A volume of 100μl of supernatant 
was removed, mixed with 100μl 2xLSB and sonicated to disrupt the nuclei. Samples 
were stored at -80
 o
C, until use. 
 
2.9.7 Determination of protein concentration 
To ensure even loading of protein on western gels the concentration of the protein 
samples was determined using the Bradford protein assay. Standards of 1, 2, 3, 5, 
7.5, 10, 15, 20µl BSA were made up in eppendorfs to 800µl with PBS and 5µl of the 
extracted protein was added to 795µl PBS for each sample, with 200µl of Bradford 
dye added to each tube. The samples were then read on a lightwave 
spectrophotometer at 595nm absorbance. The blank sample of 800µl PBS and 200µl 
Bradford dye was read first, then the BSA standards followed by the extracted 
protein samples. The readings for the BSA standards were plotted using Excel and a 
trend line added to the data points. The equation of this trendline was used to work 
out the concentration of the samples as y is protein concentration and x is absorbance 
of the sample. If you put the value for x into the equation you can work out the 
concentration of your sample and then divide by 5 to get the concentration in µg/µl. 
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2.9.8 Western blotting 
Western blot analysis was conducted to investigate the expression of various proteins 
in granulosa cells. For each gel 5l of MWt ladder and 10l (approx 10g protein) of 
sample was loaded and resolved on 4–20%
 
Tris-glycine gels (NOVEX, Invitrogen) 
and transferred onto a polyvinylidene difluoride fluorescent (PVDF-fl) membrane 
(Millipore
 
Corp., Watford, UK) using the Trans-Blot SD Semi-Dry Transfer Cell 




C in Rockland Near Infra Red 





rabbit anti-phospho-p42/44 ERK (1:1000, 4370 Cell 
Signalling Technologies, New England Biolabs,
 
Hertfordshire, UK), rabbit anti-
phospho-p38 (1:500, 9215 Cell Signalling Technologies), FOXO1 (1:1000, 2880 
Cell Signalling Technologies), pTie-2 (1:1000, AF2720 R&D Systems), HIF1α 
(1:500, sc-10790 Santa Cruz) VEGF (1:200, sc-507 Santa Cruz), Tie-1 (1:1000, sc-
342 Santa Cruz), Tie-2 (1:1000, sc-324 Santa Cruz) or Ang-2 (1:1000, AB3121 
Millipore) and β-actin (1:1000, sc-1616 Santa Cruz). After washing in PBS 
containing
 
0.5% Tween, membranes were incubated for 1h at 25
o
C in the dark in 
donkey anti goat IgG conjugated to IRDYE 800 (605-732-125 Tebu-Bio) and donkey 
anti rabbit IgG conjugated to AlexaFluor
 
680 (A10043 Invitrogen) both at a dilution 
of 1:5000 in blocking buffer.
 
Membranes were washed and proteins visualized and 
quantified
 
using an Odyssey Infrared Imaging System (Li-Cor Bioscience, 
Cambridge,
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2.10  RNA knockdown 
RNA knockdown was performed to investigate the importance of various genes in 
the angiogenic cascade. First experiments were carried out to confirm that lentiviral 
delivery would be effective in this cell type and also to establish the conditions 
required for efficient transfection, by culturing granulosa cells that were isolated as 
described above (2.9.1 and 2.9.2) with green fluorescent protein (GFP)-expressing 
lentivirus (see Chapter 6 for details). The efficiency of transfection was then 
determined by culturing granulosa cells with lentivirus containing miRNA for LacZ 
at 1 virus/cell. Granulosa cells were cultured for 48h before being cultured with the 
LacZ-expressing lentivirus for 8h. After 8h the lentivirus was removed and cells 
were fixed in PBS containing 2% formaldehyde and 0.2% gluteraldehyde for 5min at 
room temperature. Cells were washed and then stained with X-gal staining solution 
(23ml 0.5M NaH2PO4, 77ml 0.5M Na2HPO4, 1.06g potassium ferrocyanide, 0.82g 
potassium ferricyanide, 5ml 1% deoxycholate, 5ml 2% NP40, 1ml 1M MgCl2, made 
up to 500ml with dH20; 2ml X-gal added per 100ml staining solution) overnight at 
37
o
C. To assess the efficiency of transfection the total number of cells and total 
number of X-gal stained cells (blue) were counted in 10 random fields of view and 
the averages were used to estimate the transfection efficiency using the calculation: 
 
Total number of blue cells  x 100  = % transfection 
       Total number of cells 
 
 
To determine the level of GFP-expressing cells the total number of cells and total 
number of GFP-expressing cells (green) were counted in 10 random fields of view 
and the averages were used to estimate the percentage of cells expressing GFP. 
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RNA knockdown was performed to investigate the importance of Tie-1, Tie-2 and 
Ang-2 in the angiogenic cascade and follicle health. Transient transfection of 
granulosa cells were performed using microRNA (miRNA) constructs. 
Oligonucleotides encoding miRNA constructs for Tie-1, Tie-2 and Ang-2 were 
obtained from Invitrogen and also designed by the in-house Biomolecular Core 
Facility. The in-house Biomolecular Core Facility then inserted these miRNA 
constructs into a cloning vector, prior to being inserted into GFP-expressing 
lentivirus.  
 
After the initial experiments to determine optimal conditions for efficient 
transfection (see Chapter 6), granulosa cells were isolated as described above (2.9.1 
and 2.9.2) and cultured on tissue culture grade 12-well plastic plates (Corning Inc.) 
which were precoated with 0.5ml donor calf serum (Lonza) and washed twice with 
PBS (0.5 ml) before inoculating with 0.5ml M199 medium containing 0.1% BSA, 2 
mmol L-glutamine, 50µg/ml streptomycin and 50 IU/ml penicillin, containing 1.5 x 
10
5
 cells/ml for 48h before being cultured with the GFP-expressing lentivirus 
containing the miRNA construct at 10 viruses/cell, for 8h. After 8h the lentivirus was 
removed and replaced with fresh medium for 24h. The cells were then treated with 
0.5ml M199 medium containing the compound of interest for 48h before protein or 
RNA was extracted from the cells to allow quantification of expression of genes of 
interest. 
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2.11  Marmoset Tissue 
2.11.1 Marmoset husbandry  
All marmosets were housed in a primate facility located at the R. V. Short Building, 
Bush Estate, Edinburgh. Staff at the centre were responsible for the care and 
maintenance of the animals. Common marmoset monkeys were housed in rooms 




C, which were artificially lit between the hours of 07:00 
and 19:00. The animals were housed in cages measuring 1.15m x 1.1m x 0.6m, 
containing larch branches and a nest box, and the floor was filled with wood 
chippings to allow foraging. 
 
The animals were fed daily with a selection of fruit and SDS Mazuri (E) primate diet 
pellets. In addition, they were given high protein porridge with multivitamin 
supplements three times per week and water was continuously available. Adult 
females with a body weight of approximately 350g, and who had regular ovarian 
cycles based on their progesterone cycling, were housed together with a younger 
sister or prepubertal female, unless otherwise stated.  Blood samples were collected 
three times per week by femoral venepuncture without anaesthesia, while the animals 
were held in a restraining device (Hearn et al., 1978). Syringes were sealed and 





2.11.2 PGF2α-induced luteolysis 
To synchronise follicular development and the stage of the ovarian cycle in the 
marmoset monkey luteolysis was induced in all control and experimental animals by 
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administering 1µg of a prostaglandin PGF2 analogue (cloprostenol, Planate, 
Coopers Animal Health Ltd., Crewe, UK) (Gilchrist et al., 2001). It has been shown 
that a single intramuscular injection of a PGF2 analogue induces luteolysis when 
given after day 8 of the luteal phase (Summers et al., 1985). Therefore the PGF2 
analogue was injected intramuscularly between days 12-16 of the luteal phase, in the 
pre-treatment cycle, and this was designated day zero of the follicular phase. It has 
previously been shown that after luteolysis is induced by administration of PGF2 it 
takes approximately 10 days for dominant follicles to develop to the preovulatory 
stage (Summers et al., 1985). In addition, PGF2 administration is a commonly used 
tool in the investigation of marmoset luteal regression (Summers et al., 1985, Webley 
et al., 1989, Michael and Webley, 1993, Duncan et al., 1998, Fraser et al., 1999). 
 
2.11.3 Treatment regimes 
Experiments were carried out in accordance with the Animals (Scientific Procedures) 
Act, 1986, and approved by the Local Ethical Review Process Committee. 
Administration of treatments was undertaken by staff at the primate centre under the 
supervision of Prof. Hamish Fraser. All experiments were carried out in accordance 
with the Animals (Scientific Procedures) Act, 1986. To synchronise the timing of the 
initiation of follicular development all control and experimental animals were given 
1µg PGF2 analogue as described above. Specific details of the dose, timing and 
duration of treatment can be found in the relevant experimental chapter (Chapter 5). 
One of the parameters used to measure angiogenesis was cell proliferation. In order 
to visualise proliferation bromodeoxyuridine (BrdU; Boehringer Mannheim, Sussex, 
UK) was administered to all animals. BrdU is a thymidine derivative which is 
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incorporated into the DNA of proliferating cells during the S phase of the cell cycle. 
Twenty milligrams, dissolved in 500µl physiological saline, was administered to all 
animals 1h prior to tissue collection. 
 
2.11.4 Collection of tissue 
Animals were sedated with 200µl ketamine hydrochloride (Park-Davis Veterinary, 
Pontypool, UK) intramuscularly, euthanised with a 400µl intravenous injection of 
Euthetal (sodium pentobarbitone, Rhone Merieux, Harlow, Essex, UK) and 
exsanguinated with a needle and syringe. Ovaries were removed immediately, 
weighed, and fixed in 4% NBF for 24h before paraffin wax embedding. 
 
2.11.5 Progesterone radioimmunoassay 
To monitor the marmoset ovulatory cycles plasma concentration was measured three 
times weekly for several cycles prior to use of the animal. Progesterone 
concentrations were also measured during, and post-, treatment. Progesterone 
radioimmunoassay was carried out by the in-house assay lab according to Smith et 
al., (Smith et al., 1990).  
 
2.11.6 ABT-898 ELISA 
The ABT-898 assay was carried out by the in-house assay lab. ABT-898 was 
measured by an ELISA, using biotinylated ABT-898 to capture and an antibody to 
ABT-898 as the reporter. Serum samples were diluted in assay buffer
 
and run against 
standards also prepared in assay buffer. Each
 
dilution level was assayed, and those 
that read on the linear
 
part of the standard curve, in which the samples ran parallel
 
to 
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that of the reference standard, were selected for analysis.
 
If in the initial assay, values 
were below the limit of detection,
 
samples were re-assayed neat and the standards 
spiked with an
 
equivalent volume of mouse serum. Assay sensitivity was 2ng/well, 
and interassay variation based on low-, medium-,
 
and high-quality controls were less 
than 10%. Concentration
 
vs. time curves were constructed from ELISA-generated 
ABT-898
 
values obtained from individual animals. The pharmacokinetic
 
parameter 
estimates were determined by fitting the serum concentration
 
vs. time profile to a 
non-compartmental model (WinNonLin, version
 
2.0, Pharsight Corp., Mountain 
View, CA). 
 
2.11.7 Specific immunohistochemistry techniques in the 
marmoset 
2.11.7.1  Caspase-3 (apoptotic cells) 
Detection of the expression of activated caspase-3 in the marmoset was performed as 
described previously in 2.7.4.1. 
2.11.7.2  Bromodeoxyuridine (BrdU) (proliferating cells) 
5-bromo-2-deoxyuridine (BrdU) is a base analogue of thymidine, one of the bases of 
the nucleic acid found in DNA. Since the 1970s BrdU incorporation has been used as 
a tool for measuring DNA synthesis in cells and tissues and is a common chemical 
used in the detection of proliferating cells (Dolbeare, 1995). BrdU injected into 
animals one hour prior to euthanasia will incorporate into the DNA of cells 
replicating during the interval before euthanasia. Newly synthesised DNA will 
(partly) incorporate BrdU instead of thymidine and this can be visualised by 
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immunohistochemistry. Other endogenous markers of cellular proliferation are 
available, such as proliferating cell nuclear antigen (PCNA) and Ki67, although these 
are often thought of as ‘soft’ markers, as their expression is rarely restricted to a 
specific cell cycle phase, owing to time delays in synthesis and degradation (Rew 
and Wilson, 2000). 
 
After performing antigen retrieval, the slides were washed three times with TBS for 
5min and then blocked in NRS (diluted 1:5 in TBS containing 5% BSA) for 30min. 
The sections were incubated overnight at 4°C with an antibody to BrdU (Boeringer 
Mannheim 1170376) diluted 1:30 in NRS. After three 5min washes with TBS, a 
rabbit anti-mouse secondary antibody was added 1:60 in NRS and incubated for 
40min, followed by mouse APAAP 1:100 in NRS for 40min. Slides were washed 
with TBS and then transferred to NBT buffer (40ml 0.5M MgCl, 40ml 1M Tris/1M 
NaCl, 320ml H2O) for 10min before staining with NBT solution (10ml NBT buffer + 
45l NBT substrate (Boehringer Mannheim) + 35l Xphosphate (Boehringer 
Mannheim) +10l levamisole) for 10-15min. Reactions were stopped in tap water, 
slides were then counterstained in haematoxylin for approximately 10 seconds before 
being air dried, cleared in xylene and mounted using Pertex. 
2.11.7.3  CD31 (endothelial cells) 
After performing antigen retrieval, the slides were washed three times with TBS for 
5min and then blocked in NRS for 30min. The sections were incubated overnight at 
4°C with an antibody to CD31 antibody (Dako M0823) diluted 1:20 in NRS. After 
three 5min washes with TBS, a rabbit anti-mouse secondary antibody was added 
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1:60 in NRS and incubated for 40min, followed by mouse APAAP 1:100 in NRS for 
40min. Slides were washed with TBS and then staining was detected using fast red in 
solution at 1mg/ml in fast red buffer (20mg naphol AS-MX phosphate, 2ml dimethyl 
formamide to 98ml 0.1M tris, pH 8.2) and left for approximately 20-30min until a 
red colour developed.  Reactions were stopped in tap water. Slides were air dried 
before being cleared in xylene and mounted in Pertex 
2.11.7.4  BrdU/ CD31 Co-localisation  
To allow the detection of two antigens on the same slide, two separate detection 
systems were used. For the purposes of this thesis, it was required that BrdU and 
CD31 were dual stained. The antibodies used were raised in different species, sheep 
and mouse respectively, ensuring that no cross reactivity occurs. The secondary 
antibody to be used for both antibodies was raised in rabbit. Thus the blocking serum 
is the same for both antibodies, in this case NRS.  
 
After performing antigen retrieval, the slides were washed three times with TBS for 
5min and then blocked in NRS for 30min. The sections were incubated overnight at 
4°C with an antibody to CD31 diluted 1:20 in NRS. After three 5min washes with 
TBS, a rabbit anti-mouse secondary antibody was added 1:60 in NRS and incubated 
for 40min, followed by mouse APAAP 1:100 in NRS for 40min. Slides were washed 
with TBS and then staining was detected using fast red as per the CD31 protocol 
described above (2.11.7.3) 
 
Sections were then washed and Sequenzas flushed through with TBS before 
performing a Streptavidin block for 15min, followed by TBS washes and a Biotin 
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block for 15min. Slides were washed with TBS before the sheep BrdU primary 
antibody (Fitzgerald Industries international, Concord, MA, USA) was added, diluted 
to 1:5000 in NRS and incubated overnight at 4C. After three 5min washes with 
TBS, a rabbit anti-sheep biotinylated secondary antibody was added 1:500 in NRS 
and incubated for 40min, followed by TBS washes and then mouse ABC-AP (Dako 
K0376; 5ml Tris-buffer, 1 drop of bottle A and 1 drop bottle B) for 30min. Slides 
were then washed and transferred to NBT buffer  for 10min before staining with 
NBT solution for 10-15min. Reactions were stopped in tap water, slides were then 
counterstained in haematoxylin for approximately 10 seconds before being air dried, 
cleared in xylene and mounted using Pertex. 
2.11.7.5  Tie-2 
Detection of the expression of Tie-2 in the marmoset was performed as described 
previously in 2.7.4.2. 
 
2.11.8  Image Analysis 
2.11.8.1  Caspase-3  
The total area of caspase-3 staining in the granulosa cell layer of each follicle was 
determined using Image Pro Plus software (Media Cybernetics). For each follicle, the 
section containing the oocyte with a nucleus present was used for quantification of 
staining. The cross-sectional area of staining for activated caspase-3 was calculated 
as a proportion of total cross-sectional area of granulosa cells within each follicle.  
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2.11.8.2  Tie-2 
The expression of Tie-2 was analysed manually at x40 magnification using a tally 
counter. Expression was determined in the granulosa and thecal layers of preantral, 
early antral and mid-antral follicles with the intensity of Tie-2 expression being 
classified in each follicle using a visual scoring system (1=weak; 2=moderate; 
3=strong staining). The percentage of follicles at each intensity was then calculated 
for each follicle stage and expressed as a mean HSCORE value (Budwit-Novotny et 
al., 1986). HSCORE is a semiquantitative analysis that has been shown to have low 
intra- and inter-observer error (Lessey et al., 2000). Only those follicles with a 
visible oocyte containing a nucleus were considered to ensure proper follicular 
classification. 
2.11.8.3  BrdU 
Sections were analysed under x40 magnification and quantified using Image ProPlus 
software (Media Cybernetics). The image analysis software was set up to analyse the 
number of BrdU positive cells and the total number of cells in the outlined cellular 
compartment of interest. This was done for both the thecal layer and granulosa cells. 
The proliferation index is expressed as the percentage of cells proliferating from the 
total number of cells in that compartment. Calculated for the granulosa and thecal 
compartments separately, the proliferation index is expressed as a mean value for 
each follicular stage.  
2.11.8.4  CD31 
The endothelial cell area was measured at x40 magnification and quantified using 
Image ProPlus software (Media Cybernetics). The whole area of the thecal 
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compartment and the CD31 positive area were measured, and the CD31 positive area 
was calculated per unit area of the thecal compartment. It is expressed as a mean 
value for each follicular stage.  
2.11.8.5  BrdU/CD31 Co-localisation 
Dual-stained follicles were analysed manually at x40 magnification using a tally 
counter. The number of dual-stained cells (both BrdU and CD31 positive cells) and 
the total number of proliferating cells (BrdU positive cells) were counted in the 
thecal compartment. The proportion of dual-stained cells of proliferating endothelial 
cells (dual-stained cells) is expressed as a percentage of the total number of 
proliferating cells. The mean value was calculated for the number of follicles 
assessed within each follicular class and per animal. Non-endothelial cell 
proliferation was calculated by multiplying the total thecal proliferation index (BrdU 
index) by the percentage of proliferation that was not endothelial (not dual stained, 
BrdU positive cells on a dual stained slide), per follicle class per animal. 
 
2.12  Statistical analysis 
Data are presented as mean ± SEM. Results were analysed statistically by means of a 
one-way ANOVA. Although an ANOVA was chosen for the majority of the results it 
would have been possible to perform multiple t-tests to compare the different 
experimental groups but this could introduce errors and an ANOVA is a more 
powerful technique in complex analyses and allows easier interpretation of the 
results. An ANOVA uses an F-ratio to determine the statistical significance of the 
results and if a significant F-value is returned this can be followed up with post-hoc 
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tests to assess which groups are different from each other. In this thesis a statistically 
significant ANOVA was followed by a Bonferroni post-hoc test using Graph Pad 
Prism 5 software (Graph Pad Software, Inc. San Diego, CA) to determine 
significance between all of the experimental groups. For the results on change in 
follicle size (Fig 3.1, Fig 3.3) the results were analysed using paired two-tailed t-tests 
as only two groups were compared at a time and the results for Fig 5.4, Fig 5.5. Fig 
5.6 were analysed by using unpaired two-tailed t-tests as the ovaries either came 
from control or treated animals. For the progesterone results (Fig 5.3), the post-
treatment period data were subjected to statistical analysis and this was based on the 
duration of the normal luteal phase. This was achieved by comparing the area under 
the curve for pre-treatment and post-treatment cycles. P values <0.05 were accepted 
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3 Chapter 3 Development of a Novel in vitro Angiogenesis 
Assay 
3.1 Introduction 
Angiogenesis is the formation of new blood vessels from existing blood vessels. It is 
rare in the healthy adult, except in the female reproductive tract, where angiogenesis 
occurs in a cyclical manner. Angiogenesis plays an important role in many 
pathological conditions including cancer, coronary artery disease, polycystic ovary 
syndrome and endometriosis and is therefore an area of great interest and much 
research is carried out in this field.  
 
There are many models available to investigate angiogenesis, including both in vitro 
and in vivo systems. In vitro systems commonly used to investigate angiogenesis 
include the rat aortic ring assay, the chick aortic arch assay, the mouse metatarsal 
assay and human umbilical vein endothelial cell (HUVEC) bead assays (Nehls and 
Drenckhahn, 1995a, Nehls and Drenckhahn, 1995b, Auerbach et al., 2000, Auerbach 
et al., 2003, Staton et al., 2004, Goodwin, 2007, Nakatsu and Hughes, 2008), and 
whilst all of these methods have enhanced the understanding of angiogenesis and of 
the mechanisms involved in it, they also have limitations.  
 
Angiogenesis is primarily microvascular event so the use of large vessels, such as in 
the rat aortic ring assay, the chick aortic arch assay and HUVEC bead assays is not 
truly representative of in vivo angiogenesis. The use of tissues that have been 
obtained from growing embryos is also not representative of physiological 
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angiogenesis as the cells are undergoing rapid cell division and proliferation, before 
explantation. Therefore the vessel outgrowth seen is not representative of the 
stimulation of angiogenesis from non-proliferative endothelial cells (Staton et al., 
2004, Goodwin, 2007). In addition, these assays are time consuming – often taking 
up to 2 weeks to provide results (Auerbach et al., 2000, Auerbach et al., 2003, Staton 
et al., 2004, Goodwin, 2007) and many are limited by variability of the tissues used, 
making it necessary to use large numbers to achieve significance.  
 
There are also many in vivo angiogenesis models used in current research and these 
are more representative of the stimulation of angiogenesis under normal in vivo 
conditions. However, they are limited by numerous challenges due to the complexity 
of the system used and the need to reduce the use of live animals in scientific 
research.  
 
Of the many factors involved in the regulation of angiogenesis, vascular endothelial 
growth factor (VEGF) is considered to be the key factor involved in stimulating 
angiogenesis. Various studies have highlighted the role of VEGF in ovarian 
physiology by demonstrating its essential role in follicular development, as well as 
its impact upon angiogenesis (Geva and Jaffe, 2000, Danforth et al., 2003, 
Zimmermann et al., 2003, Abramovich et al., 2006). In addition, the observation that 
VEGF is up-regulated in many pathological conditions (Krasnow et al., 1996, 
Agrawal et al., 1998b) has led to the proposed use of anti-VEGF treatments, such as 
Aflibercept (VEGF Trap), to inhibit pathological angiogenesis (Strawn et al., 1996, 
Presta et al., 1997, Taylor et al., 2007). Indeed, investigation regarding the use of 
Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 3 Development of a Novel in vitro Angiogenesis Assay 96 
Aflibercept in cancer treatment is already underway (Ferrara et al., 2007). With these 
facts in mind, Aflibercept (VEGF Trap) presents an ideal ‘gold standard’ molecule to 
investigate in vitro. 
 
Aflibercept is a soluble VEGF receptor fusion protein with anti-angiogenic actions 
mediated by the inhibition of the pro-angiogenic factor VEGF. This inhibition is 
achieved by direct binding to VEGF, rendering it unable to act via its receptors 
VEGFR-1 (KDR) and VEGFR-2 (Flt-1) (Fraser, 2006). These receptors mediate the 
pro-angiogenic effects of VEGF via actions on endothelial cell proliferation (Ferrara 
and Davis-Smyth, 1997, Pandya et al., 2006) and a possible role in immature vessel 
survival (Folkman, 2004). However, Aflibercept is a high molecular weight protein 
and it may be that its size restricts its accessibility in vitro and in vivo so for this 
reason the action of a small molecule tyrosine kinase inhibitors of VEGF, ZM323881 
(Whittles et al., 2002) will also be examined. ZM323881 selectively inhibits 
VEGFR-2, a range of other tyrosine kinases. It also inhibits VEGF-A induced 
endothelial cell proliferation, in vitro (Whittles et al., 2002).  
 
Overall these factors show that the development of a novel in vitro angiogenesis 
assay, that would be representative of in vivo angiogenesis, be easily reproducible 
and provide a method for mechanistic studies would be a valuable tool in 
angiogenesis research. As angiogenesis occurs in a cyclical manner in the female 
reproductive tract and as, to our knowledge, no system exists for the manipulation 
and assessment of follicular angiogenesis in an in vitro setting, it was suggested that 
the ovary would be an ideal tissue for investigation into angiogenesis. In fact, the 
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female reproductive system is unique as no other healthy adult tissues undergo 
spontaneous angiogenesis. The tissues in ovarian follicles recruit blood vessels from 
the ovarian stroma at the preantral stage of development, to form vascular sheaths in 
the thecal layer and, as this process occurs naturally, it was proposed that the 
angiogenic properties of ovarian follicles could be utilised to provide a novel 
angiogenesis assay. Therefore, in this chapter an in vitro angiogenesis assay has been 
developed and optimised using the culture of intact isolated pre- and early antral rat 
follicles, to provide a new approach to the study of follicular angiogenesis. 
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3.2 Materials and Methods 
3.2.1 Follicle culture 
For all experiments, preantral/early antral follicles were cultured individually in flat-
bottomed 12-well plates, embedded in the centre of a 20µl droplet of growth-factor 
reduced Matrigel. The Matrigel provides a three-dimensional extracellular matrix 
support for follicle growth and allows the vascular outgrowths to develop in three-
dimensions, as they would in vivo. Follicles were incubated for 6 days in a sterile 
humidified air atmosphere with 5% CO2 at 37°C in 600µl serum-free medium, with 
culture medium refreshed every 48h.  
 
To optimise this assay, a variety of media and media supplements were tested to 
investigate which were best for follicle health but also best for the development of 
angiogenic outgrowths.  
 
In order to test the efficacy of the assay, the known angiogenesis inhibitor 
Aflibercept (Regeneron Pharmaceuticals, NY, USA) was used. Aflibercept is a 
soluble decoy receptor created by fusing the extracellular domains of the human 
VEGF receptors (VEGFR-1 and -2) to the Fc portion of a human immunoglobulin. 
The incorporation of the Fc domain results in homodimerisation of the recombinant 
protein, creating a high affinity Aflibercept (Holash et al., 2002).  Follicles were 
randomly placed into groups of 6 and cultured in control medium or in the presence 
of 1, 10, or 100µg/ml Aflibercept. Medium containing the Fc portion of human 
immunoglobulin (Regeneron) at 100µg/ml was used as the control.  
 
Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 3 Development of a Novel in vitro Angiogenesis Assay 99 
To investigate whether the small molecule ZM323881 (Tocris Bioscience, Bristol, 
UK) would have greater efficacy than the larger molecule Aflibercept follicles were 
randomly placed into groups of 12 and cultured in control medium or in the presence 
of 10, 100, or 1000nM ZM323881.  
 
3.2.2 Immunohistochemistry 
To confirm the endothelial nature of the angiogenic sprouting, a sample of follicles 
was analysed for labelling for Dil-Ac-LDL, CD31, αSMA and also dual stained for 
CD31 and αSMA (see Chapter 2). Staining was detected using confocal microscopy 
at 488nm and 568nm. 
 
3.2.3 Activated caspase-3 immunohistochemistry 
 To determine the localization and changes in the number of dying cells, a rabbit 
antibody to activated caspase-3 was used on sections from fixed follicle slides. The 
sections were incubated overnight at 4°C with activated caspase-3 antibody (1:100 in 
NGS) and visualization was achieved by 3-3‘-diaminobenzidine (DAB) Substrate 
(see Chapter 2). 
 
3.2.4 Granulosa Cell Experiments 
3.2.4.1 Isolation and culture of granulosa cells 
To investigate whether Aflibercept can induce apoptosis in granulosa cells directly, 
isolated granulosa cells were cultured in 0.1ml M199 medium containing 1 x 10
4
 
cells/well. Following overnight preincubation in a sterile humidified air atmosphere 
with 5 % CO2 at 37°C, prewarmed 0.1ml medium containing with 0, 1, 10 or 100 
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µg/ml Aflibercept was added to each well for 48h. This potential effect was also 
investigated after treatment with 0, 10, 100 or 1000nM ZM323881. Treatments were 
carried out in triplicate and experiments were repeated three times. 
3.2.4.2 Caspase-3 and -7 activity assay 
To measure caspase-3 and -7 activities in isolated granulosa cells, the Caspase-Glo 
3/7 assay was
 
performed according to the manufacturer’s instructions, 48h after 
treating the cells (see Chapter 2). Treatments were carried out in triplicate and 




As serum can generate a background caspase activity signal,
 
an additional 
two wells contained cell culture medium and carrier
 
solution without any cells and 
TNFα was used as a positive control. 
 
3.2.5 Quantification 
3.2.5.1 Analysis of Angiogenic Sprouting 
To assess the impact of the treatments on angiogenic sprouting, follicles were 
examined and photographed directly in the 12-well plates under an inverted light 
microscope, at x10 magnification, with Axiovision image capturing software on days 
0 and 6 of the culture period. The total area of angiogenic sprouting for each follicle 
was determined using Image Pro Plus software, by drawing an area of interest around 
the outgrowths (but excluding the follicle) and the sum of the area of all sprouts was 
measured and calculated by the software. The mean area of angiogenic sprouting for 
each treatment was then compared to the control.  
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3.2.5.2 Analysis of immunohistochemistry 
The total area of caspase-3 staining in the granulosa cell layer of each follicle was 
determined using Image Pro Plus software. For each follicle, the section containing 
the oocyte with a nucleus present was used for quantification of staining. The cross-
sectional area of staining for activated caspase-3 was calculated as a proportion of 
total cross-sectional area of granulosa cells within each follicle.  
 
3.2.6 Statistical Analyses 
Data are presented as mean ± SEM and all results were analysed statistically using 
Graph Pad Prism 5 software (Graph Pad Software). Figures 3.1 and 3.3 were 
analysed by paired two-tailed t-tests with a 95% confidence interval to compare the 
day 0 data with day 6 data and significance is indicated by *. The other results were 
analysed by means of a One-way ANOVA with a Bonferroni post-hoc test performed 
if the 95% confidence interval was reached to determine significance between all of 
the data groups. P values <0.05 were accepted as statistically significant. 
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3.3 Results 
Throughout this study ovaries from the 21-day-old rats used for the angiogenesis 
assay were fixed, sectioned and stained for both haematoxylin and eosin and 
activated caspase-3. The ovaries contained large numbers of pre- and early antral 
follicles and very little staining for activated caspase-3 was visible.  
 
3.3.1 Optimisation of Medium 
To develop and optimise an in vitro angiogenesis assay intact pre- and early antral rat 
follicles were isolated from 21-day-old Wistar rats and cultured for six days in 
various types of medium, containing a variety of supplements. Previous preliminary 
experiments (unpublished data) had been carried out and in these experiments 
follicles were cultured in endothelial basal medium (EBM)-2 supplemented with 
BSA, heparin and GA-1000 – the Basic control. Follicles cultured in this medium 
were not optimally healthy and had few angiogenic outgrowths, despite the system 
being intended to produce outgrowths.  
 
To optimise this assay improvement in the health of the follicles and production of 
an increased number of angiogenic outgrowths was required. Although other types of 
media are usually used for follicle culture, EBM-2 medium has been shown to be 
important for the development of angiogenic outgrowths and is often used for human 
umbilical vein endothelial cell (HUVEC) network assays (Bishop et al., 1999, 
Albaugh et al., 2001, Kawai et al., 2007, Ye and Yuan, 2007). Therefore follicles 
were cultured in EBM-2 medium with various types of supplements to determine 
which would provide the best conditions for the assay.  
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Follicles were cultured in the Basic control (n=12) (as described above), in EBM-2 
medium supplemented with BSA (0.1%), L-glutamine (3mM), penicillin (100 
IU/ml), streptomycin (0.1 mg/ml), and L-ascorbic acid sodium salt (50 µg/ml) 
(Thomas 2001) – the Supplemented control (n=8). Follicles were also cultured in the 
supplemented control treated with insulin (10.0ng/ml), transferrin (2.5µg/ml) and 
selenium (4.0ng/ml) (ITS) (n=8) or VEGF (n=9) and then analysed for follicle health 
and development of angiogenic outgrowths. ITS was added to the culture medium as 
previous experiments have shown that these factors support follicle growth in vitro 
(Wright et al., 1999, Jeong et al., 2008). In addition, it has been used in in vitro 
maturation systems as it can improve oocyte health and growth (De La Fuente et al., 
1999, Gardner et al., 2001, Herrick et al., 2004). We found that follicles cultured in 
the supplemented control treated with ITS were healthier than follicles cultured in 
other types of media and also produced more angiogenic outgrowths. Therefore it 
was decided that for future experiments, follicles would be cultured in EBM-2 
medium supplemented with BSA (0.1%), L-glutamine (3mM), penicillin (100 
IU/ml), streptomycin (0.1 mg/ml), L-ascorbic acid sodium salt (50 µg/ml) and insulin 
(10.0ng/ml), transferrin (2.5µg/ml) and selenium (4.0ng/ml) (ITS). 
 
As EBM-2 has been found to be important for the development of outgrowths but is 
not ideal for follicle health, different types of media that are commonly used for 
follicle culture were also investigated to establish whether it is possible for follicles 
to develop angiogenic outgrowths in these types of medium. Follicles were cultured 
in M199 medium, McCoys medium, EBM2 treated with Activin A and McCoys 
treated with Activin A, all treated with BSA (0.1%), L-glutamine (3mM), penicillin 
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(100 IU/ml), streptomycin (0.1 mg/ml), and L-ascorbic acid sodium salt (50 µg/ml) 
and ITS. Activin A was investigated at a concentration of 100ng/ml as it has been 
shown to improve follicle and oocyte health in cultures (Telfer et al., 2008). 
 
3.3.2 Determination of follicle health 
One of the indicators of follicle health in culture is an increase in size over the 
culture period and this was investigated by culturing follicles in EBM-2 medium 
with a variety of supplements to determine the optimum conditions for follicle 
health. Follicles were cultured for six-days and they were measured at the start and 
end of the culture period so that the change in follicle size could be monitored. 
Follicle size on day 0, for the different treatment groups, was analysed using a One-
way ANOVA with a Bonferroni post-hoc test to determine any statistical difference 
in the initial follicle size and no difference was found (results not shown). Follicles 
cultured in the basic control, the supplemented control and the supplemented control 
treated with VEGF showed no significant increase in size. However, follicles 
cultured in the supplemented control treated with ITS showed a significant increase 
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Figure 3.1 The change in follicle size over the 6-day culture period, for the different 
media treatments 
Isolated preantral and early antral follicles were cultured in EBM2 media treated with a 
variety of supplements including vascular endothelial growth factor (VEGF) and insulin, 
transferring and selenium (ITS) (n=6 per treatment) to determine optimum conditions for 
follicle culture. The size of the follicles before and after the culture was measured using 
Image Pro-Plus software as an indicator of follicle health. These data were analysed and 
compared using paired two-tailed t-tests to determine any significance between the day 0 
and day 6 results. This showed that follicles cultured in the supplemented control +ITS 




To further investigate follicle health, follicles were fixed, sectioned and stained for 
activated caspase-3. Follicles cultured in the supplemented control treated with ITS 
had lower levels of staining for activated caspase-3 than follicles in the other groups, 
although levels of staining were similar to those seen in the basic control (Figure 
3.2), further suggesting that the addition of ITS to the media improves the health of 
cultured follicles. 
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Figure 3.2 The change in levels of staining for activated caspase-3 for the different 
media treatments 
Isolated preantral and early antral follicles were cultured in EBM2 media treated with a 
variety of supplements including vascular endothelial growth factor (VEGF) and insulin, 
transferring and selenium (ITS) (n=6 per treatment) and at the end of culture these follicles 
were fixed, sectioned and stained for activated caspase-3 to determine the level of apoptosis 
in these follicles, as an indicator of follicle health. These data were analysed using a One-
way ANOVA to compare all the different treatment groups to the Basic Control. A difference 
between the treatment groups was apparent but it was not statistically significant. 
Experiments were repeated in triplicate. 
 
 
Different types of media have different compositions and are designed to support 
different cell types, therefore follicles were also cultured in various types of basal 
media to determine if a specific medium would be more beneficial for the health and 
growth of the isolated follicles. Follicle size on day 0, for the different treatment 
groups, was analysed using a One-way ANOVA with a Bonferroni post-hoc test to 
determine any statistical difference in the initial follicle size (results not shown) and 
there was a small difference in initial follicle size in the different groups. This 
difference in initial follicle size could be due to the follicles being at different stages 
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of development as both pre-antral and early antral follicles were isolated and pooled 
before being cultured. As both stages of follicles could have been used in this 
experiment this may have affected the final size of the different follicles, however, 
the follicle size on day 6 is directly compared to that of the same follicle on day 0 
and it is the change in follicle size during culture, not the actual follicle size, which 
was used when comparing the different treatment groups. It could still have been 
possible that different sized follicles at the start would grow differently in the various 
media investigated, but as it was found that all follicles increased in size when 
cultured in specific media, it suggests that this did not affect the results or 
conclusions in any major way. Follicles cultured in McCoys medium, EBM2 
medium and M199 medium showed a significant increase in follicle size over the 
culture period, whereas follicles cultured in McCoys medium with Activin A and 
EBM2 medium with Activin A showed no significant change in follicle size (Figure 
3.3). In addition, these follicles were fixed, sectioned and stained for activated 
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Figure 3.3 The change in follicle size over the 6-day culture period, for the different 
media types 
Isolated preantral and early antral follicles were cultured in a variety of media including 
traditional follicle culture media (McCoys and M199) as well as media used for vascular 
cell culture (EBM2) (n=6 per treatment) to determine the optimum media for this assay. The 
size of the follicles before and after the culture was measured as an indicator of follicle 
health. These data were analysed and compared using paired two-tailed t-tests to determine 
any significance between the day 0 and day 6 results. This showed that follicles cultured in 
EBM2 medium, McCoys medium and M199 medium significantly increased in size 
(*P<0.05) over the six days. Experiments were repeated in triplicate. 
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Figure 3.4 The change in levels of staining for activated caspase-3 for the different 
media types 
Isolated preantral and early antral follicles were cultured in a variety of basal media 
including traditional follicle culture media (McCoys and M199) as well as media used for 
vascular cell culture (EBM2) (n=6 per treatment) and at the end of culture these follicles 
were fixed, sectioned and stained for activated caspase-3 to determine the level of apoptosis 
in these follicles, as an indicator of follicle health. These results were analysed statistically 
using a One-way ANOVA with a Bonferroni post-hoc test to compare all treatment groups to 
EBM2. Follicles cultured in EBM2 medium, McCoys medium, McCoys medium with Activin 
A (McCoys AA) and M199 medium had low levels of staining for activated caspase-3, 
indicating that follicles cultured in these types of media were healthy. Follicles cultured in 
EBM2 medium with Activin A (EBM2 AA) had significantly (***P<0.001) higher levels of 
staining for activated caspase-3 than the EBM2 cultured follicles, suggesting that these 
follicles were atretic. Experiments were repeated in triplicate. 
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3.3.3 Establishment of angiogenesis  
These studies showed for the first time that follicles in culture develop angiogenic 
outgrowths and that follicles cultured in the supplemented control treated with ITS 
produced more angiogenic outgrowths compared to follicles cultured in the basic 
control, the supplemented control and in the supplemented control treated with 
VEGF (Figure 3.5). Due to the variability between follicles this result was not 
significant but a clear trend was observed. It was anticipated that these vessels would 
grow from the cultured follicles as the thecal layer is already vascularised in the 
stages of follicles cultured in this assay and therefore blood vessels would be present 
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Figure 3.5 The change in angiogenic outgrowth area over the 6-day culture period, for 
the different media treatments  
Isolated preantral and early antral follicles were cultured in EBM2 media treated with a 
variety of supplements including vascular endothelial growth factor (VEGF) and insulin, 
transferring and selenium (ITS) (n=6 per treatment) to determine optimum conditions for 
follicle culture. At the end of the culture period the area of the angiogenic outgrowths was 
measured using Image Pro-Plus software. Representative images show follicles cultured in 
the basic control (A) and the supplemented control treated with ITS (B). The results were 
quantified (C) and analysed statistically using a One-way ANOVA to compare the 
differences between the different media treatments and the Basic Control. Follicles cultured 
with ITS were observed to have a higher area of angiogenic outgrowths but due to 
variability of size between the follicles the results were not significant, although a clear 
trend can be seen. Scale bars represent 100µm. Experiments were repeated in triplicate. 
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EBM2 medium has been found to be important for the development of angiogenic 
outgrowths but is not ideal for follicle health. The question of whether other types of 
media would allow the development of outgrowths was therefore investigated. The 
different types of basal media have different nutritional composition and therefore 
some types of media are more suitable for certain cell types than others. Follicles 
cultured in EBM2 medium produced significantly more angiogenic outgrowths than 
follicles cultured in McCoys medium, McCoys medium with Activin A and in M199 
medium and a clear trend in decreasing angiogenesis can also be seen for follicles 
cultured in the other types of media (Figure 3.6).  
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Figure 3.6 The change in angiogenic outgrowth area over the 6-day culture period, for 
the different media types 
Isolated preantral and early antral follicles were cultured in a variety of media including 
traditional follicle culture media ((McCoys and M199) as well as media used for vascular 
cell culture (EBM2) (n=6 per treatment) to determine the optimum media for this assay. At 
the end of the culture period the area of the angiogenic outgrowths was measured using 
Image Pro-Plus software. Representative images show follicles cultured in EBM2 medium 
(A), EBM2 medium plus Activin A (EBM2 AA) (B), McCoys medium (C), McCoys medium 
plus Activin A (McCoys AA) (D) and M199 medium (E). The results were analysed 
statistically using a One-way ANOVA with a Bonferroni post-hoc test to compare the 
differences between the treated follicles and the EBM2-cultured follicles (F). Follicles 
cultured in EBM2 medium produced significantly (*P<0.05) more angiogenic outgrowths 
than did follicles cultured in McCoys medium, McCoys AA or M199 medium. White arrows 
indicate the endothelial outgrowths. Scale bars represent 200µm.Experiments were repeated 
in triplicate. 
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From these results it was decided that follicles cultured in EBM2 medium 
supplemented with BSA (0.1%), L-glutamine (3mM), penicillin (100 IU/ml), 
streptomycin (0.1 mg/ml), and L-ascorbic acid sodium salt (50 µg/ml) and ITS 
produced significantly more angiogenic outgrowths than follicles cultured in a 
variety of other types of media and were as healthy as follicles cultured in McCoys 
medium, which is routinely used for follicle culture, so it was decided that this would 
be the optimal medium to use for the in vitro angiogenesis assay.  
 
3.3.4 Characterisation of vascular outgrowths  
To establish whether angiogenesis occurred in our novel in vitro system, follicles 
were cultured for 6 days in serum-free EBM-2 medium. Follicles were photographed 
at the start and end of the culture period and the day 6 images were compared to the 
day 0 images.  In Fig 1, representative images of a late preantral/early antral follicle 
at day 0 (Figure 3.7A) and day 6 (Figure 3.7B) of the culture period are shown.  
Follicles displayed angiogenic sprouting during the culture period (Figure 3.7B).  
Once it had been established that angiogenesis was occurring in the in vitro system, 
follicles were treated with endothelial cell markers to confirm that the cells were 
endothelial in nature. First, follicles were treated with the fluorescent endothelial cell 
marker Dil-Ac-LDL (20µg/ml, Serotec, Oxford, UK) (Voyta et al., 1984) on day 4 
and the results were visualized on day 6, using fluorescence microscopy. Dil-Ac-
LDL is a fluorescent-labelled acetylated low-density lipoprotein that is taken up via 
the “scavenger” metabolic pathway and is also be known as Dii-Ac-LDL. Dil-Ac-
LDL is a commonly used and widely accepted method for the detection of 
endothelial cells (Voyta et al., 1984, Jimenez et al., 2000, Nor et al., 2000, Tong et 
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al., 2006, Werner et al., 2008, Burciaga-Nava et al., 2009, Janic et al., 2010, Szoke et 
al., 2011) and it has several advantages over labelling with other endothelial cell 
markers. Once the Dil-Ac-LDL is degraded by the lysosomal enzymes the fluorescent 
label, Dil, is internalized and accumulates in the intracellular membranes rendering 
them fluorescent. Scavenger receptors are a specific property of endothelial cells but 
not an exclusive one as they are also on macrophages; despite this Dil-Ac-LDL is 
one of the most specific endothelial cell markers available (Okaji et al., 2004). In our 
system Dil-Ac-LDL should specifically stain endothelial cells as macrophages which 
are not present in our system. Dil-Ac-LDL is able to identify endothelial cells from 
complex cell cultures as the most common contaminants in endothelial cell cultures 
(such as fibroblasts, smooth muscle cells, pericytes and epithelial cells) are not 
labelled by it. 
 
 In addition, control follicles were fixed at the end of culture and were stained for 
CD31, CD34 or αSMA to further identify the nature of the outgrowths. Dil-Ac-LDL 
was incorporated into the outgrowths (Figure 3.7C), and the vessels were stained for 
CD31 (Figure 3.7D and F), CD34 (Figure 3.7E) αSMA (Figure 3.7G) or CD31 and 
αSMA (Figure 3.7H), showing that the outgrowths are endothelial in nature and 
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Figure 3.7 Establishment of angiogenesis in vitro  
Isolated preantral and early antral follicles were cultured and then fixed and stained by 
wholemount IHC to determine the cellular nature of the outgrowths. Representative images 
show a late preantral/early antral follicle on the first day of culture (A) and a follicle at the 
end of culture with vascular outgrowths (B). Vascular outgrowths were characterized by 
uptake of Dil-Ac-LDL (C). In addition, representative images of the outgrowths at higher 
magnification are shown labelled with CD31 (D) and CD34 (E). Dual labelling of 
outgrowths with CD31 and αSMA was also performed, and the dual fluorescence image has 
been separated into the individual channels to show CD31 (F) and αSMA (G) labelling. The 
CD31 labelling (red) is overlaid by the αSMA labelling (green) in (H). Arrows indicate the 
endothelial outgrowths and labelling for CD31, CD34 and Dil-Ac-LDL. Arrowheads 
indicate labelling with αSMA. Scale bars in A-C represent 200µm and in D-H represent 
100µm. 
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3.3.5 Effect of Aflibercept on angiogenesis 
Once the medium had been optimised and the endothelial nature of the vessels 
confirmed, this culture system was employed to investigate the effect of various pro- 
and anti-angiogenic compounds. As Aflibercept is an established angiogenesis 
inhibitor it was used to establish the efficacy of this culture system and it was 
expected that Aflibercept would inhibit follicular angiogenesis. Preantral and early 
antral follicles (n=6 per treatment) were cultured in serum-free EBM2 medium (as 
described above) treated with control medium containing 100µg/ml Fc or with 1, 10 
or 100µg/ml Aflibercept for 6 days. This resulted in a dramatic and significant 
reduction in follicular angiogenesis, in a dose dependent manner (Figure 3.8) 
(P<0.01). 
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Figure 3.8 Effect of Aflibercept on angiogenesis  
To determine the effect of Aflibercept on angiogenesis in this assay, isolated preantral and 
early antral follicles were cultured with varying doses of Aflibercept (n=6 per treatment). At 
the end of the culture period the area of the angiogenic outgrowths was measured using 
Image Pro-Plus software. Representative images show a control follicle (A) and follicles 
after treatment with Aflibercept at 1g/ml (B), 10g/ml (C), or 100g/ml (D). Results were 
analysed statistically using a One-way ANOVA with a Bonferroni post-hoc test to compare 
the Aflibercept treated follicles to the control follicles. Treatment with Aflibercept resulted in 
a significant dose-dependent decrease in outgrowth area (E). ** indicates P<0.01, *** 
indicates P<0.001, in comparison with Fc Control. White arrows indicate the endothelial 
outgrowths. Scale bars represent 200µm. Experiments were repeated in triplicate. 
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3.3.6 Effect of Aflibercept on follicular apoptosis 
In addition, the effect of Aflibercept on follicular apoptosis was investigated to 
establish whether it affects follicle health as well as inhibiting follicular 
angiogenesis. This was investigated by culturing isolated granulosa cells with 0, 1, 
10 or 100µg/ml Aflibercept for 48h followed by quantification of apoptosis using a 
luminescent caspase-3/7 assay (see Chapter 2). There was no difference in levels of 
activated caspase-3/7 activity in granulosa cells treated with increasing doses of 
Aflibercept (Figure 3.9), showing that Aflibercept does not induce apoptosis.  
 


































Figure 3.9 Effect of Aflibercept on granulosa cell apoptosis  
To determine the effect of Aflibercept on apoptosis in this assay granulosa cells were 
isolated from preantral and early antral follicles and they were cultured with varying doses 
of Aflibercept (n=6 per treatment). At the end of the culture period these granulosa cells 
were analysed for expression of activated caspase-3/7 activity using a luminescent caspase 
activity assay, as an indicator of follicle health. A One-way ANOVA was performed on the 
results to determine any significance between the Aflibercept treated follicles and the control 
follicles and there was no significant difference in the levels of expression of activated 
caspase-3/7. Luminescence is given in arbitrary units (au). Experiments were repeated in 
triplicate. 
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3.3.7 Effect of a VEGFR2 antagonist, ZM323881, on angiogenesis 
Aflibercept is a large molecule and it is conceivable that smaller molecules could 
have greater efficacy, being able to access tissues more readily than Aflibercept. A 
potent small molecule antagonist of the VEGFR2, ZM323881, was selected to 
investigate its effects on angiogenesis. 
 
Preantral and early antral follicles (n=12 per treatment) were cultured in serum-free 
EBM2 medium treated with 0, 10, 100, or 1000nM ZM323881 for 6 days. This 
resulted in a significant decrease in follicular angiogenesis in a dose dependent 
manner (Figure 3.10) (P<0.001).  
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Figure 3.10 Effect of ZM323881 on angiogenesis  
To determine the effect of ZM323881, a VEGFR2 antagonist, on angiogenesis, isolated 
preantral and early antral follicles were cultured with varying doses of ZM323881 (n=12 
per treatment). At the end of the culture period the area of the angiogenic outgrowths was 
measured using Image Pro-Plus software. Representative images show a control follicle (A) 
and follicles after treatment with ZM323881 at 10 (B), 100 (C), or 1000nM (D). The results 
were analysed statistically using a One-way ANOVA with a Bonferroni post-hoc test to 
compare the ZM323881 treated follicles to the control follicles. Treatment with ZM323881 
resulted in a significant dose-dependent decrease in outgrowth area (E). *** indicates 
P<0.001, in comparison with the Control. White arrows indicate the endothelial outgrowths. 
Scale bars represent 200µm. Experiments were repeated in triplicate. 
 
Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 3 Development of a Novel in vitro Angiogenesis Assay 122 
In addition, the follicles were fixed, sectioned and stained for caspase-3 to 
investigate the effect on follicle health and the results show that there was no 
difference in staining for activated caspase-3 with the different doses of ZM323881 




































Figure 3.11 The change in levels of staining for activated caspase-3 for the different 
doses of ZM323881 
To determine the effect of ZM323881 on apoptosis in this assay granulosa cells were 
isolated from preantral and early antral follicles and they were cultured with varying doses 
of ZM323881 (n=12 per treatment). At the end of the culture period these granulosa cells 
were analysed for expression of activated caspase-3/7 activity using a luminescent caspase 
activity assay, as an indicator of follicle health. A One-way ANOVA was performed on the 
results to compare the ZM323881 treated follicles to the control follicles and treatment with 
varying doses of ZM323881 resulted in no change in the levels of expression of activated 
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3.4 Discussion 
A novel in vitro system has been developed that utilizes intact ovarian follicles to 
investigate follicular angiogenesis. This chapter has shown for the first time that 
follicles can develop angiogenic outgrowths in culture. In this system, tube-like 
structures with branch points representing angiogenic sprouting are formed and they 
readily take up endothelial cell markers.  
 
Angiogenesis is a key feature of many pathological conditions and as anti-angiogenic 
therapies could become a powerful tool in the treatment of those conditions an in 
vitro system that allows easy quantification of the potential effect of these therapies, 
as well as being robust and reproducible, would provide a new approach to 
angiogenesis research. Although there are many models available for the 
investigation of angiogenesis they all have limitations. Moreover, our group studies 
the regulation of follicular angiogenesis so the availability of an in vitro follicular 
angiogenesis assay would enable manipulation of the process and of factors of 
interest.  
 
In this chapter an in vitro assay has been developed and by culturing follicles in a 
variety of types of media and with various media supplements to establish the 
optimal culture conditions for follicle health and the development of angiogenic 
outgrowths. Different types of media have different compositions and this provides 
the different conditions that different cell types require to grow. Media commonly 
used for follicle culture, such as McCoys media, is composed of amino acids, 
vitamins, inorganic salts and serum and/or glucose which provide the nutrients 
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required for follicles to grow and develop in vitro. EBM-2 is specifically designed to 
support the growth of primary derived endothelial cells and contains no growth 
factors, cytokines or supplements and has a low serum content. The exact 
composition of EBM-2 is unknown but it appears to contain nutrients that stimulate 
angiogenesis in cultured endothelial cells. This property of EBM-2 is exploited in our 
assay and the growth of follicles in this media is enhanced by the addition of 
supplements to this basal medium. The cultured follicles were analysed for indicators 
of follicle health, including follicle growth and staining for activated caspase-3, and 
the area of angiogenic outgrowths was quantified. Follicles cultured in serum-free 
EBM2 medium with BSA (0.1%), L-glutamine (3mM), penicillin (100 IU/ml), 
streptomycin (0.1 mg/ml), L-ascorbic acid sodium salt (50 µg/ml) and ITS produced 
more angiogenic outgrowths and were healthy when compared to follicles cultured in 
other media types or in EBM2 medium with different supplements. This suggests 
that, although EBM-2 is not typically used for follicle culture, that this medium 
would provide the best conditions to maintain follicle health whilst allowing 
angiogenic outgrowths to develop. Therefore it was decided that this was the optimal 
media to use for the in vitro angiogenesis assay.  
 
As it has been shown for the first time that cultured follicles can produce angiogenic 
outgrowths, it was important to confirm that the outgrowths were endothelial in 
nature. The fluorescent marker Dil-Ac-LDL is commonly used to identify endothelial 
cells (Voyta et al., 1984) especially in angiogenesis assays (Gaffney et al., 1985, 
Yamazaki et al., 1995, Tong et al., 2006, Zan et al., 2008) and this chapter has shown 
that it is incorporated into the outgrowths from the follicles suggesting that they are 
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vascular in nature. To further clarify the vascular nature of the outgrowths control 
follicles were fixed and fluorescently labelled for CD31, CD34 and dual labelled 
with CD31 and αSMA. The vessels labelled for the endothelial cell markers CD31 
and CD34 and also dual labelled for CD31 and the pericyte marker αSMA. When 
angiogenesis occurs in vivo pericytes surround the developing vessels and stabilise 
them, therefore the factors that the outgrowths produced in this assay label for show 
that they are endothelial in nature and are representative of physiological 
angiogenesis. 
 
In addition to optimising this assay the efficacy of this assay was established. The 
extensive literature describing the anti-angiogenic effect of Aflibercept lead to the 
decision to use it as the ‘gold standard’ compound to determine the efficacy of this 
assay. Follicles cultured with increasing doses of Aflibercept resulted in a significant 
(P<0.01) reduction in follicular angiogenesis, showing that this assay is a valid 
system for the investigation of follicular angiogenesis and also for the study of a 
variety of pro- and anti-angiogenic compounds. 
 
As such the effect of the VEGFR2 antagonist ZM323881 on angiogenesis was also 
investigated and this was found to significantly inhibit follicular angiogenesis. The 
effect of this VEGF inhibitor was investigated as it was believed that it may have 
greater efficacy than Aflibercept, due to its smaller size. However, the inhibition of 
angiogenesis after treatment with ZM323881 was not as dramatic as that seen after 
treatment with Aflibercept suggesting that the size of Aflibercept does not impede its 
efficacy in vitro. 
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In summary, a novel in vitro assay for the quantification of follicular angiogenesis 
has been developed and optimised using the culture of isolated ovarian follicles. The 
evaluation of this culture system suggests that it is a valid method for the study of 
follicular angiogenesis and that the vessels produced are representative of in vivo 
angiogenesis. In addition, this system has been utilised to show that both Aflibercept 
and a VEGFR-2 antagonist are able to inhibit follicular angiogenesis, without 
inducing apoptosis. In the following chapter this system will be utilised to investigate 
the roles of factors involved in regulating in vitro follicular angiogenesis and their 
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4 Chapter 4 Thrombospondin-1 Inhibits Follicular 
Angiogenesis and Promotes Atresia in vitro 
4.1 Introduction 
Follicles recruit blood vessels from the ovarian stroma to form vascular sheaths in 
the thecal layer at the preantral stage of development. These blood vessels surround 
the developing follicle and begin to circulate blood to and from the follicle, allowing 
nutrient and gaseous exchange (Geva and Jaffe, 2000). It is essential for rapidly 
expanding follicles to undergo increased angiogenesis, to sustain development of 
these follicles (Fraser, 2006). 
 
Vascular endothelial growth factor (VEGF) is the key factor involved in promoting 
angiogenesis while thrombospondin-1 (TSP-1) is a putative anti-angiogenic factor 
(Ferrara, 2004, Tamanini and De Ambrogi, 2004, Greenaway et al., 2007). The 
members of the thrombospondin family TSP-1 and TSP-2 are large extracellular 
matrix glycoproteins and their effects are mediated through interaction with the cell 
surface receptors CD36 and CD47 (Dawson et al., 1997, Lawler, 2002). TSP-1 has 
been shown to inhibit angiogenesis both in vitro and in vivo and studies have shown 
that treatment with TSP-1 renders endothelial cells unable to respond to many pro-
angiogenic factors (Lawler, 2002, Folkman, 2004). Several studies have used knock-
out mice to show that the absence of TSP-1 leads to increased vascularisation 
(Lawler et al., 1998, Lawler et al., 2001, Wang et al., 2003, Sund et al., 2005, 
Greenaway et al., 2007), providing the first evidence for a role of TSP-1 in vivo as an 
inhibitor of angiogenesis. However, few studies have investigated the role of TSP-1 
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in the ovary. A previous study has made the interesting observation that TSP-1 
mRNA and protein is up-regulated during follicular atresia in vivo (Thomas et al., 
2008), suggesting that TSP-1 may be involved in the cessation of angiogenesis in 
follicles undergoing atresia. Alternatively, TSP-1 may be an autocrine/paracrine 
factor acting on granulosa and/or endothelial cells to promote follicular atresia, as the 
CD36 receptor for TSP-1 is present in both cell types (Thomas et al., 2008).  
 
Studies in rat, bovine and marmoset models have demonstrated a decrease in both 
TSP-1 and CD36 expression as follicular development progresses (Greenaway 2005; 
Petrik 2002), leading to the suggestion that it inhibits angiogenesis during early 
follicular development. In addition, a correlation between down regulation of TSP-1 
and tumour angiogenesis and invasiveness (Rodriguez-Manzaneque et al., 2001, 
Miyanaga et al., 2002, Tanaka et al., 2002, Ren et al., 2006), has led to the proposed 
use of TSP-1 as a therapeutic inhibitor of angiogenesis (Weinstat-Saslow and Steeg, 
1994, Streit et al., 1999, Greenaway et al., 2009). As angiogenesis is tightly regulated 
by both pro- and anti-angiogenic factors it is possible that these factors may be able 
to interact with each other. The direct effect of TSP-1 on granulosa cell apoptosis has 
not been investigated previously, nor has it been investigated in primary granulosa 
cells, thus one hypothesis of this chapter was to investigate whether TSP-1 is able to 
directly induce apoptosis in a more physiological setting. Phospho-ERK1/2 (pERK) 
and p38 mitogen-activated protein kinase (MAPK) are key factors involved in anti- 
and pro-apoptotic pathways, respectively, that either lead to the inhibition or 
induction of the caspase cascade (Donnini et al., 2004, Nakagawa et al., 2005, 
Ridnour et al., 2005). Previous studies have suggested that TSP-1 can interact with 
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the ERK and MAPK pathways (Wilson et al., 1999, Sengupta et al., 2004, Tan et al., 
2009) so the effect of TSP-1 treatment on the expression of pERK and p38 was 
investigated to determine the mechanisms of TSP-1-induced induction of apoptosis.  
 
In this chapter, the role of TSP-1 in regulating in vitro follicular angiogenesis and its 
effect on follicle development and survival has been investigated, using the in vitro 
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4.2 Materials and Methods 
4.2.1 Follicle Culture 
For all experiments, preantral/early antral follicles were cultured individually in flat-
bottomed 12-well plates, embedded in the centre of a 20µl droplet of growth-factor 
reduced Matrigel. The Matrigel provides a three-dimensional extracellular matrix 
support for follicle growth and allows the vascular outgrowths to develop in three-
dimensions, as they would in vivo. Follicles were incubated for 6 days in a sterile 
humidified air atmosphere with 5% CO2 at 37°C in 600µl serum-free EBM-2 
medium supplemented with BSA (0.1%), L-glutamine (3mM), penicillin (100 
IU/ml), streptomycin (0.1mg/ml), transferrin (2.5µg/ml), selenium (4ng/ml), insulin 
(10ng/ml) and L-ascorbic acid, sodium salt (50µg/ml), with culture medium 
refreshed every 48h.  
 
In order to test the effects of TSP-1, follicles were randomly placed into groups and 
cultured in control medium or in the presence of 1 (n=31), 10 (n=28), 100 (n=29) or 
1000ng/ml (n=30) TSP-1 (EMP Genetech, Ingolstadt, Germany).  
 
In order to test the effects of co-culturing TSP-1 with VEGF, follicles were randomly 
placed into groups and cultured in control medium (n=25) or in the presence of 
10ng/ml TSP-1 with 0 (n=20), 1 (n=22), 10 (n=23), 100 (n=23) or 1000ng/ml (n=22) 
VEGF (Perbio Science UK Limited, Cramlington, UK).  
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4.2.1.1 Analysis of Angiogenic Sprouting 
To assess the impact of the treatments on angiogenic sprouting, follicles were 
examined and photographed directly in the 12-well plates under an inverted light 
microscope, at x10 magnification, with Axiovision image capturing software on days 
0 and 6 of the culture period. The total area of angiogenic sprouting for each follicle 
was determined using Image Pro Plus software. This was done by drawing an area of 
interest around the outgrowths (but excluding the follicle), and the sum of the area of 
all sprouts was calculated by the software. The mean area of angiogenic sprouting for 
each treatment was then compared to the control.  
 
4.2.2 Effect of TSP-1 on follicular atresia 
4.2.2.1 Activated caspase-3 immunohistochemistry 
Follicles (n=21 per treatment group) were fixed at the end of the culture period in 4% 
NBF for 24h then stained with 70% ethanol containing eosin for 24h before being 
embedded in paraffin wax and serially sectioned. Tissue sections (5µm) were placed 
onto BDH SuperFrost slides. To determine the localization and changes in the 
number of dying cells, a rabbit antibody to activated caspase-3 was used on sections 
from fixed follicle slides. The sections were incubated overnight at 4°C with 
activated caspase-3 antibody (1:100 in NGS and visualization was achieved by 3-3‘-
diaminobenzidine (DAB) Substrate (see Chapter 2). For the negative controls, 
primary antibody was omitted. 
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4.2.2.2 Analysis of immunohistochemistry 
The total area of caspase-3 staining in the granulosa cell layer of each follicle was 
determined (n=21 follicles per treatment) using Image Pro Plus software. For each 
follicle, the section containing the oocyte with a nucleus present was used for 
quantification of staining. The cross-sectional area of staining for activated caspase-3 
was calculated as a proportion of total cross-sectional area of granulosa cells within 
each follicle.  
4.2.2.3 TdT-mediated dUTP-biotin nick end labelling (TUNEL) 
To provide an additional method for investigation of the effect of TSP-1 on cell 
death, whole follicles from control and TSP-1 treatment groups (n=3 per group) were 
subjected to TUNEL. Wholemount TUNEL was performed as described previously 
(Thomas et al., 2001). Follicles were visualized in PBS via fluorescence microscopy 
using a confocal microscopy at 488nm (green channel to show TUNEL labelled 
cells) and 568nm (red channel to show propidium iodide stained cells) 
simultaneously.  
 
4.2.3 Granulosa Cell Experiments 
To investigate whether TSP-1 can induce apoptosis in granulosa cells directly, 
isolated granulosa cells were cultured in 0.1ml M199 medium containing 1 x 10
5
 
cells/ml. Following overnight preincubation in a sterile humidified air atmosphere 
with 5% CO2 at 37°C, prewarmed 0.1ml M199 medium containing with 0, 10, 100 or 
1000ng/ml TSP-1 was added to each well for 48h. Twenty-one-day old female 
Wistar rats were used as described previously (Chapter 2). To investigate the 
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possibility that TSP-1 induces apoptosis through inhibition of VEGF, isolated 
granulosa cells were cultured with control medium and 100ng/ml TSP-1 plus 0, 1, 
10, 100 or 1000ng/ml VEGF for 48h. To investigate the effect of TSP-1 on various 
factors by western blotting isolated granulosa cells were cultured in 1.5ml medium 
containing 3 x 10
5
 cells/ml. Following overnight preincubation in a sterile humidified 
air atmosphere with 5% CO2 at 37°C, prewarmed 1.5ml medium containing with 0, 
1, 10, 100 or 1000ng/ml TSP-1 was added to each well for 96h, with medium 
refreshed every 48h. All treatments were carried out in triplicate and experiments 
were repeated three times. 
4.2.3.1 Caspase-3 and -7 activity assay 
To measure caspase-3 and -7 activities in isolated granulosa cells, the Caspase-Glo 
3/7 assay was
 
performed according to the manufacturer’s instructions, 48h after 
treating the cells (see Chapter 2). Treatments were carried out in triplicate and 




As serum can generate a background caspase activity signal,
 
an additional 
two wells contained cell culture medium and carrier
 
solution without any cells and 
TNFα was used as a positive control. 
4.2.3.2 Western Blotting 
Protein was extracted from isolated granulosa cells as described previously (Chapter 
2) and they were resolved on 4–20%
 
Tris-glycine gels and transferred onto a PVDF-
fl. Membranes were blocked for 1h at
 
25°C in Rockland Near Infra Red blocking 
buffer and incubated overnight at 4°C in blocking buffer containing
 
rabbit anti-
phospho-p42/44 ERK (1:1000), rabbit anti-phospho-p38 (1:500), FOXO1 (1:1000), 
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pTie-2 (1:1000) or HIF1α (1:500) and β-actin (1:1000). After washing in PBS 
containing
 
0.5% Tween, membranes were incubated for 1h at 25°C in the dark in 
donkey anti goat IgG conjugated to IRDYE 800 and donkey anti rabbit IgG 
conjugated to Alexa Fluor
 
680 both at a dilution of 1:5000 in blocking buffer.
 
Membranes were washed and proteins visualised and quantified
 
using an Odyssey 




4.2.4 Statistical Analyses 
Data are presented as mean ± SEM and all results were analysed statistically using 
Graph Pad Prism 5 software (Graph Pad Software). The results in this chapter were 
analysed by means of a One-way ANOVA with a Bonferroni post-hoc test performed 
if the 95% confidence interval was reached to determine significance between all of 
the data groups. P values <0.05 were accepted as statistically significant.  
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4.3 Results 
4.3.1 Effect of TSP-1 on angiogenesis 
To investigate the effect of TSP-1 on follicular angiogenesis, preantral/early antral 
follicles were cultured in serum-free medium treated with 1, 10, 100 and 1000ng/ml 
TSP-1 for 6 days. Treatment with TSP-1 resulted in a significant inhibition of 
follicular angiogenesis, in a dose dependent manner, (Figure 4.1) (P<0.01), showing 
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Figure 4.1 Effect of TSP-1 on angiogenesis  
To determine the effect of TSP-1 on angiogenesis isolated preantral and early antral follicles 
were cultured with varying doses of TSP-1. At the end of the culture period the area of the 
angiogenic outgrowths was measured using Image Pro-Plus software. Representative 
images show endothelial outgrowths from a control follicle (n=25) (A) and follicles after 
treatment with TSP-1 at 1ng/ml (n=31) (B), 10ng/ml (n=28) (C), 100ng/ml (n=29) (D) or 
1000ng/ml (n=36) (E). Results were analysed statistically using a One-way ANOVA with a 
Bonferroni post-hoc test to compare the TSP-1 treated follicles to the control follicles. 
Treatment with TSP-1 resulted in a significant dose-dependent decrease in outgrowth area 
(F). ** indicates P<0.01, *** indicates P<0.001, in comparison with the Control.  White 
arrows indicate the endothelial outgrowths. Scale bars represent 200µm. Experiments were 
repeated in triplicate. 
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4.3.2 Effect of TSP-1 on follicular atresia 
To investigate the effect of TSP-1 on follicular apoptosis in vitro, preantral/early 
antral follicles that were cultured with 1, 10, 100 and 1000ng/ml TSP-1 for 6 days 
were then fixed, sectioned and stained for activated caspase-3. Representative images 
show a control follicle (Figure 4.2A) and a follicle treated with TSP-1 (Figure 4.2B), 
stained for activated caspase-3. A negative control for the immunohistochemistry is 
represented in Figure 4.2C. A dramatic increase in the level of staining for activated 
caspase-3 can be seen with TSP-1 treatment, and quantification of this staining 
indicates a significant increase in levels of follicular atresia in the presence of TSP-1 
(P<0.05) (Figure 4.2D). To confirm these findings, TUNEL labelling was performed. 
Representative images show a control follicle (Figure 4.2E) and a TSP-1 treated 
follicle (Figure 4.2F) labelled for TUNEL.  A dramatic increase in cell death, shown 
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Figure 4.2 Effect of TSP-1 on follicular atresia 
To determine the effect of TSP-1 on angiogenesis isolated preantral and early antral follicles 
were cultured with varying doses of TSP-1. At the end of the culture period the follicles were 
fixed and analysed for the expression of apoptotic markers. Fixed preantral/early antral 
follicles were sectioned and stained for activated caspase-3 (brown) and counterstained with 
haematoxylin (blue) and representative sections show a control follicle (A) and a follicle 
treated with TSP-1 (B), stained for activated caspase-3. A negative control for the 
immunohistochemistry is shown in C. These results were quantified (D) and analysed using a 
One-way ANOVA with a Bonferroni post-hoc test to compare TSP-1 treated follicles to the 
control follicles. Treatment with TSP-1 resulted in a significant dose-dependent increase in 
staining for activated caspase-3. * indicates P<0.05, *** indicates P<0.001, in comparison 
with the Control. Follicles were also stained for TUNEL to confirm the presence of apoptotic 
cells and a representative control follicle (E) and a TSP-1 treated follicle (F) are shown. 
Black arrows indicate the expression of activated caspase-3, white arrows indicate apoptotic 
cells and white arrowheads indicate healthy cells. Scale bars represent 50µm. Experiments 
were repeated in triplicate. 
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4.3.3 Effect of TSP-1 on granulosa cell apoptosis 
It was proposed that TSP-1 could be acting directly on granulosa cells to induce 
apoptosis and this was investigated by culturing isolated granulosa cells with 0, 10, 
100 and 1000ng/ml of TSP-1 for 48h followed by quantification of apoptosis using a 
luminescent caspase-3/7 assay. There was a significant increase in activated caspase-
3/7 activity in granulosa cells treated with increasing doses of TSP-1 (P<0.05) 
(Figure 4.3), showing that TSP-1 does act directly on granulosa cells to induce 
apoptosis.  
 





































Figure 4.3 Effect of TSP-1 on granulosa cell apoptosis  
To determine the effect of TSP-1 on apoptosis granulosa cells were isolated from preantral 
and early antral follicles and they were cultured with varying doses of TSP-1 (n=4 per 
treatment). At the end of the culture period these granulosa cells were analysed for 
expression of activated caspase-3/7 activity using a luminescent caspase activity assay, as an 
indicator of follicle health. Results were analysed statistically using a One-way ANOVA with 
a Bonferroni post-hoc test to compare the TSP-1 treated granulosa cells to the control 
granulosa cells. Treatment with TSP-1 resulted in a significant dose-dependent increase in 
activated caspase-3 expression * indicates P<0.05, ** indicates P<0.01, in comparison to 
the control. Luminescence is given in arbitrary units (au). Experiments were repeated in 
triplicate. 
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4.3.4 Effect of TSP-1 and VEGF co-culture on angiogenesis 
To investigate whether the addition of VEGF to the culture could attenuate the anti-
angiogenic effect of TSP-1, preantral/early antral follicles were cultured in serum-
free medium in the presence of 100ng/ml TSP-1 and either 0, 1, 10, 100 or 
1000ng/ml VEGF for 6 days. Figure 4.4A shows that follicles cultured with both 
TSP-1 alone and TSP-1 plus 1ng/ml VEGF had significantly reduced follicular 
angiogenesis compared with controls (P<0.05). However, increasing concentrations 
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Figure 4.4 Effect of TSP-1 and VEGF co-culture on angiogenesis (A) and on granulosa 
cell apoptosis (B; activation of caspase-3/7) 
Preantral/early antral follicles were cultured with either 100ng/ml TSP-1 (n=29) alone, with 
100ng/ml TSP-1 plus 1 (n=33), 10 (n=34), 100 (n=35) or 1000ng/ml VEGF (n=33) (A). 
Addition of VEGF to follicles cultured with TSP-1 led to a reduction in the anti-angiogenic 
effect of TSP-1, in a dose dependent manner. VEGF at all dose levels prevented the TSP-1 
induced increase in caspase-3/7 activity (B). Results were analysed statistically using a One-
way ANOVA with a Bonferroni post-hoc test to compare all the different treatment groups to 
their respective control (no TSP-1 or VEGF). * indicates P<0.05, in comparison with 
respective control value; 
a 
indicates P<0.05, in comparison with TSP-1 alone or with TSP-1 
+ 1ng/ml VEGF. Luminescence is given in arbitrary units (au).    
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4.3.5 Effect of TSP-1 and VEGF co-culture on granulosa cell 
apoptosis 
Having shown that treatment with VEGF can rescue the inhibition of angiogenesis 
by TSP-1, it was hypothesised that the inhibition of VEGF activity by TSP-1 could 
also contribute to its ability to induce follicular atresia. To investigate this, isolated 
granulosa cells were cultured with both TSP-1 and VEGF. As 100ng/ml TSP-1 was 
shown to induce apoptosis in isolated granulosa cells (Figure 4.3), the granulosa cells 
were cultured with 100ng/ml TSP-1, alone or in combination with either 1, 10 or 
100ng/ml VEGF for 48h, followed by quantification of caspase-3/7 activity. Figure 
4.4B shows that granulosa cells cultured with 100ng/ml TSP-1 alone had 
significantly increased levels of activated caspase-3/7 activity (P<0.05) in 
comparison to granulosa cells cultured in control medium. Addition of all 
concentrations of VEGF in combination with TSP-1 resulted in the reduction of 
caspase-3/7 activity to control levels, suggesting that VEGF is able to rescue 
granulosa cells from the apoptosis that is induced by TSP-1. 
 
4.3.6 Mechanisms of anti-angiogenesis 
4.3.6.1  Quantification of HIF1α expression by western blotting 
Angiogenesis is stimulated under hypoxic conditions and one of the main compounds 
involved in stimulating hypoxia-induced angiogenesis is hypoxia-inducible factor-1α 
(HIF1α). As conditions become more hypoxic levels of HIF1α rise and this 
stimulates the production of VEGF, resulting in the induction of angiogenesis (Berra 
et al., 2000, Mukhopadhyay and Datta, 2004, Liao and Johnson, 2007, Fong, 2009). 
As TSP-1 has been shown to inhibit angiogenesis and also to act, at least in part, via 
Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 4 Thrombospondin-1 Inhibits Angiogenesis and Promotes Follicular Atresia in vitro 
  144 
interaction with VEGF it was investigated whether treatment with TSP-1 would 
affect the expression of HIF1α. To investigate this isolated granulosa cells were 
treated with 0, 1, 10, 100 and 1000ng/ml of TSP-1 for 48h followed by quantification 
of the expression of HIF1α by western blotting (Figure 4.5) and there was a decrease 
in the expression of HIF1α after treatment with TSP-1, which was significant 
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Figure 4.5 Levels of HIF1α expression after treatment with TSP-1 
Isolated granulosa cells were cultured with varying doses of TSP-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To attempt to 
determine a potential mechanism of anti-angiogenesis the level of hypoxia-inducible factor-
1α (HIF1α) expression was measured by western blotting (A). L – size ladder. Gels were laid 
out with the size marker on the left-hand side of the gel, the control samples and then the 
samples treated with TSP-1. The control samples were used on each gel so that a direct 
comparison to the expression in the control, on that gel, could be made. The size of the 
bands of interest has been shown on the right of the figure with the size marker bands on the 
left. These data were quantified (B) and analysed statistically using a One-way ANOVA with 
a Bonferroni post-hoc test to compare the TSP-1 treated granulosa cells to the control 
granulosa cells. The results show that there is a decrease in the expression of HIF1α after 
treatment with TSP-1 that is statistically significant for granulosa cells cultured in 
1000ng/ml TSP-1 when compared to the control (*P<0.05). Experiments were repeated in 
triplicate. 
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4.3.7 Mechanisms of induction of apoptosis  
4.3.7.1  Quantification of pERK expression by western blotting 
As this chapter has shown that TSP-1 is able to induce apoptosis further 
investigations were performed to establish the mechanisms by which TSP-1 can 
induce apoptosis. Phospho-ERK (pERK) plays an important role in anti-
apoptotic/pro-survival pathways and it is possible that TSP-1 could be inhibiting 
pERK expression, resulting in the induction of apoptosis. To investigate this isolated 
granulosa cells were cultured with 0, 1, 10, 100 and 1000ng/ml of TSP-1 for 48h 
followed by quantification of the expression of pERK by western blotting (Figure 
4.6). The results showed that there was no difference in expression of pERK after 
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Figure 4.6 Levels of pERK expression after treatment with TSP-1 
Isolated granulosa cells were cultured with varying doses of TSP-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of apoptosis induction the level of pERK expression was measured by 
western blotting (A). L – size ladder. Gels were laid out with the size marker on the left-hand 
side of the gel, the control samples and then the samples treated with TSP-1. The control 
samples were used on each gel so that a direct comparison to the expression in the control, 
on that gel, could be made. The size of the bands of interest has been shown on the right of 
the figure with the size marker bands on the left. These data were quantified (B) and 
analysed statistically using a One-way ANOVA to compare the TSP-1 treated granulosa 
cells to the control granulosa cells. The results show that there is no change in the 
expression of pERK after treatment with TSP-1. Experiments were repeated in triplicate. 
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4.3.7.2 Quantification of p38 expression by western blotting 
As there was no difference in the expression of the pro-survival factor pERK after 
treatment with TSP-1 the expression of the pro-apoptotic factor p38 was 
investigated. Isolated granulosa cells were treated with 0, 1, 10, 100 and 1000ng/ml 
of TSP-1 for 48h followed by quantification of the expression of p38 by western 
blotting (Figure 4.7). The results showed that there was no difference in expression 
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Figure 4.7 Levels of p38 expression after treatment with TSP-1 
Isolated granulosa cells were cultured with varying doses of TSP-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of apoptosis induction the level of p38 expression was measured by 
western blotting (A). L – size ladder. Gels were laid out with the size marker on the left-hand 
side of the gel, the control samples and then the samples treated with TSP-1. The control 
samples were used on each gel so that a direct comparison to the expression in the control, 
on that gel, could be made. The size of the bands of interest has been shown on the right of 
the figure with the size marker bands on the left. These data were quantified (B) and 
analysed statistically using a One-way ANOVA to compare the TSP-1 treated granulosa 
cells to the control granulosa cells. The results show that there is no change in the 
expression of p38 after treatment with TSP-1. Experiments were repeated in triplicate.  
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4.3.7.3 Quantification of FOXO1 expression by western blotting 
FOXO1 is a transcription factor that blocks cell division and promotes apoptosis and 
as FOXO1 has been shown to be expressed on granulosa cells it was investigated 
whether this could be involved in the induction of apoptosis after treatment with 
TSP-1. To investigate this isolated granulosa cells were treated with 0, 1, 10, 100 and 
1000ng/ml of TSP-1 for 48h followed by quantification of the expression of FOXO1 
by western blotting (Figure 4.8). The results showed that there was an increase in the 
expression of FOXO1 in granulosa cells treated with TSP-1; however this did not 
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Figure 4.8 Levels of FOXO1 expression after treatment with TSP-1 
Isolated granulosa cells were cultured with varying doses of TSP-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of apoptosis induction the level of FOXO1 expression was measured by 
western blotting (A). L – size ladder. Gels were laid out with the size marker on the left-hand 
side of the gel, the control samples and then the samples treated with TSP-1. The control 
samples were used on each gel so that a direct comparison to the expression in the control, 
on that gel, could be made. The size of the bands of interest has been shown on the right of 
the figure with the size marker bands on the left. These data were quantified (B) and 
analysed statistically using a One-way ANOVA to compare the TSP-1 treated granulosa 
cells to the control granulosa cells. A trend in increasing expression of FOXO1 can be seen 
in granulosa cells treated with TSP-1 although results were not statistically significant. 
Experiments were repeated in triplicate. 
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4.4 Discussion 
In this chapter the in vitro angiogenesis assay described in Chapter 3 was utilised to 
demonstrate that TSP-1 is a potent inhibitor of follicular angiogenesis. Furthermore, 
it has been shown that TSP-1 promotes follicular atresia in vitro by directly inducing 
apoptosis of granulosa cells. 
 
TSP-1 is an endogenous angiogenesis inhibitor and as it is most highly expressed 
during the preantral and early antral stages of follicular development, when 
vascularisation is occurring, it is likely that TSP-1 acts to limit any overgrowth of the 
vasculature that develops in response to the high levels of pro-angiogenic factors 
expressed at these stages. VEGF is one of the main factors involved in the 
stimulation of angiogenesis and TSP-1 has been shown to bind to VEGF and inhibit 
its action (Greenaway et al., 2007), suggesting that the anti-angiogenic action of 
TSP-1 could, at least in part, be regulated through interaction with VEGF.  
 
This possibility was investigated by culturing granulosa cells with a combination of 
TSP-1 and VEGF. The results showed that treatment with VEGF attenuated the TSP-
1-induced inhibition of angiogenesis, suggesting that TSP-1 inhibits angiogenesis via 
the inhibition of VEGF activity. In the presence of TSP-1, CD36 can interact with 
VEGFR2 and form receptor-complexes that can inhibit the phosphorylation of 
VEGFR2 by VEGF (Zhang et al., 2009). This suggests that the role of TSP-1 in 
inhibiting angiogenesis is modulated both through its receptors and through 
interaction with VEGF, but also that the formation of receptor complexes could play 
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a role in regulating the function of TSP-1. The mechanisms of TSP-1-induced 
inhibition of angiogenesis were investigated by quantifying the levels of some of the 
factors involved in the angiogenic cascade. As the production of HIF1α is one of the 
main triggers for the induction of angiogenesis (Ferrara, 2005) it was suggested that 
TSP-1 could be acting on HIF1α. This study has shown that treatment with TSP-1 
reduces the expression of HIF1α, in a dose dependent manner. This would lead to 
reduced production of pro-angiogenic factors such as VEGF and the inhibition of 
angiogenesis, suggesting that one of the mechanisms by which TSP-1 inhibits 
angiogenesis is via the suppression of HIF1α. This, along with the inhibition of the 
action VEGF, would constrain the initiation of angiogenesis and impede the 
development of new blood vessels. 
 
It has previously been shown, in a descriptive study, that TSP-1 expression is up-
regulated during follicular atresia in the marmoset ovary (Thomas et al., 2008). It 
was proposed that this phenomenon would also occur in the rat ovary and this 
chapter has confirmed that TSP-1 is expressed in the granulosa cells of late preantral 
and antral follicles in the rat ovary. Since CD36 is expressed in granulosa cells, it 
was hypothesised that TSP-1 may be acting directly on these cells in an autocrine 
fashion to promote follicular atresia via an apoptotic mechanism (Thomas et al., 
2008). Moreover, an extravascular role for TSP-1 has been suggested (Jimenez et al., 
2000, Nor et al., 2000, Greenaway et al., 2007) and, using a granulosa cell line, 
Greenaway and colleagues showed that TSP-1 treatment decreased VEGF levels and 
rendered cells more susceptible to TNF-α-induced apoptosis (Greenaway et al., 
2007). Therefore it was investigated whether treatment with TSP-1 would be able to 
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induce follicular atresia. This chapter has shown for the first time that TSP-1 directly 
induces apoptosis of primary granulosa cells via the activation of caspase-3. This 
effect on granulosa cell apoptosis occurred both in intact follicles and isolated 
granulosa cells. TSP-1 acts via the receptor CD36 and since CD36 receptors are 
present on granulosa cells, it is likely that the promotion of follicular apoptosis by 
TSP-1 is due to a direct effect on the granulosa cells.  
 
In addition, VEGF has been shown to have a cytoprotective role in the ovary 
(Greenaway et al., 2004) and to promote cell survival. As TSP-1 binds to VEGF and 
inhibits its action (Greenaway et al., 2007), it was proposed that TSP-1 could be 
inducing apoptosis via the inhibition of the survival-promoting effects of VEGF. The 
present study has shown that the addition of VEGF to the granulosa cell cultures was 
sufficient to rescue the cells from the pro-apoptotic effects of TSP-1, suggesting that 
TSP-1 may act via the inhibition of VEGF action. However, since TSP-1 is capable 
of directly activating pro-apoptotic pathways in other cell types (Guo et al., 1997, 
Jimenez et al., 2000, Nor et al., 2000), a direct mechanism of action of TSP-1 in 
granulosa cells cannot be ruled out. As VEGF is a principal factor involved in 
follicular angiogenesis and development (Wulff et al., 2001a, Wulff et al., 2001b, 
Wulff et al., 2002, Ferrara, 2004, Fraser et al., 2006), it may be that addition of 
VEGF to the granulosa cells is sufficient to override the negative effects of TSP-1, 
regardless of the mechanism of action of TSP-1. As TSP-1 induces apoptotic 
signalling in other cell types via CD36 (Dawson et al., 1997, Guo et al., 1997), and 
we have shown that VEGF can inhibit the pro-apoptotic effect of TSP-1, it is 
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possible that TSP-1 induces apoptosis in the ovary by two mechanisms; directly via 
CD36 signalling and indirectly via the inhibition of VEGF.  
 
The mechanisms by which TSP-1 can induce apoptosis were further investigated by 
quantifying the expression of pro- or anti-apoptotic factors in isolated granulosa 
cells. It was anticipated that TSP-1 could have an effect on the expression of pERK 
and/or p38 (Donnini et al., 2004, Nakagawa et al., 2005, Ridnour et al., 2005) as they 
are key factors involved in anti- and pro-apoptotic pathways, respectively, that either 
lead to the inhibition or induction of the caspase cascade. As treatment with TSP-1 
increases follicular atresia via activated caspase-3 signalling, one of the main 
molecules involved in the induction of apoptosis, it is likely that TSP-1 also regulates 
pro- or anti-apoptotic pathways further upstream. There was no difference in the 
expression of the pro-survival factor pERK after treatment with TSP-1. This suggests 
that the mechanism by which TSP-1 induces follicular atresia is not due to the 
inhibition of pro-survival pathways but could be due to stimulation of pro-apoptotic 
pathways. It was observed that there was a trend for increasing expression of p38 
after treatment with TSP-1, suggesting that TSP-1 may induce follicular atresia 
through the induction of pro-apoptotic pathways.  
 
In addition, FOXO1 is a transcription factor that is involved in the induction of 
apoptosis and it has been shown to increase the level of CD36 expression in cell 
membranes (Bastie et al., 2005, Nahle et al., 2008). This suggests that FOXO1 may 
play a role in the induction of apoptosis induced by treatment with TSP-1. The 
expression of FOXO1 after treatment with TSP-1 was quantified to further elucidate 
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the mechanisms of TSP-1-induced follicular atresia but there was no difference in the 
expression of FOXO1. As there was no significant change in the expression of key 
factors involved in both pro- and anti-apoptotic pathways after treatment with TSP-1, 
other than activated caspase-3, this suggests that the regulation of TSP-1-induced 
follicular atresia is complex and involves a delicate balance between pro- and anti-
apoptotic pathways. However, expression of activated caspase-3 was significantly 
increased, and there was a trend of increasing expression of p38, after treatment with 
TSP-1 which suggests that TSP-1-induced follicular atresia could be due to the 
induction of pro-apoptotic pathways rather than the inhibition of pro-survival 
pathways.  
 
In summary, this chapter has shown for the first time that TSP-1 inhibits 
angiogenesis in the ovarian follicle and has a functional role in the induction of 
follicular atresia. In addition, it has been demonstrated that TSP-1 directly promotes 
apoptosis in primary granulosa cells, indicating an extravascular role for TSP-1 
during follicular development. Increased angiogenesis and decreased follicular 
atresia are hallmarks of PCOS (Agrawal et al., 1998a, Franks et al., 2000), therefore 
the use of TSP-1 as a therapeutic for this disorder is an exciting possibility.  TSP-1 
treatment could potentially have a dual effect by targeting the abnormal ovarian 
angiogenesis in PCOS, as well as facilitating the atresia of abnormal follicles via 
induction of apoptosis. To support this hypothesis the effects of a small peptide 
mimetic of TSP-1 were analysed using an in vivo marmoset model to confirm that 
these effects would occur in vivo as well as in vitro. 
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5   Chapter 5 A Thrombospondin-1-mimetic Peptide, ABT-
898, Suppresses Angiogenesis and Promotes Follicular 
Atresia in vivo  
5.1 Introduction 
Angiogenesis is a complex process that is tightly regulated by pro- and anti-
angiogenic factors such as VEGF and TSP-1 (Tolsma et al., 1993, Stouffer et al., 
2001, Armstrong and Bornstein, 2003, Folkman, 2004, Fraser and Duncan, 2005, 
Folkman, 2007, Fraser and Duncan, 2009). The action of pro-angiogenic factors is 
offset by the action of anti-angiogenic factors, although the importance of a balance 
between these factors in regulating physiological angiogenesis is largely unknown.   
 
Angiogenesis is a key feature of many pathological conditions and polycystic ovary 
syndrome (PCOS) is characterised by aberrant angiogenesis (Agrawal et al., 2002), 
hyperandrogenism, and the accumulation of small anovulatory antral follicles with 
reduced follicular atresia (Franks et al., 2000). PCOS is the most common endocrine 
disorder in women of reproductive age and existing treatments for PCOS are limited. 
They are either aimed at controlling symptoms by changing hormone levels within 
the body or cauterisation of PCOS ovaries can be carried out, resulting in a period 
where ovarian cycles become ovulatory. This effect is partly due to the destruction of 
accumulated non-ovulatory follicles. There is currently no therapy that specifically 
targets abnormal ovarian angiogenesis in PCOS, or that facilitates the destruction of 
accumulated antral follicles. Therefore, a novel therapy with a dual effect of 
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inhibiting angiogenesis and inducing atresia could be of benefit in treating PCOS, 
especially if it did not interfere with ovulation of dominant follicles. 
 
It has been demonstrated that there is a decrease in both TSP-1 and CD36 expression 
during follicular development (Petrik et al., 2002, Greenaway et al., 2005), therefore 
TSP-1 signalling may be involved in restricting angiogenesis in early follicular 
development (Fraser et al., 2006). In addition, it has been observed that TSP-1 
mRNA and protein is up-regulated during follicular atresia in vivo (Thomas et al., 
2008), suggesting that TSP-1 may be involved in the cessation of angiogenesis in 
follicles undergoing atresia. In a subsequent study, a functional role for TSP-1 in the 
inhibition of follicular angiogenesis and promotion of follicular atresia has been 
demonstrated, using a novel in vitro angiogenesis assay (Chapter 4). In the ovaries of 
the TSP-1 null mouse, there is an increase in follicle number which may reflect a 
reduced rate of follicular atresia (Lawler et al., 1998).  TSP-1 has been reported to 
induce apoptosis in cultured
 
cells derived from the vascular endothelium (Guo et al., 
1997), suggesting
 
that this factor may inhibit angiogenesis by promoting endothelial 
cell degradation (Jimenez et al., 2000). Further to this, in the previous chapter it has 
been shown that TSP-1 promotes apoptosis of isolated granulosa cells, thus it is 
likely that the promotion of follicular atresia by TSP-1 involves a direct effect on the 
granulosa cells (Garside et al., 2010).  
 
TSP-1 is a large multifunctional glycoprotein, and its anti-angiogenic activity has 
been isolated to a smaller sequence within TSP-1 (TSR-1) (Zhang and Lawler, 
2007). A much smaller heptapeptide sequence within TSR-1, GVITRIR, has been 
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mimicked by the modified nonapeptide, ABT-510: Ac-Sar-GV-DalloIle-T-Nva-IRP-
ethylamide, which has been shown to be active anti-angiogenically in slowing 
tumour growth in preclinical models (Anderson et al., 2007, Yang et al., 2007) and 
reduces VEGF production in a model of ovarian cancer (Greenaway et al., 2009). It 
has also been demonstrated to be efficacious in the treatment of spontaneously 
occurring cancer in companion dogs (Rusk et al., 2006), and has been in clinical 
trials, mainly as monotherapy (Hoekstra et al., 2005, Hoekstra et al., 2006, Gietema 
et al., 2006, Markovic et al., 2007). The thrombospondin mimetic peptide-A-428898 
(ABT-898) (Abbott Laboratories, N. Chicago, IL, USA), a substituted octapeptide 
Ac-GV-DalloIle-SQIRP-ethylamide, is a second generation mimetic of the anti-
angiogenic activity of TSP-1, having greatly increased potency over that of ABT-510 
as well as slower clearance in primates. ABT-898 is thus expected to have greater 
efficacy than the other available TSP-1-mimetic peptides. 
 
In this chapter the effect of ABT-898 on follicular angiogenesis was investigated 
using the in vitro angiogenesis assay described in Chapter 3, prior to studying its 
effects in vivo in the common marmoset (Callithrix jacchus). The present study first 
determined the inhibitory effect of ABT-898 on follicular angiogenesis and survival 
in vitro. Subsequently, in vivo treatment during the follicular phase in marmosets was 
studied to confirm a functional role for this peptide in a physiological setting. 
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5.2 Materials and Methods 
5.2.1 Follicle Culture 
For all experiments, preantral/early antral follicles were cultured individually in flat-
bottomed 12-well plates, embedded in the centre of a 20µl droplet of growth-factor 
reduced Matrigel. The Matrigel provides a three-dimensional extracellular matrix 
support for follicle growth and allows the vascular outgrowths to develop in three-
dimensions, as they would in vivo. Follicles were incubated for 6 days in a sterile 
humidified air atmosphere with 5% CO2 at 37°C in 600µl serum-free EBM-2 
medium supplemented with BSA (0.1%), L-glutamine (3mM), penicillin (100 
IU/ml), streptomycin (0.1mg/ml), transferrin (2.5µg/ml), selenium (4ng/ml), insulin 
(10ng/ml) and L-ascorbic acid, sodium salt (50µg/ml), with culture medium 
refreshed every 48h.  
 
In order to test the effects of ABT-898, follicles were randomly placed into groups of 
6 and cultured in control medium or in the presence of 0.1, 1, 10, 100 or 1000ng/ml 
ABT-898 (A-428898 amino acid sequence N-Acetyl-glycine-valine-D-
alloisoleucine-serine-glutamine-isoleucine-arginine-proline-ethylamide, Abbott 
Laboratories) and the experiment was carried out twice.  
 
5.2.1.1 Analysis of Angiogenic Sprouting 
To assess the impact of the treatments on angiogenic sprouting, follicles were 
examined and photographed directly in the 12-well plates under an inverted light 
microscope, at x10 magnification, with Axiovision image capturing software on days 
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0 and 6 of the culture period. The total area of angiogenic sprouting for each follicle 
was determined using Image Pro Plus software. This was done by drawing an area of 
interest around the outgrowths (but excluding the follicle), and the sum of the area of 
all sprouts was calculated by the software. The mean area of angiogenic sprouting for 
each treatment was then compared to the control.  
   
5.2.2 Marmosets 
Experiments were carried out in accordance with the Animals (Scientific Procedures) 
Act, 1986, and approved by the Local Ethical Review Process Committee. To 
synchronize follicular recruitment, selection and ovulation during treatment cycles, 
adult (2-4 years old) female common marmoset monkeys with
 
a body weight of 350-
400g and regular ovulatory cycles, housed as described previously (Chapter 2), were 
injected with 1µg prostaglandin PGF2 analogue (cloprostenol) per animal, i.m. on 
day 13-15 of the luteal phase to induce luteolysis. The day of prostaglandin injection 
was designated follicular d 0. This method of synchronizing follicular recruitment is 
followed by follicle selection on cycle d 5 and ovulation between d 9-11 (Summers 
et al., 1985, Gilchrist et al., 2001).  
 
To determine the pharmacokinetics of ABT-898 in the marmoset, 4 adult females 
were given a single sc injection of 2.5mg/kg of ABT-898 dissolved in 5% glucose 
solution followed by sterile filtration using a Ministrat, (Sartarius AG, Gottingen, 
Germany). Blood samples (300μl) were collected from the femoral vein at 0, 0.25, 1, 
2, 4, 6, 8, 12 and 24h. Plasma was stored at -20C until required for assays. 
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5.2.2.1 Treatment with ABT-898 throughout the follicular phase 
To investigate the effect of ABT-898 on follicular angiogenesis and atresia in vivo, 
ABT-898 was administered to marmosets (n=5) by twice daily sc injections of 
2.5mg/kg, prepared as above, on d0-9 of the follicular phase. Control marmosets 
(n=5) were treated with vehicle. On d10, of the follicular phase which corresponds to 
the peri-ovulatory period in controls, all animals were injected i.v. with 20mg BrdU 
in saline one hour before being sedated using 200µl ketamine hydrochloride and 
200µl Saffan. After perfusion with 4% NBF, tissues were removed immediately, 
weighed, and fixed in 4% NBF for 24h. Plasma progesterone was measured 
throughout the study using assays described previously (Smith et al., 1990).   
 
5.2.2.2 Long-term in vivo treatment with ABT-898 depot 
To investigate the effect of long-term high-dose treatment with ABT-898 on 
ovulatory cycles, a depot formulation of 25mg ABT-898 in biodegradable 
microspheres was suspended in 500μl diluent and injected sc during the late luteal 
phase in 3 marmosets with regular ovulatory cycles. This was followed by a second 
injection 14 days later. The first injection was accompanied by treatment with a 
prostaglandin analogue to induce luteolysis. Thus, this treatment period was designed 
to cover the entire follicular phase and early luteal phase. The second injection was 
designed to cover the luteal phase in the event of ovulation occurring. Blood samples 
were collected three times per week for 3 cycles prior to treatment and for 3 months 
after the first injection.  
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5.2.3 Immunohistochemistry 
The effects of the treatment on granulosa cell proliferation
 
was determined by 
quantifying the number
 
of proliferating cells stained for BrdU and the effect on 
vascular density was determined by localising endothelial
 
cells using CD31. Dual 
staining for BrdU and CD31 was also performed to enable quantification of 
proliferating endothelial cells. Immunohistochemistry was performed as described 
previously (Chapter 2) using the primary antibodies CD31 (monoclonal,
 
diluted 1:20 
in TBS) or BrdU
 
(monoclonal, diluted 1:30 in TBS). Incubation with the primary 




with the secondary 
antibody (rabbit antimouse Ig,
 
1:60 diluted in TBS) was for 40min at room 
temperature, followed by
 
incubation of the APAAP complex (1:100 dilution in NRS 
and TBS) for 40min
 
at room temperature. Visualisation was performed using NBT 
solution. 
 
For detection of proliferating endothelial cells, dual staining was obtained by 
immunohistochemistry with CD31 and BrdU. For CD31 detection, the protocol was 
followed as described above but visualisation was performed with fast red. The 
second primary to BrdU was then added, diluted 1:5000 in NRS, and incubated 
overnight at 4
o
C. After post-incubation washes with TBS, a biotinylated rabbit anti-
sheep secondary antibody was added, followed by ABC-AP. After incubation with 
the ABC-AP complex, slides were transferred to NBT buffer before staining with 
NBT for 15min.  
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5.2.3.1 Caspase-3 
To assess follicular atresia, immunohistochemistry for activated
 
caspase-3 was 
performed as described previously (Fraser et al., 2006, Thomas et al., 2007).
 
To 
determine the localisation and changes in the number of dying cells, a rabbit 
antibody to activated caspase-3 was used. The sections were incubated overnight at 
4
o
C with activated caspase-3 antibody at 1:100 dilution in NGS. Slides were then 
washed in TBS and incubated with labelled polymer-HRP as secondary antibody 
(rabbit EnVison kit) for 30mins. Visualisation was achieved by DAB Substrate. 
 
5.2.3.2 Quantification of immunohistochemistry 
Slides stained with H&E were used to assess morphology of the ovaries. Stages of 
follicular development were defined as previously reported (Chapter 2(Wulff et al., 
2002, Thomas et al., 2007). Only those follicles with a visible oocyte containing a 
nucleus were considered to ensure proper follicular classification in these follicles. In 
addition, preovulatory follicles >2mm and early corpora lutea were identified and 
counted.  
 
The extent of follicular atresia was investigated by analysis of H&E-stained sections 
and sections stained for activated caspase-3. In the initial analysis, H&E stained 
follicles were classed as atretic if they had more than 10% pyknotic nuclei and 
follicles stained for activated caspase-3 were classified as atretic if they had greater 
than 10% caspase-3 staining. This classification is based on previously described 
criteria for the measurement of follicular cell death (Byskov, 1974). Follicles with 
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morphological signs such as granulosa cell shrinkage and detachment of cells from 
the oocyte or basement membrane were also classed as atretic.  
 
Granulosa cell proliferation was measured by counting both the number of BrdU-
positive nuclei and the total number of nuclei in the selected fields. A proliferation 
index (i.e. BrdU-positive nuclei expressed as a percentage of the total number of 
nuclei) was calculated for each follicle. Relative vascularisation was quantified by 
measuring the total area of CD31 staining and the total area of the thecal layer so that 
the area of endothelial cells could be expressed as a percentage of total thecal area, 
using Image Pro Plus software. Endothelial cell proliferation was measured by 
counting the number of dual-stained cells
 
(BrdU- and CD31-positive cells) and the 
total number of proliferating
 
cells (i.e. BrdU-positive cells) in the thecal layer.
 
The 
proportion of proliferating endothelial cells (dual-stained
 
cells) was expressed as a 
percentage of the total number of
 
proliferating cells. All vessels in the theca of each 
follicle were counted for quantification of relative vascularisation and endothelial 
cell proliferation.  
 
For all of these quantifications early preantral, preantral and antral follicles in both 
ovaries of control and treated animals were analysed. The numbers of follicles 
analyzed for each quantification were as follows: controls (early preantral n=18, 
preantral n=71; antral n=64), ABT-898 (early preantral  n=14 , preantral n=58; antral 
n=68). 
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5.3 Assays 
Blood samples were collected three times per week for 6-8 weeks pre-treatment and 
during the study period in ABT-898 treated marmosets, for the determination of 
plasma progesterone and ABT-898 levels. Progesterone concentrations were 
determined by radioimmunoassay (RIA) using antiserum R31/12 as described 
previously (Smith et al., 1990).  
 
5.3.1.1 ABT-898 ELISA 
The anti-ABT-898 polyclonal antibody 983-1c was prepared by Abbott Laboratories. 
It was generated using Invitrogen Custom Peptide/Antibody Services (Invitrogen, 
Carlsbad CA). A cysteine appended synthetic peptide analogue of ABT-898 (Ac-
Gly-val-(d)alloile-ser-gln-ile-arg-pro-cys-amide) was coupled to keyhole limpet 
hemocyanin  (KLH) and used to immunize rabbits. The resulting ABT-898-cross 
reactive antisera were affinity purified and serum # 983-1c was utilized for 
development of an ABT-898 ELISA by Abbott Laboratories. Plasma concentrations 
of ABT-898 were determined using a competition ELISA carried out by Mr Ian 
Swanston. A biotinylated peptide analogue of ABT-898 was diluted in blocking 
buffer (0.1%BSA, 0.05% Tween in PBS (0.1M phosphate, 0.15M NaCl, pH 6.9-7.2) 
and added to neturavidin pre-blocked plates (Pierce Biotech, Rockford, IL ) at room 
temperature for 1 h. Wells were washed three times with a wash buffer containing 
0.05% Tween-20 in PBS. ABT-898 standards diluted in serum or test serum samples 
were then added to appropriate wells followed by the immediate addition of anti-898 
Ab, 983-1c. The plates were then incubated for 30min. After incubation, wells were 
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washed three times with wash buffer. A goat anti-rabbit peroxidase secondary 
antibody solution was added to the wells and plates were incubated at room 
temperature for 30min. Next, 1-step ultra TMB solution (Pierce Biotech, Rockford, 
IL) was added for 15min and the reaction was stopped by addition of 2N Sulphuric 
Acid. The OD was determined at 450nM. Assay sensitivity was 2ng/well, and 
interassay variation based on low-, medium-,
 
and high-quality controls were less than 
10%. Concentration
 
vs. time curves were constructed from ELISA-generated ABT-
898
 
values obtained from individual animals. The pharmacokinetic
 
parameter 
estimates were determined by fitting the serum concentration
 
vs. time profile to a 
noncompartmental model (WinNonLin, version
 
2.0, Pharsight Corp., Mountain 
View, CA). 
 
5.3.2 Statistical Analyses 
Data are presented as mean ± SEM and all results were analysed statistically using 
Graph Pad Prism 5 software (Graph Pad Software). The data for figures 5.4, 5.5, 5.6 
and 5.7 were analysed by two-tailed t-tests with a 95% confidence interval to 
compare the day 0 data with the day 6 data and statistical significance is indicated by 
*. For the progesterone results (Fig 5.3), the post-treatment period data was subjected 
to statistical analysis and this was based on the duration of the normal luteal phase. 
This was achieved by comparing the area under the curve for pre-treatment and post-
treatment cycles. The rest of the results in this chapter were analysed by means of a 
One-way ANOVA with a Bonferroni post-hoc test performed if the 95% confidence 
interval was reached to determine significance between all of the data groups. P 
values <0.05 were accepted as statistically significant. 
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Results 
5.3.3 Effect of ABT-898 on follicular angiogenesis in vitro  
To investigate the effect of ABT-898 on follicular angiogenesis in vitro, preantral 
and early antral rat follicles (n=12 per treatment) were cultured in serum-free 
medium treated with 0.1, 1, 10, 100 and 1000ng/ml ABT-898 for 6 days. Treatment 
with ABT-898 resulted in a significant inhibition of follicular angiogenesis, in a dose 
dependent manner, (Figure 5.1) (P<0.001), showing that ABT-898 is able to inhibit 
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Figure 5.1 Effect of ABT-898 on angiogenesis in vitro 
To determine the effect of ABT-898 on angiogenesis isolated preantral and early antral 
follicle (n=6 per treatment) were with varying doses of ABT-898. At the end of the culture 
period the area of the angiogenic outgrowths was measured using Image Pro-Plus software. 
Representative images show endothelial outgrowths from a control follicle (A) and follicles 
after treatment with ABT-898 at 0.1ng/ml (B), 1ng/ml (C), 10ng/ml (D), 100ng/ml (E) or 
1000ng/ml (F). The results were analysed statistically using a One-way ANOVA with a 
Bonferroni post-hoc test to compare the ABT-898 treated follicles to the control follicles. 
Treatment with ABT-898 resulted in a significant dose-dependent decrease (***P<0.001) in 
outgrowth area (G). Arrows indicate the endothelial outgrowths. Scale bars represent 
200µm. Experiments were repeated in triplicate. 
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5.3.4 Treatment with ABT-898 throughout the follicular phase 
Prior to the in vivo study, the concentration of ABT-898 in plasma following a single 
injection of 2.5mg/kg was measured and it found to be detectable for up to 8h. At 
15min after injection, plasma concentrations of ABT-898 reached a mean value of 
26,500 ng/ml, falling to 1,747 ng/ml by 4h. The last time-point at which ABT-898 
was still detectable, average 147ng/ml, was at 8h post-injection but was below 
detection limit (5ng/ml) after 12 hours. The half life was 0.83h with clearance 
parameter of 0.039. This compares with values of 1.2h and 0.12 respectively in 
cynomolgus monkeys (Abbott Laboratories, unpublished). Therefore, for the 
treatment schedule, it was decided to administer ABT-898 twice daily to ensure that 
levels remained within the effective range.  
 
5.3.5 Effect of ABT-898 on ovulation and progesterone production 
In ovaries (n=10) from control marmosets (n=5) the predominant structures on day 
10 were preovulatory follicles (n=6; mean per ovary=0.6) and newly formed corpora 
lutea (n=9; mean per ovary=0.9) (Figure 5.2A-B). Ovaries from ABT-898 treated 
marmosets (n=5) were also dominated by pre-ovulatory follicles (n=7; mean per 
ovary=0.7) or newly formed corpora lutea (n=9; mean per ovary=0.9) (Figure 5.2C-
D), showing that treatment with ABT-898 did not suppress follicle selection or 
ovulation. In accordance with this data, paired ovarian weights of ABT-898 treated 
marmosets at day 10 (260mg ±49) were not significantly different from controls 
(223mg ±43). There was also no difference in the size of the preovulatory follicles or 
the corpora lutea between the control ovaries and the ABT-898 treated ovaries.  
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Figure 5.2 Effect of ABT-898 on follicular development and ovulation 
To investigate the effects of a TSP-1-mimetic peptide, ABT-898, in vivo, marmoset monkeys 
were treated with ABT-898 or a vehicle control. At the end of the treatment the ovaries were 
removed and fixed, sectioned and stained for histological analysis. Representative images 
show haematoxylin and eosin staining in marmoset ovaries 10 days after treatment with 
vehicle control (A, B) or with ABT-898 (C, D). Note the main structures in the control 
ovaries were preovulatory follicles (POF) and corpora lutea (CL (outlined)), together with 
large antral follicles, the majority of which are healthy. The main structures in the treated 
ovaries were also POFs and CLs but the majority of the remaining large follicles were 
atretic (At). Both ovaries from 5 control and 5 treated marmosets were analysed and 3 slides 
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It has previously been shown that treatment with angiogenesis inhibitors can block 
ovulation and inhibit progesterone secretion (Taylor et al., 2007). Long-term 
treatment with ABT-898 depot resulted in maintenance of high levels of the peptide 
in the circulation, but this had no effect on the timing or magnitude of the normal rise 
in plasma progesterone levels, which occurred around 10 days after the initiation of 
treatment. The second injection also failed to affect the length of the luteal phase or 


















Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 5 A Thrombospondin-1-mimetic Peptide, ABT-898, Suppresses Angiogenesis and 





Figure 5.3 Effect of ABT-898 depot on ovulatory cycles 
Marmosets were treated with a vehicle control or ABT-898 for 10 days and blood samples 
were taken from these marmosets every three days for three cycles prior to treatment and for 
two cycles during and then post-treatment to allow hormonal profiling. The concentration of 
plasma progesterone (PG) during three pre-treatment control cycles is shown (A). At the 
third cycle, PG injection is used to induce luteolysis simultaneous to the first injection of 
ABT-898 depot (arrow). Ovulation occurred at the normal time. A second depot injection of 
ABT-898 given at the resulting early luteal phase failed to effect progesterone 
concentrations or the timing of the next ovulation. Data was analysed by comparing the area 
under the curve for the pre- and post-treatment cycles. The plasma profiles of ABT-898 
following the two injections are shown (B). Note the high levels of peptide maintained 
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5.3.6 Effect of ABT-898 on angiogenesis and granulosa cell 
proliferation 
As the ovary is dynamic and undergoes intense angiogenesis during both 
folliculogenesis and corpus luteum formation, there are normally a high number of 
proliferating endothelial cells within the thecal layer of developing follicles and in 
the corpus luteum. Although treatment with ABT-898 failed to block the emergence 
of the dominant follicles or ovulation, there were significant changes in other classes 
of developing follicles within these ovaries. ABT-898 treatment resulted in a 
significant reduction in follicular angiogenesis in preantral and early antral follicles, 
as determined by the reduction in the proportion of proliferating endothelial cells 
(shown by dual staining with BrdU and CD31) (Figure 5.4A) compared with controls 
(Figure 5.4B). The inhibition of angiogenesis was found to be significant in late 
preantral and antral follicles (Figure 5.4C), but not in early preantral or preovulatory 
follicles (Figure 5.4D). Quantification of the area of CD31 staining in the theca 
showed a significant reduction (P<0.05) in vascular area after treatment with ABT-
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Figure 5.4 Effect of ABT-898 on endothelial cell proliferation 
To investigate the effects of ABT-898 on in vivo angiogenesis marmoset monkeys were 
treated with ABT-898 or a vehicle control. At the end of the treatment the ovaries were 
removed and fixed, sectioned and stained for histological analysis. Representative images 
show dual staining for BrdU and CD31 in marmoset ovaries to identify proliferating 
endothelial cells (arrows), in control (A) and treated (B) follicles. The results were analysed 
statistically using two-tailed t-tests to compare the different treatment groups. There was a 
significant decrease in follicular angiogenesis after treatment with ABT-898, when 
compared to the control, in both preantral and early antral follicles (**P<0.01) (C). There 
was no change in follicular angiogenesis after treatment with ABT-898 in both early 
preantral and preovulatory follicles (D). Both ovaries from 5 control and 5 treated 
marmosets were analysed and 3 slides at different points through each ovary were counted. 
Scale bars represent 50µm. 
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Figure 5.5 Effect of ABT-898 on relative vascularisation 
To investigate the effects of ABT-898 on in vivo angiogenesis marmoset monkeys were 
treated with ABT-898 or a vehicle control. At the end of the treatment the ovaries were 
removed and fixed, sectioned and stained for histological analysis. The level of 
vascularisation in the thecal layer of follicles in both the control and treated ovaries were 
quantified and the results were analysed statistically using two-tailed t-tests to compare the 
ABT-898 treated ovaries to the control ovaries. There was a significant decrease in the 
relative vascular investment after ABT-898 treatment in all stages of follicle development 
(*P<0.05). The left and right ovaries from 5 control and 5 treated marmosets were analysed 





In addition, treatment with ABT-898 resulted in a significant reduction in granulosa 
cell proliferation from ovaries of control (Figure 5.6A) and ABT-898 treated 
marmosets (Figure 5.6B). The inhibition of granulosa cell proliferation was found to 
be significant in early preantral, late preantral and early antral follicles when 
compared with control ovaries (Figure 5.6C), but not in dominant, preovulatory 
follicles (Figure 5.6D). 
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Figure 5.6 Effect of ABT-898 on granulosa cell proliferation 
To investigate the effects of ABT-898 on cellular proliferation marmoset monkeys were 
treated with ABT-898 or a vehicle control. At the end of the treatment they were injected 
with BrdU and the ovaries were removed and fixed, sectioned and stained for histological 
analysis. Representative images show staining for BrdU in marmoset ovaries to identify 
proliferating granulosa cells, in control (A) and treated (B) follicles. Early antral follicles 
are shown from both control (A) and ABT-898 treated ovaries (B). The results were analysed 
statistically using two-tailed t-tests to compare the ABT-898 treated ovaries to the control 
ovaries. There was a significant decrease in granulosa cell proliferation after treatment with 
ABT-898 in early preantral, preantral and early antral follicles, when compared to their 
respective control (**P<0.01) (C). There was no change in granulosa cell proliferation after 
treatment with ABT-898 in preovulatory follicles (D). Both ovaries from 5 control and 5 
treated marmosets were analysed and 3 slides at different points through each ovary were 
counted. Scale bars represent 200µm.  
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5.3.7 Effect of ABT-898 on follicular atresia 
A proportion of developing follicles undergo atresia during normal follicular 
development (Figure 5.7A and B). Treatment with ABT-898 resulted in a significant 
increase in the level of staining for activated caspase-3 (Figure 5.7C and D) in 
preantral and early antral follicles. There was no difference in the level of activated 
caspase-3 staining in early preantral and preovulatory follicles (results not shown). 
This was indicative of a significantly higher number of atretic follicles in the ABT-
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Figure 5.7 Effect of ABT-898 on follicular atresia 
To determine the effect of ABT-898 on follicular atresia marmoset monkeys were treated 
with ABT-898 or a vehicle control. At the end of the treatment the ovaries were removed and 
fixed, sectioned and stained for histological analysis and then analysed for the expression of 
apoptotic markers. Representative preantral and early antral follicles from control (A and B) 
and ABT-898 treated marmoset ovaries (C and D) are shown. The results were analysed 
statistically using a two-tailed t-test to compare the ABT-898 treated ovaries to their 
respective control ovaries. There was no difference in the level of activated caspase-3 
staining in early preantral and preovulatory follicles (results not shown). Treatment with 
ABT-898 resulted in a significant difference in % of atretic follicles between control and 
ABT-898 treated ovaries in pre- and early antral follicles (E). * indicates P<0.05, *** 
indicates P<0.001, in comparison with the respective control value. Both ovaries from 5 
control and 5 treated marmosets were analysed and 3 slides at different points through each 
ovary were counted. Arrows indicate staining for activated caspase-3 (brown). Scale bars 
represent 100µm. 
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5.4 Discussion 
This chapter has shown for the first time the effects of the thrombospondin-1 
mimetic peptide ABT-898 on follicular angiogenesis and development. Treatment 
with ABT-898 resulted in the suppression of follicular angiogenesis, a reduction in 
endothelial cell proliferation at the pre- and early antral stages of follicular 
development and the suppression of granulosa cell proliferation at early preantral, 
preantral and early antral stages of follicular development. In addition to the 
inhibition of angiogenesis, ABT-898 treatment also resulted in a significant increase 
in the number of preantral and early antral follicles undergoing apoptosis. However, 
follicle selection and ovulation were not inhibited by treatment, suggesting that the 
effects of ABT-898 are stage-specific.  
 
Angiogenesis is necessary for normal follicular development and is stimulated in 
preantral follicles by the pro-angiogenic factor VEGF (Wulff et al., 2002, Ferrara, 
2004, Tamanini and De Ambrogi, 2004). The previous chapter showed that TSP-1 is 
able to inhibit follicular angiogenesis in vitro and the present study has demonstrated 
that the peptide ABT-898 inhibits follicular angiogenesis in vitro and in vivo. 
Treatment with ABT-898 resulted in specific changes in cellular proliferation within 
developing follicles. Endothelial cell proliferation in the thecal layer of preantral and 
early antral follicles was inhibited and there was reduced overall vascularisation in 
the theca of ABT-898 treated marmosets. Treatment with ABT-898 was also 
associated with the suppression of granulosa cell proliferation in developing follicles. 
TSP-1 is expressed most highly in follicles at the pre- and early antral stages of 
development and expression decreases as follicles progress to the preovulatory stage 
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(Petrik et al., 2002). As treatment with ABT-898 both in vitro and in vivo leads to the 
inhibition of follicular angiogenesis, and as TSP expression declines with increased 
follicular angiogenesis, it is likely that TSP acts to restrict angiogenesis in follicles 
during early follicular development. It has previously been shown that TSP-1 and 
VEGF are expressed in an inverse pattern (Greenaway et al., 2005) and as VEGF 
expression increases as folliculogenesis progresses it is likely that the greater levels 
of VEGF expressed in antral and preovulatory follicles would counteract the 
inhibitory effect of TSP-1 on follicular angiogenesis, meaning that preantral and 
early antral follicles would be more susceptible to the inhibition of angiogenesis 
caused by TSP-1.  
 
Regulation of the inhibitory effects of TSP-1 on follicular angiogenesis is likely to be 
complex. It has been shown that TSP-1 signals through both the CD36 and CD47 
receptors which induce different responses, as they interact with different 
downstream molecules. TSP-1 signalling via CD36 inhibits angiogenesis and 
VEGFR2 which results in the blockade of the pro-angiogenic activity of VEGF 
(Dawson et al., 1997, Zhang et al., 2009). Follicles at the pre- and early antral stages 
of development also have lower expression of VEGF (Ferrara, 2004, Fraser et al., 
2005a) so the balance of the numerous other factors involved in angiogenesis 
becomes more significant and ABT-898 is able to reduce follicular angiogenesis. 
However, TSP-1 signalling via CD47 has been shown to up regulate the expression 
of matrix metalloproteinase (MMP)-9 (Qian et al., 1997, Donmez et al., 2009). 
MMPs play an important role in angiogenesis as they degrade basement membrane 
collagens, thus allowing endothelial cells to migrate and proliferate (Bendeck, 2004). 
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In addition, MMP-9 can stimulate the expression of VEGF (Donmez et al., 2009), 
suggesting that TSP-1 could increase the expression of pro-angiogenic factors 
despite being an endogenous angiogenesis inhibitor. Moreover, VEGF has been 
shown to inhibit the expression of TSP-1 and as the expression of VEGF increases as 
follicle development progresses it is likely that inhibitory actions of ABT-898 are 
overcome in dominant follicles due to higher expression of VEGF.  It is not 
surprising that TSP-1 has both stimulatory and inhibitory effects on angiogenesis as  
it interacts with numerous receptors and proteases, however, in the ovary all the 
evidence so far suggests that it has an inhibitory role. Importantly, it has recently 
been shown that the levels of TSP-1 expression are reduced in women with PCOS 
(Tan et al., 2009), supporting the evidence for TSP-1 inhibiting angiogenesis in the 
ovary. 
 
Expression of TSP-1 has been shown to be up-regulated in follicles undergoing 
atresia (Thomas et al., 2008) and the previous chapter showed that TSP-1 treatment 
in vitro induces follicular apoptosis. Therefore it was hypothesised that treatment 
with ABT-898 in vivo would have a similar effect. This chapter has demonstrated for 
the first time that treatment with ABT-898 induces follicular atresia in a stage-
specific manner in the ovary and this, along with the in vitro data (Garside et al., 
2010), suggests that TSP may play an important role in the clearance of non-
dominant follicles within the ovary. TSP-1 has been shown to inhibit the 
proliferation and migration of endothelial cells (Lawler, 2002, Folkman, 2004) and 
the resulting decrease in angiogenesis may be at least partly responsible for the 
induction of follicular atresia. In addition, treatment with TSP-1 has been shown to 
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directly induce apoptosis of endothelial cells (Guo et al., 1997, Jimenez et al., 2000, 
Nor et al., 2000). Since the TSP-1 receptor CD36 is expressed on granulosa cells 
(Dawson et al., 1997, Petrik et al., 2002, Thomas et al., 2008) and TSP-1 has been 
shown to induce granulosa cell apoptosis directly (Garside et al., 2010), it is also 
likely that TSP-1 is able to induce follicular atresia in vivo independently of 
angiogenesis inhibition. Here we have demonstrated that treatment with ABT-898 
reduced both granulosa and endothelial cell proliferation, suggesting a dual effect of 
TSP-1 to promote follicular atresia. It is possible that the effect on granulosa cell 
death could be due to a cytotoxic effect of ABT-898. However, toxicology studies 
performed by Abbott Laboratories (unpublished observations) both in vitro and in 
vivo have shown that ABT-898 does not induce mutangenesis or clastogenesis in a 
variety of cells, including Chinese hamster ovary cells. In this study we have shown 
that treatment with ABT-898 induces follicular atresia but that a cohort of healthy 
follicles is present in all of the treated ovaries. If this effect was due to cytotoxicity of 
the compound all follicles would be affected equally and this is not the case, 
suggesting that the apoptosis seen is a manifestation of ABT-898 mimicking the 
physiological effect of TSP. 
 
Previous studies have investigated the effect of several anti-angiogenic agents in the 
marmoset and treatment with Aflibercept, a VEGF inhibitor, at specific stages of the 
cycle has been shown to inhibit follicle selection, prevent ovulation, induce rapid 
luteolysis and suppress progesterone secretion (Wulff et al., 2002, Fraser et al., 
2006). It was hypothesised that treatment with ABT-898 may have similar effects 
due to its anti-angiogenic activity and this was investigated in non-terminal studies. 
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Marmosets treated with ABT-898 in a long-acting depot formulation showed no 
inhibition of progesterone production and went on to cycle normally, producing 
preovulatory follicles and corpora lutea that were of comparable size and frequency 
to those seen in control animals. Progesterone secretion continued as normal after 
treatment with ABT-898, showing that ABT-898 does not induce luteolysis nor 
inhibit ovulation, unlike Aflibercept. TSP-1 has been shown to act, at least in part, 
through inhibition of VEGF (Greenaway et al., 2007) but it appears that this partial 
inhibition of VEGF action is not sufficient to inhibit progesterone production and 
ovulation. To assess function of the preovulatory follicles apparently unaffected by 
treatment with ABT-898 it would have been informative to determine peak levels of 
plasma estradiol. However, detecting subtle differences in estradiol in marmosets 
may be confounded by high levels of circulating estrone (unpublished observations). 
To overcome this, the effects of ABT-898 depot treatment on estradiol secretion 
were investigated in the stump-tailed macaque. No change in serum estradiol was 
detected (H.M. Fraser, unpublished observations). 
 
The depot treatment was designed to investigate the immediate effects on major 
cycling events, such as ovulation and luteal function, as it has been shown that 
inhibition of angiogenesis can block ovulation (Taylor et al., 2007). As ABT-898 
treatment targets follicles at the preantral and early antral stages of development it is 
likely that any effects on ovulation and progesterone secretion would not be seen in 
the treatment cycle, but future cycles, as that would be when the targeted follicles 
would reach ovulation. In this study blood samples were collected for three months 
after treatment but as this is only 2 cycles post-treatment it is possible that effects on 
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ovulation and progesterone secretion would be seen later on. On the other hand, it is 
possible that ABT-898 targets follicles that are not destined to ovulate and this would 
explain why ovulation still occurred as normal, both in the treatment cycle and in the 
post-treatment cycles. It has previously been shown that treatment with Aflibercept 
blocked ovulation with immediate effect (Taylor et al., 2007) and this is likely to be 
due to the absolute requirement for VEGF for adequate follicular angiogenesis. TSP 
also inhibits angiogenesis but as TSP targets preantral and early antral follicles, 
angiogenesis still occurs in more developed follicles in the presence of TSP, thus 
allowing sufficient follicle developments during the treatment cycle to allow 
ovulation to occur.  
 
This chapter has shown for the first time that treatment of marmosets with a potent 
TSP-1 mimetic peptide, ABT-898, results in the reduction of angiogenesis in 
preantral and early antral follicles. In addition we have shown that ABT-898 is able 
to induce follicular atresia, in vivo. Angiogenesis is an important process in many 
pathological conditions and the regulation of angiogenesis is complex due to the 
interaction of the many pro- and anti-angiogenic factors involved in this process. 
Therefore, research that helps elucidate the role of these factors in angiogenesis and 
the ability to manipulate angiogenesis in vivo is of clinical importance. Angiogenesis 
is increased in PCOS and atresia of antral follicles is reduced (Agrawal et al., 1998a, 
Franks et al., 2000) so TSP-1 could be a potential treatment for this condition as it 
could have a dual role in targeting the increased angiogenesis and inducing atresia of 
accumulated antral follicles without affecting preovulatory follicle development and 
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ovulation. To further investigate the clinical possibilities of treatment of PCOS with 
TSP-1 studies in an animal model of PCOS would be required.  
 
There are many animal models available for the study of PCOS that have been 
developed over several decades and they provide insight into the pathophysiology of 
PCOS. The animals most commonly used for PCOS models are rodents, sheep and 
non-human primates and whilst they have all contributed to the understanding of the 
pathophysiology of PCOS, several of these models lack the traits required to be 
classed as PCOS models (Abbott et al., 2007, Franks, 2009). Models based on foetal 
programming appear to be the most representative of human PCOS and also exhibit 
the metabolic defects that are common in women with PCOS (Abbott DH et al., 
2006). Models of foetal programming use various developmental windows to expose 
foetuses to high levels of androgen and whilst they all result in PCOS, there are  
phenotypic differences in the presentation of PCOS in early treated and late treated 
animals (Vendola et al., 1998, West et al., 2001, Abbott et al., 2002, Abbott DH et 
al., 2006).  
 
The rhesus monkey is commonly used for non-human primate PCOS models and 
many studies have shown that the prenatally androgenised rhesus monkey develops 
PCOS-like abnormalities including multi-follicular ovaries, hyperandrogenism, 
altered LH production and metabolic abnormalities such as insulin resistance (Steiner 
et al., 1976, Abbott et al., 1998, Abbott et al., 2002, Eisner et al., 2002, Eisner et al., 
2003, Dumesic et al., 2005, Franks, 2009), suggesting that this model reliably 
produced traits that are closely related to PCOS in women.  
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More recent experiments with prenatally androgenised female sheep (Robinson et al., 
1999, West et al., 2001) support the findings in the rhesus monkey that prenatal 
androgen exposure to high levels of androgen at key windows of development results 
in a PCOS-like phenotype. Studies in prenatally androgenised rodents also support 
these findings (Sullivan and Moenter, 2004, Foecking et al., 2005), which indicates 
that the effects of prenatal exposure to high levels of androgen are concurrent across 
the different species. The various animal models have helped to improve the 
understanding of the pathophysiology of PCOS but no one model can provide all the 
answers as each have their advantages and disadvantages. Therefore, to investigate 
the potential effects of TSP-1 in PCOS it would be most informative to use a variety 
of animal models. There are many other factors that play an important role in the 
angiogenic cascade so the role of Ang-1 in ovarian angiogenesis will be investigated 
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6 Chapter 6 Angiopoietins Promote Angiogenesis and 
Follicle Survival  
6.1 Introduction 
Although VEGF is the key factor involved in stimulating angiogenesis, the 
angiopoietins are considered to be the most important class of proteins that act in 
concert with VEGF to produce and maintain stable blood vessels (Maisonpierre et 
al., 1997). The angiopoietins are cytokine glycoproteins which act in a competitive 
manner via the tyrosine kinase receptor Tie-2 (Maisonpierre et al., 1997). Four 
angiopoietins have been identified so far, with the best characterised being 
angiopoietin (Ang)-1 and Ang-2. Previous studies have shown that Ang-1 and Tie-2 
knockout mice exhibit embryonic lethality and have a high degree of blood vessel 
immaturity and disorganisation (Dumont et al., 1994, Sato et al., 1995, Suri et al., 
1996, Jones et al., 2001), showing that the angiopoietins are essential for vascular 
development and remodelling. It has been shown that Ang-1 plays a role in 
supporting and stabilising newly developed blood vessels (Thurston et al., 2005) and 
that it is able to induce angiogenesis in endothelial cells, in vitro (Koblizek et al., 
1998). Ang-2 has considerable sequence homology to Ang-1 but can both aid the 
development of new blood vessels and aid vascular regression, dependent on the 
circumstances, through antagonism of the Tie-2 receptor (Maisonpierre et al., 1997, 
Asahara et al., 1998, Witzenbichler et al., 1998). 
 
Ang-1 and Tie-2 are expressed in the ovarian follicle in the rodent, bovine and 
primate; however the expression pattern of this ligand and its receptor varies across 
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species. In the primate, specifically the marmoset, Tie-2 expression is localised in the 
vasculature of the thecal layer of antral follicles, but is also apparent in the granulosa 
cells of primordial, early preantral and preantral follicles as determined by in situ 
hybridisation (Wulff et al., 2001a). The bovine follicle expresses mRNA for Ang-1 
and Tie-2 in the thecal layer; however the granulosa cells express mRNA for the 
ligand only (Hayashi et al., 2003). Finally, it has been shown by IHC in the rat that 
Ang-1 expression is confined to the thecal endothelium of follicles; that it increases 
as the follicle develops, and is not present at any stage in the granulosa cells 
(Abramovich et al., 2009). 
 
Treatment of rat ovaries in vivo with an antibody to Ang-1 has been shown to 
promote follicular atresia (Parborell et al., 2008), suggesting that Ang-1 may have an 
anti-apoptotic effect on granulosa cells. Since Tie-2 receptors have not been 
previously localized in rat granulosa cells, it was concluded that Ang-1 promoted 
granulosa cell survival in a paracrine manner mediated via the Tie-2 receptor in the 
endothelial cells of the thecal layer. However, the presence of Tie-2 expression in 
granulosa cells of primordial, primary and preantral follicles in the marmoset ovary 
(Wulff et al., 2001a), and in antral follicles in the horse and sheep (Ellenberger et al., 
2009, Chowdhury et al., 2010), suggests that Ang-1 may have an extravascular role 
during follicular development by acting directly on granulosa cells.  
 
It has previously been shown that phosphorylation of Tie-2 by Ang-1 activates Akt 
(Augustin et al., 2009), which then activates pro-survival pathways and suppresses 
mediators of apoptotic pathways. There is increasing evidence that important 
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interactions occur between the PI-3 kinase/Akt pathway and members of the MAPK 
family (Papapetropoulos et al., 2000, Gratton et al., 2001, Harfouche et al., 2003, 
DeBusk et al., 2004). The best characterized members of the MAPKs include the 
extracellular signal-regulated kinases (ERKs) and the p38 kinases (Robinson and 
Cobb, 1997), which have anti- and pro-apoptotic functions, respectively. In addition, 
Akt signalling leads to inactivation of the forkhead transcription factor, FOXO1 
(Augustin et al., 2009), which blocks cell division and promotes apoptosis and has 
been shown to be expressed on granulosa cells (Bastie et al., 2005). It has also been 
reported that VEGF is able to activate the Tie-2 receptor in HUVECS independently 
of Ang-1 binding via cleavage of Tie-1 (Singh et al., 2009). If this occurs in 
granulosa cells it may have important implications for follicular development. 
 
In this chapter, the effects of Ang-1 on follicular angiogenesis were investigated 
using the in vitro angiogenesis assay described in Chapter 3. In addition, as current 
literature is unclear regarding the localisation of Tie-2, expression of Tie-2 receptor 
mRNA and protein in the rat ovary was localized to elucidate the cell types involved 
in Ang-1 action. Finally, the signalling pathway(s) activated by Ang-1 and the 
functional role of Ang-1 on granulosa cell survival were evaluated in vitro. 
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6.2 Materials and Methods 
6.2.1 Follicle Culture 
For all experiments, preantral/early antral follicles were cultured individually in flat-
bottomed 12-well plates, embedded in the centre of a 20µl droplet of growth-factor 
reduced Matrigel. The Matrigel provides a three-dimensional extracellular matrix 
support for follicle growth and allows the vascular outgrowths to develop in three-
dimensions, as they would in vivo. Follicles were incubated for 6 days in a sterile 
humidified air atmosphere with 5% CO2 at 37°C in 600µl serum-free EBM-2 
medium supplemented with BSA (0.1%), L-glutamine (3mM), penicillin (100 
IU/ml), streptomycin (0.1mg/ml), transferrin (2.5µg/ml), selenium (4ng/ml), insulin 
(10ng/ml) and L-ascorbic acid, sodium salt (50µg/ml), with culture medium 
refreshed every 48h.  
 
In order to test the effects of Ang-1, follicles were pooled and randomly placed into 
groups and cultured in serum-free EBM-2 medium (as described above) in the 
presence of 0.01 (n=17), 1 (n=18), 10 (n=16)  or 100μg/ml (n=18) Ang-1 (Bow-Ang-
1, a recombinant Ang-1 tetramer containing an Fc fusion protein (Koblizek et al., 
1998, Davis et al., 2003, Huang et al., 2009) (gift from Regeneron Pharmaceuticals, 
NY, USA). Medium containing an Fc portion of a human immunoglobulin 
component (gift from Regeneron) at 100µg/ml was used as the control (n=18).  
 
6.2.2 Immunohistochemistry 
In order to characterise Tie-2 expression during follicular development, ovaries from 
4 immature Wistar rats were fixed, embedded and serially sectioned, and tissue 
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sections (5µm) were placed onto BDH SuperFrost slides. The sections were 
incubated overnight at 4°C with Tie-2 antibody (1:100 in NGS) and visualisation was 
achieved by DAB Substrate (see Chapter 2). For the negative controls, the primary 
antibody was omitted. 
 
6.2.3 Granulosa Cell Experiments 
6.2.3.1 Isolation and culture of granulosa cells 
To investigate whether Ang-1 directly affects the health of granulosa cells, isolated 
granulosa cells were cultured in 0.1ml M199 medium containing 1 x 10
4
 cells/well. 
Following overnight preincubation in a sterile humidified air atmosphere with 5% 
CO2 at 37°C, prewarmed 0.1ml M199 medium containing with containing 0, 0.01, 
0.1, 1, 10 and 100µg/ml Ang-1 was added to each well for 48h. Treatments were 
carried out in triplicate and experiments were repeated three times. 
6.2.3.2 Caspase-3 and -7 activity assay 
To measure caspase-3 and -7 activities in isolated granulosa cells, the Caspase-Glo 
3/7 assay was
 
performed according to the manufacturer’s instructions, 48h after 
treating the cells (see Chapter 2). Treatments were carried out in triplicate and 




As serum can generate a background caspase activity signal,
 
an additional 
two wells contained cell culture medium and carrier
 
solution without any cells and 
TNFα was used as a positive control. 
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6.2.3.3 qRT-PCR 
At the end of the culture period, RNA was extracted for analysis, using the RNeasy 
micro-kit, following the manufacturer’s instructions (see Chapter 2). To avoid 
contamination by genomic DNA, each total RNA sample was treated with 
deoxyribonuclease, using the DNA-free kit. After RNA extraction, cDNA synthesis 
was performed using the Vilo cDNA synthesis kit as described in Chapter 2.  
 
Expression of Tie-2 and Ang-2 mRNA in granulosa cells, cultured in the presence or 
absence of test compounds, was examined using Taqman quantitative PCR as 
described in Chapter 2. Briefly, a master mix containing 18S primers and probes, 
100ng cDNA and primers and probes for the gene of interest were added to each 
sample. Samples were added in triplicate to a 96 well MicroAmp fast optical reaction 
PCR plate and analysed using an ABI 7900HT Real-Time PCR System. Expression 
of analysed genes was normalised to 18S and results are expressed as a percentage 
change from vehicle treated cells. 
6.2.3.4 RNA interference 
Granulosa cells that were isolated as described above were cultured with GFP-
expressing lentivirus to confirm that the lentivirus would be incorporated into this 
cell type and also to establish the conditions required for efficient transfection and 
lentivirus that did not express GFP was used as a negative control. The efficiency of 
transfection was determined by culturing isolated granulosa cells with lentivirus 
containing miRNA for LacZ at 1 virus/cell. Granulosa cells were isolated and 
cultured for 48h before being cultured with the LacZ-expressing lentivirus for 8h. 
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Lentivirus that did not express LacZ was used as a negative control.  After 8h the 
lentivirus was removed and cell were fixed in PBS containing 2% formaldehyde and 
0.2% gluteraldehyde for 5min at room temperature. Cells were washed and then 
stained with X-gal staining solution (23ml 0.5M NaH2PO4, 77ml 0.5M Na2HPO4, 
1.06g potassium ferrocyanide, 0.82g potassium ferricyanide, 5ml 1% deoxycholate, 
5ml 2% NP40, 1ml 1M MgCl2, made up to 500ml with dH20; 2ml X-gal added per 
100ml staining solution) overnight at 37°C.  
 
RNA knockdown was performed to investigate the importance of Tie-1, Tie-2 and 
Ang-2 in the angiogenic cascade and follicle health. Oligonucleotides encoding 
miRNA constructs for Tie-1, Tie-2 and Ang-2 were obtained from Invitrogen and 
also designed by Pamela Brown and Laura Milne from the in-house Biomolecular 
Core Facility. The in-house Biomolecular Core Facility then inserted these miRNA 
constructs into a cloning vector, prior to being inserted into GFP-expressing 
lentivirus.  
 
Granulosa cells were isolated and cultured for 48h before being cultured with the 
GFP-expressing lentivirus containing the miRNA construct at 10 viruses/cell, for 8h. 
After 8h the lentivirus was removed and replaced with fresh medium for 24h. The 
cells were then treated with Ang-1 for 48h before protein or RNA was extracted from 
the cells to allow quantification of expression of genes of interest. 
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6.2.4 Western blotting 
Protein was extracted from isolated granulosa cells as described previously (Chapter 
2) and were resolved on 4–20%
 
Tris-glycine gels and transferred onto a PVDF-fl 
membrane. Membranes were blocked for 1h at
 
25°C in Rockland Near Infra Red 
blocking buffer and incubated overnight at 4°C in blocking buffer containing
 
rabbit 
anti-phospho-p42/44 ERK (1:1000), rabbit anti-phospho-p38 (1:500), FOXO1 
(1:1000), pTie-2 (1:1000), HIF1α (1:500), Tie-1 (1:1000), Tie-2 (1:1000) or Ang-2 
(1:1000) and β-actin (1:1000). After washing in PBS containing
 
0.5% Tween, 
membranes were incubated for 1h at 25°C in the dark in donkey anti goat IgG 
conjugated to IRDYE 800 and donkey anti rabbit IgG conjugated to Alexa Fluor
 
680 
both at a dilution of 1:5000 in blocking buffer. Membranes were washed and proteins 
visualised and quantified
 
using an Odyssey Infrared Imaging System. Sample loading 





6.2.5.1 Analysis of Angiogenic Sprouting 
To assess the impact of the treatments on angiogenic sprouting, follicles were 
examined and photographed directly in the 12-well plates under an inverted light 
microscope, at x10 magnification, with Axiovision image capturing software on days 
0 and 6 of the culture period. The total area of angiogenic sprouting for each follicle 
was determined using Image Pro Plus software, by drawing an area of interest around 
the outgrowths (but excluding the follicle) and the sum of the area of all sprouts is 
measured and calculated by the software. The mean area of angiogenic sprouting for 
each treatment was then compared to the control.  
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6.2.5.2 Analysis of immunohistochemistry 
The expression of Tie-2 was analysed manually at x40 magnification using a tally 
counter. Expression was determined in the granulosa and thecal layers of early 
preantral (n=37), preantral (n=49) and early antral (n=75) follicles with the intensity 
of Tie-2 expression being classified in each follicle using a visual scoring system 
(1=weak; 2=moderate; 3=strong staining). The percentage of follicles at each 
intensity was then calculated for each follicle stage and expressed as a mean 
HSCORE value (Budwit-Novotny DA 1986).  
6.2.5.3 Quantification of X-gal staining and GFP expression 
To assess the efficiency of transfection the total number of cells and total number of 
X-gal stained cells (blue) were counted in 10 random fields of view and the averages 
were used to estimate the transfection efficiency using the calculation: 
 
Total number of blue cells  x 100  = % transfection 
       Total number of cells 
 
To determine the level of GFP-expressing cells the total number of cells and total 
number of GFP-expressing cells (green) were counted in 10 random fields of view 
and the averages were used to estimate the percentage of cells expressing GFP. 
 
6.2.6 Statistical Analyses 
Data are presented as mean ± SEM and all results were analysed statistically using 
Graph Pad Prism 5 software (Graph Pad Software) where appropriate. The results 
were analysed by means of a One-way ANOVA with a Bonferroni post-hoc test 
performed if the 95% confidence interval was reached to determine significance 
Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 6 Angiopoietins Promote Angiogenesis and Follicle Survival  199 
between all of the data groups. P values <0.05 were accepted as statistically 
significant.  
Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 6 Angiopoietins Promote Angiogenesis and Follicle Survival  200 
6.3 Results 
6.3.1   Expression of Tie-2 in the rat ovary 
Tie-2 expression has previously been reported to be expressed exclusively in the 
thecal endothelium in the rodent ovary (Abramovich et al., 2009). In this chapter, it 
has been shown for the first time that Tie-2 is expressed both in the granulosa and 
thecal layers of rat follicles (Figure 6.1A-D). Using immunohistochemistry, 
expression of Tie-2 protein was found to be higher in granulosa cells of preantral and 
early antral follicles compared to early preantral follicles (p<0.01) (Figure 6.1E). In 
the thecal layer, there was no change in the intensity of Tie-2 expression between 
early preantral, preantral and antral follicles (Figure 6.1F). 
 
RT-PCR was performed to detect expression of Tie-2 mRNA in granulosa cell 
samples (n=4 animals). Results are expressed as relative amount compared to 
expression of 18S and show that Tie-2 mRNA was expressed in granulosa cells, 
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Figure 6.1 Expression of Tie-2 in the rat ovary 
To determine the expression of Tie-2 in the rat ovary immature rat ovaries (n=5) were fixed, 
sectioned and stained for Tie-2. Representative images show early preantral (A), preantral 
(B), and early antral (C) follicles stained for Tie-2 (brown staining). An early antral follicle 
from a negative control slide is also shown (D). Expression of Tie-2 was quantified by 
HSCORE (E) and analysed by One-way ANOVA with a Bonferroni post-hoc test to compare 
the expression of Tie-2 at the different stages of follicle development. Tie-2 expression was 
found to be significantly higher (**P<0.01) in granulosa cells of preantral and early antral 
follicles compared to early preantral follicles. In the thecal layer, there was no change in the 
intensity of Tie-2 expression between the different stages of follicular development (F). Scale 
bars represent 100µm. Experiments were repeated in triplicate. 
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Figure 6.2 Expression of Tie-2 mRNA in granulosa cells 
To confirm the expression of Tie-2 in granulosa cells, granulosa cells were cultured and then 
RNA was isolated for PCR. Expression of Tie-2 mRNA, in granulosa cell samples (n=4 
animals), was quantified by qRT-PCR and 18s mRNA as an internal control.  Tie-2 mRNA 







6.3.2 Effect of Ang-1 on angiogenesis 
To investigate the effect of Ang-1 on follicular angiogenesis, follicles were cultured 
in serum-free EBM-2 medium treated with 0.01, 1, 10 and 100µg/ml Ang-1 for six 
days. Treatment with Ang-1 resulted in a stimulation of follicular angiogenesis, in a 
dose dependent manner, (Figure 6.3) (P<0.01), showing that Ang-1 is able to induce 
angiogenesis in whole ovarian follicles in vitro. 
 
Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 6 Angiopoietins Promote Angiogenesis and Follicle Survival  203 
 
 































Figure 6.3 Effect of Ang-1 on angiogenesis  
To determine the effect of Ang-1 on angiogenesis isolated preantral and early antral follicles 
were cultured with varying doses of Ang-1 (n=6 per treatment). At the end of the culture 
period the area of the angiogenic outgrowths was measured using Image Pro-Plus software. 
Representative images show endothelial outgrowths from a control follicle (A) and follicles 
after treatment with Ang-1 at 0.01µg/ml (B), 1µg/ml (C), 10µg/ml (D) or 100µg/ml (E). The 
results were quantified and analysed statistically using a One-way ANOVA with a 
Bonferroni post-hoc test to compare the Ang-1 treated follicles to the Fc control follicles. 
Treatment with 100µg/ml Ang-1 resulted in a significant increase (**P<0.01) in outgrowth 
area (F), when compared to the Fc control. White arrows indicate the endothelial 
outgrowths. Scale bars represent 200µm. Experiments were repeated in triplicate. 
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6.3.3 Effect of Ang-1 on follicle health 
To investigate the effect of Ang-1 on follicular apoptosis, isolated granulosa cells 
were cultured with 0, 0.01, 0.1, 1, 10 and 100µg/ml Ang-1 for 48h followed by 
quantification of apoptosis using a luminescent caspase-3/7 assay. Activated caspase-
3/7 activity was significantly decreased (P<0.01) in the presence of low doses of 
Ang-1 (0.01 and 0.1µg/ml), compared to controls. In contrast, treatment with 
100µg/ml Ang-1 resulted in a significant increase (P<0.001) in caspase-3/7 activity 
(Figure 6.4). 




































Figure 6.4 Effect of Ang-1 on granulosa cell apoptosis  
To determine the effect of Ang-1 on apoptosis granulosa cells were isolated from preantral 
and early antral follicles and they were cultured with varying doses of Ang-1 (n=4 per 
treatment). At the end of the culture period these granulosa cells were analysed for 
expression of activated caspase-3/7 activity using a luminescent caspase activity assay, as an 
indicator of follicle health. A One-way ANOVA with a Bonferroni post-hoc test was 
performed to compare the Ang-1 treated granulosa cells to the Fc control granulosa cells. 
Treatment with 0.01 and 0.1µg/ml Ang-1 resulted in a significant decrease (**P<0.01) in 
activated caspase-3 expression (F), when compared to the Fc control. In contrast, treatment 
with 100µg/ml Ang-1 resulted in a significant increase (***P<0.001) in activated caspase-3 
expression (F), when compared to the Fc control. Luminescence is given in arbitrary units 
(au). Experiments were repeated in triplicate. 
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6.3.4 Mechanisms of the pro-survival and apoptotic effects of 
Ang-1 
6.3.4.1 Quantification of pERK and p38 expression by western blotting 
As we have shown that low doses of Ang-1 decrease expression of activated caspase-
3 and that high doses can increase expression of activated caspase-3 the role of Ang-
1 in promoting expression of signalling molecules involved in cell survival or 
apoptosis was investigated. To investigate this isolated granulosa cells were cultured 
with 0, 0.01, 0.1, 1, 10 and 100µg/ml of Ang-1 for 48h followed by quantification of 
the expression of pERK (Figure 6.5A) and p38 (Figure 6.6A) by western blotting. 
Consistent with the finding that low doses of Ang-1 reduced activated caspase-3 
activity, the lowest doses of Ang-1 (0.01 and 0.1µg/ml) increased the expression of 
phospho-ERK1/2 (Figure 6.5B). In contrast, higher doses (10 and 100µg/ml) of Ang-
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Figure 6.5 Levels of pERK expression after treatment with Ang-1 
Isolated granulosa cells were cultured with varying doses of Ang-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of apoptosis induction the level of pERK expression was measured by 
western blotting (A). L – size ladder. Gels were laid out with the size marker on the left-hand 
side of the gel, the control samples and then the samples treated with Ang-1. The control 
samples were used on each gel so that a direct comparison to the expression in the control, 
on that gel, could be made. The size of the bands of interest has been shown on the right of 
the figure with the size marker bands on the left. These data were quantified (B) and 
analysed statistically by One-way ANOVA with a Bonferroni post-hoc test to compare the 
Ang-1 treated granulosa cells to the Fc control granulosa cells. Treatment with 0.01 and 
0.1µg/ml Ang-1 resulted in a significant increase (*P<0.05) in the expression of pERK (F), 
when compared to the Fc control. Experiments were repeated in triplicate. 
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Figure 6.6 Levels of p38 expression after treatment with Ang-1 
Isolated granulosa cells were cultured with varying doses of Ang-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of apoptosis induction the level of p38 expression was measured by 
western blotting (A). L – size ladder. Gels were laid out with the size marker on the left-hand 
side of the gel, the control samples and then the samples treated with Ang-1. The control 
samples were used on each gel so that a direct comparison to the expression in the control, 
on that gel, could be made. The size of the bands of interest has been shown on the right of 
the figure with the size marker bands on the left. These data were quantified (B) and 
analysed statistically by One-way ANOVA with a Bonferroni post-hoc test to compare Ang-1 
treated granulosa cells to the Fc control granulosa cells. Treatment with 10 and 100µg/ml 
Ang-1 resulted in a significant increase (*P<0.05) in the expression of p38 (F), when 
compared to the Fc control. Experiments were repeated in triplicate. 
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6.3.4.2 Quantification of FOXO1 expression by western blotting 
FOXO1 is a transcription factor that blocks cell division and promotes apoptosis and 
is inactivated by Akt signalling. As Ang-1 has been shown to activate Akt we 
suggested that treatment with Ang-1 could lead to the inhibition of FOXO1 and 
therefore promote follicle health. To investigate this isolated granulosa cells were 
treated with 0, 0.01, 0.1, 1, 10 or 100µg/ml Ang-1 and then the level of FOXO1 
expression was measured by western blotting (Figure 6.7A). The results showed that 
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Figure 6.7 Levels of FOXO1 expression after treatment with Ang-1 
Isolated granulosa cells were cultured with varying doses of Ang-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of apoptosis induction the level of FOXO1 expression was measured by 
western blotting (A). L – size ladder. Gels were laid out with the size marker on the left-hand 
side of the gel, the control samples and then the samples treated with Ang-1. The control 
samples were used on each gel so that a direct comparison to the expression in the control, 
on that gel, could be made. The size of the bands of interest has been shown on the right of 
the figure with the size marker bands on the left. These data were quantified (B) and 
analysed statistically by One-way ANOVA to compare Ang-1 treated granulosa cells to the 
Fc control granulosa cells. The results show that there is no change in the expression of 
FOXO1 after treatment with Ang-1. Experiments were repeated in triplicate. 
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6.3.5 Mechanisms of the pro-angiogenic effect of Ang-1 
6.3.5.1 Quantification of pTie-2 expression by western blotting 
As Ang-1 is thought to promote blood vessel stabilisation through signalling via the 
Tie-2 receptor, the expression of phosphorylated Tie-2 (pTie-2) was quantified by 
western blotting (Figure 6.8A). These results showed that there was a trend of 
increasing pTie-2 expression in granulosa cells treated with increasing doses of Ang-
1; however this was not significant (Figure 6.8B). This suggests that with the higher 
doses of Ang-1 there may be increased signalling via the Tie-2 receptor, giving 
support to the suggestion that Ang-1 promotes blood vessel development through 
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Figure 6.8 Levels of pTie-2 expression after treatment with Ang-1 
Isolated granulosa cells were cultured with varying doses of Ang-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of Ang-1 action on angiogenesis the level of pTie-2 expression was 
measured by western blotting (A). L – size ladder. Gels were laid out with the size marker on 
the left-hand side of the gel, the control samples and then the samples treated with Ang-1. 
The control samples were used on each gel so that a direct comparison to the expression in 
the control, on that gel, could be made. The size of the bands of interest has been shown on 
the right of the figure with the size marker bands on the left. These data were quantified (B) 
and analysed statistically by One-way ANOVA to compare Ang-1 treated granulosa cells to 
the Fc control granulosa cells. A trend in increasing expression of pTie-2 can be seen in 
granulosa cells treated with Ang-1. Experiments were repeated in triplicate. 
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6.3.5.2 Quantification of HIF1α expression by western blotting  
Hypoxic conditions are a key stimulator of angiogenesis and lead to increased 
expression of HIF1α. The higher doses of Ang-1 have been shown to stimulate 
angiogenesis in vitro so the effect of Ang-1 treatment on the expression of HIF1α 
was investigated to elucidate the mechanisms of the stimulation of angiogenesis by 
Ang-1. The results showed that there was no difference in HIF1α expression after 
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Figure 6.9 Levels of HIF1α expression after treatment with Ang-1 
Isolated granulosa cells were cultured with varying doses of Ang-1 (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of anti-angiogenesis the level of hypoxia-inducible factor-1α (HIF1α) 
expression was measured by western blotting (A). L – size ladder. Gels were laid out with 
the size marker on the left-hand side of the gel, the control samples and then the samples 
treated with Ang-1. The control samples were used on each gel so that a direct comparison 
to the expression in the control, on that gel, could be made. The size of the bands of interest 
has been shown on the right of the figure with the size marker bands on the left. These data 
were quantified (B) and analysed statistically by One-way ANOVA to compare the Ang-1 
treated granulosa cells to the Fc control granulosa cells. The results show that there is no 
change in the expression of HIF1α after treatment with Ang-1. Experiments were repeated in 
triplicate. 
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6.3.6 Investigation of the effect of RNA knockdown on genes of 
interest in rat granulosa cells 
To further confirm the role of Ang-1 in angiogenesis and cell survival and the 
pathways through which they occur, the effect of knocking down Tie-1, Tie-2 or 
Ang-2 was investigated using miRNA. Ang-1 acts mainly through binding to the 
receptor Tie-2 so it was hypothesized that knocking down the expression of the Tie-2 
receptor would inhibit the actions of Ang-1. The receptor Tie-1 plays a role in 
mediating the actions of Ang-1 and Ang-2 but the importance of its role in this 
pathway is still unclear so Tie-1 was knocked down to determine whether the effects 
of Ang-1 were altered by the absence of Tie-1.  Ang-2 acts in concert with Ang-1 in 
a competitive manner via the receptor Tie-2 so it was hypothesised that knocking 
down Ang-2 could result in increased activity of Ang-1 due to the lack of 
competition for the receptor. 
6.3.6.1 Trial with GFP-expressing lentivirus 
First, isolated granulosa cells were cultured with GFP-expressing lentivirus to 
confirm that the lentivirus would be incorporated into this cell type and also to 
establish the conditions required for efficient transfection. The granulosa cells were 
cultured for either 24 or 48h before the addition of the lentivirus and the lentivirus 
was removed from the cells after 8h. The lentivirus was added to the cells at varying 
concentrations (1 virus/cell, 5 viruses/cell, 10 viruses/cell and 50 viruses/cell) to 
determine the optimum virus to cell ratio. The level of GFP expression was 
monitored over 5 days to determine the optimal time for RNA and protein extraction. 
Granulosa cells cultured for 24h prior to the addition of the lentivirus did not 
efficiently incorporate the lentivirus (Figure 6.10) and few GFP-expressing granulosa 
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cells were observed. Granulosa cells cultured for 48h prior to the addition of the 
lentivirus efficiently incorporated the lentivirus with about 85-90% of granulosa cells 
expressing GFP after 72h (Figure 6.11). In addition, approximately 85-90% of 
granulosa cells were observed to be expressing GFP 96h after the removal of the 
lentivirus (Figure 6.12), suggesting that a longer culture post-lentivirus treatment is 
not necessary. Therefore the optimum conditions for the incorporation of lentivirus 
into granulosa cells were determined to be 48h culture prior to the addition of the 
lentivirus, 8h culture with the lentivirus at 10 viruses/cell, and then a further 72h 
culture prior to RNA or protein extraction. 
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Figure 6.10 Levels of GFP expression in granulosa cells cultured for 24h prior to 
lentiviral treatment  
To investigate the effects of knocking down genes of interest on Ang-Tie signalling miRNA to 
these genes were transfected into GFP-expressing lentivirus. First it was determined 
whether the lentivirus would transfect into the isolated granulosa cells after being cultured 
for 24h prior to the addition of varying concentrations of GFP-expressing lentivirus and the 
level of GFP expression was detected after 72h. Representative fluorescent and brightfield 
images show granulosa cells cultured with a negative control lentivirus (A), with GFP-
expressing lentivirus at 1 virus/cell (B), 5 viruses/cell (C), 10 viruses/cell (D) and 50 
viruses/cell (E). Few GFP-expressing granulosa cells were observed even with 50 
viruses/cell, suggesting that granulosa cells cultured for 24h prior to the addition of the 
lentivirus do not efficiently incorporate the lentivirus. Scale bars represent 50µm. 
Experiments were repeated in triplicate. 
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Figure 6.11 Levels of GFP expression in granulosa cells cultured for 48h prior to 
lentiviral treatment  
To investigate the effects of knocking down genes of interest on Ang-Tie signalling miRNA to 
these genes were transfected into GFP-expressing lentivirus. First it was determined 
whether the lentivirus would transfect into the isolated granulosa cells after being cultured 
for 48h prior to the addition of varying concentrations of GFP-expressing lentivirus and the 
level of GFP expression was detected after 72h. Representative fluorescent and brightfield 
images show granulosa cells cultured with a negative control lentivirus (A), with GFP-
expressing lentivirus at 1 virus/cell (B), 5 viruses/cell (C), 10 viruses/cell (D) and 50 
viruses/cell (E). The results show that the lentivirus was incorporated into the granulosa 
cells and cells cultured with 10 viruses/cell or 50 viruses/cell had the highest percentage of 
GFP-expressing cells, with about 85-90% of granulosa cells expressing GFP after 72h. 
Scale bars represent 50µm. Experiments were repeated in triplicate. 
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Figure 6.12 Levels of GFP expression in granulosa cells cultured for 96h after lentiviral 
treatment  
To determine the optimum time after lentiviral treatment for detection of GFP expression the 
level of GFP was detected at both 72hr (Figure 6.11) and 96hr. Isolated granulosa cells 
were cultured for 48h prior to the addition of varying concentrations of GFP-expressing 
lentivirus and the level of GFP expression was detected after 96h. Representative fluorescent 
and brightfield images show granulosa cells cultured with a negative control lentivirus (A), 
with GFP-expressing lentivirus at 10 viruses/cell (B) and 50 viruses/cell (C). The results 
show that the lentivirus was incorporated into the granulosa cells, with about 85-90% of 
granulosa cells expressing GFP after 96h. Scale bars represent 50µm. Experiments were 
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6.3.6.2 Efficiency of transfection 
To assess the efficiency of transfection isolated granulosa cells were cultured with a 
LacZ-expressing lentivirus and then stained with X-gal. The results show that the 
lentivirus was incorporated into the granulosa cells, with about 35-40% of granulosa 
cells stained with X-gal (Figure 6.13). Due to the low titre of the lentivirus it was 
only possible to carry out this investigation with 1 virus/cell. It is expected that at a 
higher virus to cell ratio the efficiency of transfection would be greater and therefore 




Figure 6.13 Detection of X-gal staining in granulosa cells 
To assess the efficiency of transfection, isolated granulosa cells were cultured with a LacZ-
expressing lentivirus and then stained with X-gal. Isolated granulosa cells were cultured for 
48h prior to the addition of LacZ-expressing lentivirus. After 72h X-gal was added to the 
cells to detect the expression of LacZ (blue staining). Representative images show granulosa 
cells cultured with a negative control lentivirus (A) or with LacZ-expressing lentivirus at 1 
virus/cell (B). The results show that the lentivirus was incorporated into the granulosa cells, 
with about 35% of granulosa cells staining with X-gal. Scale bars represent 50µm. 
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6.3.7 Effect of Tie-1 knockdown on VEGF signalling 
6.3.7.1 Trial of miRNA constructs designed to knockdown Tie-1 
It has been reported that VEGF is able to activate the Tie-2 receptor in HUVECS 
independently of Ang-1 binding via cleavage of Tie-1 (Singh et al., 2009). To 
investigate this, miRNA either specifically targeted to Tie-1 or with a scrambled 
sequence as a control, was transfected into granulosa cells using lentiviral delivery. 
As the miRNA constructs were cloned into a GFP-expressing lentivirus the level of 
incorporation into the granulosa cells could be detected by the level of GFP 
expression. All of the miRNA constructs that were designed to knockdown Tie-1 
were highly incorporated into the granulosa cells, with approximately 85% of 
granulosa cells expressing GFP. Once this had been determined, the level of Tie-1 
expression was quantified by western blotting (Figure 6.14A). The results show that 
there was a significant decrease in the expression of Tie-1 (P<0.001) after treatment 
with the miRNA constructs (Figure 6.14B), showing that the miRNA constructs were 
able to knockdown expression of Tie-1 in these cells. Constructs LV8 and LV9 gave 
the greatest reduction in expression of Tie-1 – approximately an 85% knockdown of 








Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 6 Angiopoietins Promote Angiogenesis and Follicle Survival  221 
 
 































Figure 6.14 Levels of Tie-1 expression after treatment with miRNA 
To determine whether the miRNA constructs were able to knock down the expression of Tie-1 
isolated granulosa cells were cultured with various miRNA constructs (n=3 per treatment) 
designed to knock-down Tie-1. At the end of the culture protein was extracted from the 
granulosa cells and the level of Tie-1 expression was measured by western blotting (A). L – 
size ladder. Gels were laid out with the size marker on the left-hand side of the gel, the 
control samples and then the samples treated with Ang-1. The control samples were used on 
each gel so that a direct comparison to the expression in the control, on that gel, could be 
made. The size of the bands of interest has been shown on the right of the figure with the size 
marker bands on the left. These data were quantified (B) and analysed statistically by One-
way ANOVA with a Bonferroni post-hoc test to compare the effect of the different constructs 
to the control granulosa cells. The results show that there is a significant decrease 
(***P<0.001) in the expression of Tie-1 after treatment with the miRNA constructs when 
compared to the control. Experiments were repeated in triplicate. 
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6.3.7.2 Effect of Tie-1 knockdown on expression of VEGF 
Constructs LV8 and LV9 gave the greatest reduction in expression of Tie-1 so they 
were used to investigate the effect of Tie-1 knockdown on VEGF signalling. Isolated 
granulosa cells were treated with constructs LV8 and LV9 and with varying doses of 
Ang-1. First, westerns for Tie-1 were performed to confirm that miRNA LV8 and 
LV9 knocked down expression of Tie-1. The results showed that there is a 
significant decrease in Tie-1 expression after treatment with LV8 (Figure 6.15) and 
with LV9 (Figure 6.16). However, there was no difference in the level of knock 
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Figure 6.15 Levels of Tie-1 expression after treatment with Ang-1 and LV8 
Once it had been determined that miRNA contruct LV8 sufficiently knocked down Tie-1 
expression the effect of knocking down Tie-1 expression on the effect of Ang-1 was 
investigated. Isolated granulosa cells were cultured with miRNA construct LV8 designed to 
knock-down Tie-1 along with 0, 0.1, or 100µg/ml Ang-1 (n=3 per treatment) and then 
protein was extracted to allow western blotting to be performed and then the level of Tie-1 
expression was measured by western blotting (A). L – size ladder. Gels were laid out with 
the size marker on the left-hand side of the gel, the control samples and then the samples 
treated with Ang-1. The control samples were used on each gel so that a direct comparison 
to the expression in the control, on that gel, could be made. The size of the bands of interest 
has been shown on the right of the figure with the size marker bands on the left. These data 
were quantified (B) and analysed statistically by One-way ANOVA with a Bonferroni post-
hoc test to compare the Ang-1 treated granulosa cells to the scrambled control granulosa 
cells. The results show that there is a significant decrease (***P<0.001) in the expression of 
Tie-1 after treatment with LV8 when compared to the scrambled control. There was no 
difference in the level of knock down of Tie-1 expression after treatment with Ang-1. 
Experiments were repeated in triplicate. 
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Figure 6.16 Levels of Tie-1 expression after treatment with Ang-1 and LV9 
Once it had been determined that miRNA contruct LV9 sufficiently knocked down Tie-1 
expression the effect of knocking down Tie-1 expression on the effect of Ang-1 was 
investigated. Isolated granulosa cells were cultured with miRNA construct LV8 designed to 
knock-down Tie-1 along with 0, 0.1, or 100µg/ml Ang-1 (n=3 per treatment) and then 
protein was extracted to allow western blotting to be performed and then the level of Tie-1 
expression was measured by western blotting (A). L – size ladder. Gels were laid out with 
the size marker on the left-hand side of the gel, the control samples and then the samples 
treated with Ang-1. The control samples were used on each gel so that a direct comparison 
to the expression in the control, on that gel, could be made. The size of the bands of interest 
has been shown on the right of the figure with the size marker bands on the left. These data 
were quantified (B) and analysed statistically by One-way ANOVA with a Bonferroni post-
hoc test to compare the Ang-1 treated granulosa cells to the scrambled control granulosa 
cells. The results show that there is a significant decrease (***P<0.001) in the expression of 
Tie-1 after treatment with LV9, when compared to the scrambled control. There was no 
difference in the level of knock down of Tie-1 expression after treatment with Ang-1. 
Experiments were repeated in triplicate. 
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Subsequently westerns for VEGF were performed to investigate whether knockdown 
of Tie-1 expression had an effect on expression of VEGF. The results showed that 
there is a significant decrease (P<0.05) in VEGF expression after treatment with the 
miRNA constructs LV8 and LV9 (Figure 6.17), but only after treatment with the 0.1 
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Figure 6.17 Levels of VEGF expression after treatment with Ang-1 
Once it had been determined that the miRNA contructs sufficiently knocked down Tie-1 
expression the effect of knocking down Tie-1 expression on VEGF expression was 
investigated. Isolated granulosa cells were cultured with miRNA construct LV8 or miRNA 
construct LV9 both designed to knock-down Tie-1 along with 0, 0.1, or 100µg/ml Ang-1 
(n=3 per treatment) and protein was extracted to allow western blotting to be performed and 
then the level of VEGF expression was measured by western blotting (A). L – size ladder. 
Gels were laid out with the size marker on the left-hand side of the gel, the control samples 
and then the samples treated with Ang-1. The control samples were used on each gel so that 
a direct comparison to the expression in the control, on that gel, could be made. The size of 
the bands of interest has been shown on the right of the figure with the size marker bands on 
the left. These data were quantified (B) and analysed statistically by One-way ANOVA with a 
Bonferroni post-hoc test to compare the effect of the different constructs to the scrambled 
control granulosa cells. Treatment with 0.1 and 100ng/ml Ang-1 resulted in a statistically 
significant decrease in the expression of VEGF after knock down of Tie-1. * indicates 
P<0.05, ** indicates P<0.01, when compared to the scrambled control. Experiments were 
repeated in triplicate.  
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6.3.8 Effect of Tie-2 knockdown  
6.3.8.1 Trial of miRNA constructs designed to knockdown Tie-2 
Ang-1 acts via the receptor Tie-2 to promote angiogenesis and cell survival so it is 
likely that with the removal of this receptor there would be a negative effect on cell 
survival and possibly a destabilisation of newly developed blood vessels. To 
investigate this miRNA either specifically targeted to Tie-2 or with a scrambled 
sequence as a control, was transfected into granulosa cells using lentiviral delivery 
and then the level of Tie-2 expression was quantified by western blotting (Figure 
6.18A). These the results showed that there was a significant decrease in the 
expression of Tie-2 (P<0.05) after treatment with the miRNA constructs (Figure 
6.18B). However the level of knockdown of Tie-2 expression was only around 25% 
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Figure 6.18 Levels of Tie-2 expression after treatment with miRNA 
To determine whether the miRNA constructs were able to knock down the expression of Tie-2 
isolated granulosa cells were cultured with various miRNA constructs (n=3 per treatment). 
At the end of the culture protein was extracted from the granulosa cells and the level of Tie-2 
expression was measured by western blotting (A). L – size ladder. Gels were laid out with 
the size marker on the left-hand side of the gel, the control samples and then the samples 
treated with Ang-1. The control samples were used on each gel so that a direct comparison 
to the expression in the control, on that gel, could be made. The size of the bands of interest 
has been shown on the right of the figure with the size marker bands on the left. These data 
were quantified (B) and analysed statistically by One-way ANOVA with a Bonferroni post-
hoc test to compare the effect of the different constructs to the control granulosa cells. The 
results show that there is a statistically significant decrease in the expression of Tie-2 after 
treatment with the miRNA constructs. * indicates P<0.05, ** indicates P<0.01, when 
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6.3.8.2 Effect of Tie-2 knockdown on mRNA expression of Tie-2 
As the miRNA constructs were cloned into a GFP-expressing lentivirus the level of 
incorporation into the granulosa cells could be detected by the level of GFP 
expression. All of the miRNA constructs that were designed to knockdown Tie-2 
were highly incorporated into the granulosa cells, with approximately 85% of 
granulosa cells expressing GFP. However the level of knockdown of Tie-2 
expression was very low for this level of lentiviral incorporation into the cells. This 
suggests that the protein is very stable and changes in protein expression are not 
easily detectable. Therefore the expression of Tie-2 mRNA was determined by qRT-
PCR to investigate whether knockdown of the gene had occurred (Figure 6.19). The 
results show that that there is a significant decrease in the expression of Tie-2 mRNA 
(P<0.001) after treatment with all of the miRNA constructs and that constructs LV10 
and LV12 gave the greatest reduction in expression of Tie-2 – approximately 75-
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Figure 6.19 Levels of Tie-2 mRNA expression after treatment with miRNA 
The level of knock-down of Tie-2 protein expression was not as expected when compared to 
the GFP expression in these cells so the level of Tie-2 mRNA was investigated to determine 
whether the miRNA constructs had knocked down the expression of Tie-2. Isolated granulosa 
cells were cultured with miRNA constructs designed to knock-down Tie-2 expression and 
then the level of Tie-2 expression was measured by qRT-PCR (A). These data were 
quantified (B) and analysed statistically by One-way ANOVA with a Bonferroni post-hoc test 
to compare the effect of the different constructs to the control granulosa cells. The results 
show that there is a statistically significant decrease (***P<0.001) in the expression of Tie-2 
after treatment with the miRNA constructs, when compared to the control. Experiments were 
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6.3.9 Effect of Ang-2 knockdown 
6.3.9.1 Trial of miRNA constructs designed to knockdown Ang-2 
Ang-2 binds to the receptor Tie-2 but unlike Ang-1 does not activate it, and excess 
Ang-2 inhibits the activity of Ang-1 (Maisonpierre et al., 1997). In addition, Ang-2 
has been shown to be expressed in the rat ovary and is highly expressed in the 
granulosa cell layer of atretic follicles, suggesting that Ang-2 could both play a role 
in the regulation of angiogenesis and could have an extravascular role in the ovary.  
Therefore the effect of suppressing the expression of Ang-2 was investigated in vitro. 
Isolated granulosa cells were cultured with miRNA constructs designed to 
knockdown Ang-2 and then the level of Ang-2 expression was quantified by western 
blotting (Figure 6.20A). The results showed that there was a significant decrease in 
the expression of Ang-2 (P<0.001) after treatment with the miRNA constructs 
(Figure 6.20B). However the level of knockdown of Ang-2 expression was only 
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Figure 6.20 Levels of Ang-2 expression after treatment with miRNA 
To determine whether the miRNA constructs were able to knock down the expression of Ang-
2 isolated granulosa cells were cultured with various miRNA constructs (n=3 per treatment). 
At the end of the culture protein was extracted from the granulosa cells and the level of Ang-
2 expression was measured by western blotting (A). L – size ladder. Gels were laid out with 
the size marker on the left-hand side of the gel, the control samples and then the samples 
treated with Ang-1. The control samples were used on each gel so that a direct comparison 
to the expression in the control, on that gel, could be made. The size of the bands of interest 
has been shown on the right of the figure with the size marker bands on the left. These data 
were quantified (B) and analysed statistically by One-way ANOVA with a Bonferroni post-
hoc test to compare the effect of the different constructs to the control granulosa cells. The 
results show that there is a slight, but significant, decrease (***P<0.001) in the expression 
of Ang-2 after treatment with the miRNA constructs, when compared to the control. 
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6.3.9.2 Effect of Ang-2 knockdown on mRNA expression of Ang-2 
As the miRNA constructs were cloned into a GFP-expressing lentivirus the level of 
incorporation into the granulosa cells could be detected by the level of GFP 
expression. All of the miRNA constructs that were designed to knockdown Ang-2 
were highly incorporated into the granulosa cells, with approximately 85% of 
granulosa cells expressing GFP. However the level of knockdown of Ang-2 
expression was very low for this level of lentiviral incorporation into the cells. This 
suggests that the protein is very stable and changes in protein expression are not 
easily detectable. Therefore the expression of Ang-2 mRNA was determined by 
qRT-PCR to investigate whether knockdown of the gene had occurred (Figure 6.21). 
The results show that that there is a significant decrease in the expression of Ang-2 
(P<0.001) after treatment with all of the miRNA constructs and that constructs LV16 
and LV17 gave the greatest reduction in expression of Ang-2– approximately 80-
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Figure 6.21 Levels of Ang-2 mRNA expression after treatment with miRNA 
The level of knock-down of Ang-2 protein expression was not as expected when compared to 
the GFP expression in these cells so the level of Ang-2 mRNA was investigated to determine 
whether the miRNA constructs had knocked down the expression of Ang-2. Isolated 
granulosa cells were cultured with miRNA constructs designed to knock-down Ang-2 
expression and then the level of Ang-2 expression was measured by qRT-PCR (A). These 
data were quantified (B) and analysed statistically by One-way ANOVA with a Bonferroni 
post-hoc test to compare the effect of the different constructs to the control granulosa cells. 
The results show that there is a significant decrease (***P<0.001) in the expression of Ang-




P<0.05, in comparison with LV14, LV 18 and LV19. Experiments were repeated in 
triplicate. 
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6.4 Discussion 
This chapter has shown that Ang-1 promotes follicular angiogenesis in vitro in a dose 
dependent manner. Furthermore, it has been shown for the first that Tie-2 is 
expressed in rat granulosa cells and that Ang-1 has a direct functional role in 
promoting granulosa cell survival in vitro, independent of its role in angiogenesis.  
 
Ang-1 is known to be important for the development of new blood vessels and has 
been shown to influence the survival and apoptosis of endothelial cells. It has 
previously been shown that Ang-1 can stimulate endothelial cell proliferation in vitro 
(Koblizek et al., 1998). In this study it has been demonstrated that Ang-1 stimulates 
angiogenesis in the ovarian follicle, in vitro, however, the dose that stimulated 
angiogenesis is much higher than the expected physiological concentration of Ang-1 
suggesting that this may be a pharmacological effect. Treatment of intact ovarian 
follicles with Ang-1 resulted in the development of angiogenic outgrowths and the 
use of the in vitro angiogenesis assay described in Chapter 3 allowed follicle health 
and angiogenesis to be quantified. Different stages of follicles were cultured and 
follicles at the early antral stage of development had a tendency to undergo increased 
angiogenesis when compared with smaller follicles, regardless of treatment. 
However, the level of angiogenesis undergone by all follicles was increased after 
treatment with Ang-1, in a dose dependent manner. Ang-1 is known to act through 
the receptor Tie-2 but the specific mechanism by which it promotes angiogenesis 
required further elucidation. This was investigated and there was a trend of 
increasing expression of pTie-2 as the dose of Ang-1 increased, suggesting that the 
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higher the level of Ang-1 stimulation, the higher the activation, and therefore 
phosphorylation, of the receptor Tie-2. This agrees with previous findings (Koblizek 
et al., 1998) and highlights the importance of signalling via Tie-2 in the induction of 
angiogenesis.  
 
Ang-1 has been shown to be expressed in the rat ovary and has been localised to the 
thecal endothelium of rat ovarian follicles (Abramovich et al., 2009) with expression 
increasing as follicular development progresses. Ang-1 acts through the receptor Tie-
2 and previous studies have localised Tie-2 expression to the thecal layer of ovarian 
follicles (Abramovich et al., 2009). This contrasts with the findings of this chapter as 
the expression of Tie-2 was detected and quantified by immunohistochemistry and 
was found to be expressed in both the thecal and granulosa cell layers of rat ovarian 
follicles. The process of fixing and embedding tissues can mask antigenic epitopes so 
antigen retrieval by heat treatment (Shi et al., 1991) was performed to ensure that this 
did not occur. Abramovich et al (Abramovich et al., 2009) showed that Tie-2 was not 
expressed in granulosa cells, however in that study no antigen retrieval was 
performed prior to the IHC for Tie-2, thus suggesting that the expression of Tie-2 in 
granulosa cells was not detected due to masking of the antigenic epitopes. To 
confirm the expression of Tie-2 in rat granulosa cells qRT-PCR was performed and 
Tie-2 was found to be expressed in granulosa cells. Tie-2 has not previously been 
shown to be expressed in the granulosa cells of rat follicles but is expressed in 
granulosa cells of primordial, primary and preantral follicles in the marmoset, and in 
antral follicles in the horse and sheep (Ellenberger et al., 2009, Chowdhury et al., 
2010) suggesting that the expression detected in this thesis is genuine despite 
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disagreeing with published findings. Since the expression of Tie-2 had not been 
previously detected in rat granulosa cells it was concluded that the effects of Ang-1 
on granulosa cells were promoted in a paracrine manner via signalling through the 
Tie-2 receptors in the thecal layer. However, the discovery that Tie-2 is expressed in 
granulosa cells suggests that the effects of Ang-1 on these cells are mediated directly. 
 
Ang-1/Tie-2 signalling has been shown to play an important role in an anti-apoptotic 
system (Valable et al., 2003, Arai et al., 2004, Abramovich et al., 2006) and the 
inhibition of Ang-1 in rat ovaries in vivo promoted follicular atresia and reduced 
follicle number (Parborell et al., 2008). These findings suggest that Ang-1 may have 
an extravascular role in the ovary. This chapter investigated the role of Ang-1 in 
follicular atresia, in granulosa cell apoptosis and the mechanisms of Ang-1 action. 
Interestingly, treatment with Ang-1 at low doses resulted in the inhibition of 
activated caspase-3 expression whereas treatment with higher doses induced 
activated caspase-3 activity, suggesting that Ang-1 can have both a pro-survival and 
a pro-apoptotic effect on granulosa cells, in a dose dependent manner. 
 
It has been shown that Ang-1 signalling via Tie-2 can activate Akt, resulting in the 
activation of pro-survival pathways and the suppression of pro-apoptotic pathways 
(Augustin et al., 2009). In addition, the treatment of HUVECs with Ang-1 resulted in 
the simultaneous activation of ERK1/2 and p38 (Harfouche et al., 2003). Therefore 
the effect of Ang-1 on key pro- and anti-apoptotic signalling pathways was 
investigated to further elucidate the mechanisms of Ang-1 action. Treatment of 
isolated granulosa cells with low doses of Ang-1 resulted in the up-regulation of 
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pERK1/2 and the inhibition of p38. Moreover, treatment with high doses of Ang-1 
lead to the up-regulation of p38 showing that, dependent on the dose, Ang-1 can 
stimulate both pro-survival and pro-apoptotic pathways. This suggests that the 
overall effect on cell survival is determined by the level of Ang-1 stimulation.   
 
As the receptor for Ang-1 is expressed on granulosa cells and the treatment of this 
cell type with Ang-1 results in the direct inhibition or stimulation of pro- and anti-
apoptotic pathways it is likely that Ang-1 has a direct functional role in promoting 
granulosa cell survival, independent of its role in angiogenesis. To investigate the 
importance of the Tie receptors, Tie-1 and Tie-2, and also of Ang-2 knockdown 
experiments were performed to determine the effect on follicle health and 
angiogenesis when these factors are suppressed. Tie-1 has been shown to regulate the 
sensitivity of Tie-2 to Ang-1 activation and as Tie-1 can be cleaved by VEGF, the 
effect of Tie-1 knockdown on VEGF signalling was investigated. It was found that 
there was a reduction in VEGF expression after treatment with Ang-1, in a dose 
dependent manner. As VEGF would not be cleaving Tie-1 in these cells it is possible 
that the reduced expression is due to reduced demand for VEGF.  
 
It would have been informative to determine whether this reduction in VEGF 
expression would result in reduced angiogenesis as if this was the case it would 
suggest that Tie-1 is required for the angiogenesis induced by Ang-1 treatment. 
Unfortunately it was not possible to perform these experiments during the course of 
this thesis. This chapter has also shown that the expression of Tie-2 and Ang-2 can 
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be suppressed at the RNA level however investigation into the downstream effects of 
this knockdown was also not possible during the course of this thesis. 
 
In conclusion, this chapter has shown that Ang-1 is able to promote follicular 
angiogenesis. In addition it has been demonstrated that Tie-2 is expressed in rat 
granulosa cells, which suggests a functional role for Ang-1 in promoting granulosa 
cell survival. Treatment with Ang-1 at low doses triggers pro-survival pathways and 
at high doses induces pro-apoptotic pathways showing that Ang-1 can promote 
granulosa cell survival but can also induce apoptosis. These findings suggest that 
Ang-1 is important for follicle health and survival and this has implications for the 
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7 Chapter 7 2-Methoxyestradiol Inhibits Angiogenesis 
and Promotes Follicular Atresia in vitro 
7.1 Introduction 
Angiogenesis is a key factor in many clinical conditions so the development of anti-
angiogenic therapies is an area of great research interest. 2-methoxyestradiol (2-ME) 
is a naturally occurring derivative of 17β-estradiol that is synthesised in granulosa 
cells by hydroxylation at the 2-position and then subsequent catechol-O-
methyltransferase mediated O-methylation (Shang et al., 2001, Thurston, 2002, 
Dahut et al., 2006). There is growing evidence that 2-ME has anti-tumour and anti-
angiogenic activity (Fotsis et al., 1994, Pribluda et al., 2000, Ricker et al., 2004) and 
it has been demonstrated to directly inhibit proliferating endothelial cells and tumour 
cells. Although 2-ME is an oestrogen derivative it has low binding affinity for 
oestrogen receptors α and β, and its anti-proliferative action is not mediated through 
an oestrogen-mediated pathway (LaVallee et al., 2002). The mechanisms of 2-ME 
induced inhibition of angiogenesis need further elucidation so this was investigated 
using the in vitro angiogenesis assay described in Chapter 3. 
 
As the ovary expresses high levels of oestrogen it is likely that 2-ME is produced in 
the ovary and previous studies have shown that 2-ME is synthesised in ovarian 
follicles and is present in porcine follicular fluid, with the concentration increasing as 
folliculogenesis progresses (Basini et al., 2007, Salih et al., 2008). 2-ME has been 
shown to inhibit endothelial cell proliferation and to have anti-angiogenic activity in 
both in vitro and in vivo models of angiogenesis. Additionally it can inhibit mitosis in 
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granulosa cells suggesting that it could have anti-proliferative effects in non-vascular 
cell types (Shang et al., 2001). 2-ME can inhibit the production of VEGF and can 
also interact with HIF1 α suggesting that the anti-proliferative action of 2-ME could 
be due to negative regulation of the activity of VEGF via the inhibition of HIF1α 
(Mabjeesh et al., 2003, Basini et al., 2007, Kim et al., 2010).  
 
As 2-ME is present in ovarian follicles it has been speculated that it could have an 
extravascular role in the ovary, possibly in regulation of follicle development (Salih 
et al., 2008). 2-ME has been shown to induce apoptosis (Pribluda et al., 2000) and 
studies using immortalised granulosa cell lines have indicated that 2-ME may be able 
to induce apoptosis in granulosa cells. 2-ME has also been shown to activate the 
caspase cascade (Mooberry, 2003a, Mooberry, 2003b), induce p38 activation 
(LaVallee et al., 2003, Shimada et al., 2003) and inhibit Akt (Lin et al., 2007). 
Therefore it was hypothesised that 2-ME could be a negative regulator of cell 
survival due to the stimulation of pro-apoptotic mediators and/or the suppression of 
pro-survival pathways.  
 
The mechanisms underlying the anti-proliferative action of 2-ME are still unclear so 
the potential mechanisms of action were investigated in vitro. In this chapter, the 
effect of 2-ME on follicular angiogenesis was investigated using the in vitro 
angiogenesis assay described in Chapter 3. The present study first determined the 
inhibitory effect of 2-ME on follicular angiogenesis and then investigated its effect 
on granulosa cell survival in vitro.  
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7.2 Materials and Methods 
7.2.1 Follicle Culture  
For all experiments, preantral/early antral follicles were cultured individually in flat-
bottomed 12-well plates, embedded in the centre of a 20µl droplet of growth-factor 
reduced Matrigel. The Matrigel provides a three-dimensional extracellular matrix 
support for follicle growth and allows the vascular outgrowths to develop in three-
dimensions, as they would in vivo. Follicles were incubated for 6 days in a sterile 
humidified air atmosphere with 5% CO2 at 37°C in 600µl serum-free EBM-2 
medium supplemented with BSA (0.1%), L-glutamine (3mM), penicillin (100 
IU/ml), streptomycin (0.1mg/ml), transferrin (2.5µg/ml), selenium (4ng/ml), insulin 
(10ng/ml) and L-ascorbic acid, sodium salt (50µg/ml), with culture medium 
refreshed every 48h.  
 
In order to test the effects of 2-ME, follicles were randomly placed into groups of 6 
and cultured in control medium or in the presence of 0.01, 0.1, 1, 10µg/ml 2-ME 
(SB721 Batch 1A, Shimoda Biotech, Port Elizabeth, South Africa) and the 
experiment was carried out twice.  
 
7.2.1.1 Analysis of Angiogenic Sprouting 
To assess the impact of the treatments on angiogenic sprouting, follicles were 
examined and photographed directly in the 12-well plates under an inverted light 
microscope, at x10 magnification, with Axiovision image capturing software on days 
0 and 6 of the culture period. The total area of angiogenic sprouting for each follicle 
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was determined using Image Pro Plus software. This was done by drawing an area of 
interest around the outgrowths (but excluding the follicle), and the sum of the area of 
all sprouts was calculated by the software. The mean area of angiogenic sprouting for 
each treatment was then compared to the control.  
  
7.2.2 Granulosa Cell Experiments 
7.2.2.1 Isolation and culture of granulosa cells 
To investigate whether 2-ME can induce apoptosis in granulosa cells directly, 
isolated granulosa cells were cultured in 0.1ml medium containing 1 x 10
4
 cells/well. 
Following overnight preincubation in a sterile humidified air atmosphere with 5% 
CO2 at 37°C, prewarmed 0.1ml medium containing with 0, 0.01, 0.1, 10 or 100µg/ml 
2-ME was added to each well for 48h. All treatments were carried out in triplicate 
and experiments were repeated three times. 
  
7.2.2.2 Caspase-3 and -7 activity assay 
To measure caspase-3 and -7 activities in isolated granulosa cells, the Caspase-Glo 
3/7 assay was
 
performed according to the manufacturer’s instructions, 48h after 
treating the cells (see Chapter 2). Treatments were carried out in triplicate and 




As serum can generate a background caspase activity signal,
 
an additional 
two wells contained cell culture medium and carrier
 
solution without any cells and 
TNFα was used as a positive control. 
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7.2.2.3 Western Blotting 
Protein was extracted from isolated granulosa cells as described previously (Chapter 
2) and were resolved on 4–20%
 
Tris-glycine gels and transferred onto a PVDF-fl 
membrane. Membranes were blocked for 1h at
 
25°C in Rockland Near Infra Red 
blocking buffer and incubated overnight at 4°C in blocking buffer containing
 
rabbit 
anti-phospho-p42/44 ERK (1:1000), rabbit anti-phospho-p38 (1:500), HIF1α (1:500) 
or VEGF (1:200) and β-actin (1:1000). After washing in PBS containing
 
0.5% 
Tween, membranes were incubated for 1h at 25°C in the dark in donkey anti goat 
IgG conjugated to IRDYE 800 and donkey anti rabbit IgG conjugated to Alexa Fluor
 
680 both at a dilution of 1:5000 in blocking buffer.
 
Membranes were washed and 
proteins visualized and quantified
 
using an Odyssey Infrared Imaging System. 





7.2.3 Statistical Analyses 
Data are presented as mean ± SEM and all results were analysed statistically using 
Graph Pad Prism 5 software (Graph Pad Software). The results were analysed by 
means of a One-way ANOVA with a Bonferroni post-hoc test performed if the 95% 
confidence interval was reached to determine significance between all of the data 
groups. P values <0.05 were accepted as statistically significant.  
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7.3 Results 
7.3.1 Effect of 2-ME on angiogenesis in vitro 
To investigate the effect of 2-ME on follicular angiogenesis, follicles were cultured 
in serum-free EBM-2 medium treated with 0, 0.01, 0.1, 1 and 10µg/ml 2-ME for six 
days. Treatment with 2-ME resulted in a significant inhibition of follicular 
angiogenesis, in a dose dependent manner, (Figure 2) (P<0.001), showing that 2-ME 


















Regulation and Manipulation of Angiogenic Factors: Impact on Ovarian Function 
Chapter 7 2-Methoxyestradiol Inhibits Angiogenesis and Promotes Follicular Atresia in vitro   
  247 
 




























Figure 7.1 Effect of 2-ME on angiogenesis  
To determine the effect of 2-ME on angiogenesis isolated preantral and early antral follicles 
(n=6 per treatment) were cultured with varying doses of 2-ME. At the end of the culture 
period the area of the angiogenic outgrowths was measured using Image Pro-Plus software. 
Representative images show endothelial outgrowths from a control follicle (A) and follicles 
after treatment with 2-ME at 0.01µg/ml (B), 0.1µg/ml (C), 1µg/ml (D) or 10µg/ml (E). 
Results were quantified and analysed statistically by One-way ANOVA with a Bonferroni 
post-hoc test to compare the 2-ME treated follicles to the control follicles. Treatment with 
0.1, 1 and 10µg/ml 2-ME resulted in a significant decrease in outgrowth area when 
compared to the control (***P<0.001) (F). White arrows indicate the endothelial 
outgrowths. Scale bars represent 200µm. Experiments were repeated in triplicate. 
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7.3.2 Effect of 2-ME on granulosa cell apoptosis in vitro 
To investigate the effect of 2-ME on follicular apoptosis, isolated granulosa cells 
were cultured with 0, 0.01, 0.1, 1 and 10µg/ml 2-ME for 48h followed by 
quantification of apoptosis using a luminescent caspase-3/7 assay. There was a 
significant increase in activated caspase-3/7 activity in granulosa cells treated with 
the highest dose of 2-ME (P<0.001) (Figure 3), showing that 2-ME does act directly 
on granulosa cells to stimulate apoptosis.  
 
 



































Figure 7.2 Effect of 2-ME on granulosa cell apoptosis  
To determine the effect of 2-ME on apoptosis granulosa cells were isolated from preantral 
and early antral follicles and they were cultured with varying doses of 2-ME (n=4 per 
treatment). At the end of the culture period these granulosa cells were analysed for 
expression of activated caspase-3/7 activity using a luminescent caspase activity assay, as an 
indicator of follicle health. A One-way ANOVA with a Bonferroni post-hoc test was 
performed on the results to compare the 2-ME treated granulosa cells to the control 
granulosa cells and there is a significant increase in activated caspase-3 expression after 
treatment with 10µg/ml 2-ME when compared to the control (***P<0.001). Luminescence is 
given in arbitrary units (au). Experiments were repeated in triplicate. 
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7.3.3 Mechanisms of the pro-apoptotic effect of 2-ME 
7.3.3.1 Quantification of pERK expression by western blotting 
As treatment with 2-ME can induce apoptosis further investigations were carried out 
to establish the mechanisms by which 2-ME induces cell death. Phospho-ERK 
(pERK) is an important pro-survival factor so the effect of 2-ME on the expression 
of pERK was investigated. Isolated granulosa cells were cultured with 0, 0.01, 0.1 10 
and 100µg/ml of 2-ME for 48h followed by quantification of the expression of pERK 
by western blotting (Figure 7.3A). The results showed that there was a trend of 
decreasing expression of pERK (Figure 7.3B), suggesting that 2-ME could induce 
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Figure 7.3 Levels of pERK expression after treatment with 2-ME 
Isolated granulosa cells were cultured with varying doses of 2-ME (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of apoptosis induction the level of pERK expression was measured by 
western blotting (A). L – size ladder. Gels were laid out with the size marker on the left-hand 
side of the gel, the control samples and then the samples treated with 2-ME. The control 
samples were used on each gel so that a direct comparison to the expression in the control, 
on that gel, could be made. The size of the bands of interest has been shown on the right of 
the figure with the size marker bands on the left. These data were quantified (B) and 
analysed statistically by One-way ANOVA to compare the 2-ME treated granulosa cells to 
the control granulosa cells. The results show that there was a trend of decreasing expression 
of pERK after treatment with 2-ME; however this was not statistically significant. 
Experiments were repeated in triplicate. 
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7.3.3.2 Quantification of p38 expression by western blotting 
The expression of pro-apoptotic factor p38 was then investigated to further elucidate 
the mechanisms of apoptosis induction. To investigate this isolated granulosa cells 
were treated with 0, 0.01, 0.1 10 and 100µg/ml of 2-ME for 48h followed by 
quantification of the expression of p38 by western blotting (Figure 7.4A). The results 
showed that there was a significant increase (P<0.05) (Figure 7.4B) in the expression 
of p38 after treatment with 2-ME. As 2-ME stimulates both activated caspase-3 and 
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Figure 7.4 Levels of p38 expression after treatment with 2-ME 
Isolated granulosa cells were cultured with varying doses of 2-ME (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of apoptosis induction the level of p38 expression was measured by 
western blotting (A). L – size ladder. Gels were laid out with the size marker on the left-hand 
side of the gel, the control samples and then the samples treated with 2-ME. The control 
samples were used on each gel so that a direct comparison to the expression in the control, 
on that gel, could be made. The size of the bands of interest has been shown on the right of 
the figure with the size marker bands on the left. These data were quantified (B) and 
analysed statistically by One-way ANOVA with a Bonferroni post-hoc test to compare the 2-
ME treated granulosa cells to the control granulosa cells. The results show that there is a 
significant increase in the expression of p38 after treatment with 100µg/ml 2-ME when 
compared to the control (*P<0.05). Experiments were repeated in triplicate. 
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7.3.4 Mechanisms of the anti-angiogenesis 
7.3.4.1 Quantification of VEGF expression by western blotting 
2-ME has been shown to inhibit angiogenesis and it has previously been shown that 
2-ME can act on VEGF and suppress its expression (Basini et al., 2007). Therefore it 
was hypothesised that 2-ME could be inhibiting angiogenesis through the 
suppression of VEGF. To investigate this isolated granulosa cells were treated with 
0, 0.01, 0.1 1, 10 and 100µg/ml of 2-ME for 48h followed by quantification of the 
expression of VEGF by western blotting (Figure 7.5A). The results showed that there 
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Figure 7.5 Levels of VEGF expression after treatment with 2-ME 
Isolated granulosa cells were cultured with varying doses of 2-ME (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of anti-angiogenesis the level of vascular endothelial growth factor 
(VEGF) expression was measured by western blotting (A). L – size ladder. Gels were laid 
out with the size marker on the left-hand side of the gel, the control samples and then the 
samples treated with 2-ME. The control samples were used on each gel so that a direct 
comparison to the expression in the control, on that gel, could be made. The size of the 
bands of interest has been shown on the right of the figure with the size marker bands on the 
left. These data were quantified (B) and analysed statistically by One-way ANOVA to 
compare the 2-ME treated granulosa cells to the control granulosa cells. There was no 
significant difference in the expression of VEGF after treatment with 2-ME. Experiments 
were repeated in triplicate. 
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7.3.4.2 Quantification of HIF1α expression by western blotting  
Hypoxia is known to stimulate angiogenesis and as 2-ME inhibits angiogenesis, the 
effect of 2-ME on the expression of HIF1α was investigated (Kim et al., 2010). To 
investigate this isolated granulosa cells were treated with 0, 0.01, 0.1 10 and 
100µg/ml of 2-ME for 48h followed by quantification of the expression of HIF1α by 
western blotting (Figure 7.6A). The results showed that there was no difference in 
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Figure 7.6 Levels of HIF1α expression after treatment with 2-ME 
Isolated granulosa cells were cultured with varying doses of 2-ME (n=3 per treatment) and 
then protein was extracted to allow western blotting to be performed. To try to determine a 
potential mechanism of anti-angiogenesis the level of hypoxia-inducible factor-1α (HIF1α) 
expression was measured by western blotting (A). L – size ladder. Gels were laid out with 
the size marker on the left-hand side of the gel, the control samples and then the samples 
treated with 2-ME. The control samples were used on each gel so that a direct comparison to 
the expression in the control, on that gel, could be made. The size of the bands of interest has 
been shown on the right of the figure with the size marker bands on the left. These data were 
quantified (B) and analysed statistically by One-way ANOVA to compare the 2-ME treated 
granulosa cells to the control granulosa cells. There was no significant difference in the 
expression of HIF1α after treatment with 2-ME. Experiments were repeated in triplicate. 
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7.4 Discussion 
In this chapter the in vitro angiogenesis assay described in Chapter 3 was utilised to 
demonstrate that 2-ME is a potent inhibitor of follicular angiogenesis. Furthermore, it 
has been shown that 2-ME promotes follicular atresia in vitro by directly inducing 
apoptosis of granulosa cells, suggesting that it has a functional role in regulating 
granulosa cell survival in vitro.  
 
2-ME has been shown to have anti-proliferative activity in endothelial cells and 
therefore has been suggested as an anti-angiogenic agent. 2-ME is produced in 
granulosa cells and is present in follicular fluid in ovarian follicles (Basini et al., 
2007, Salih et al., 2008), suggesting that 2-ME could play a role in regulating 
follicular angiogenesis. This chapter has demonstrated that 2-ME inhibits follicular 
angiogenesis in a dose dependent manner. The mechanisms of 2-ME-induced 
inhibition of angiogenesis were investigated by quantifying the levels of some of the 
factors involved in the angiogenic cascade.  
 
Previous studies have suggested that the anti-proliferative effects of 2-ME may be 
due to the inhibition of HIF1α expression (Kim et al., 2010). 2-ME inhibits the 
activation of HIF1α (Mabjeesh et al., 2003, Ricker et al., 2004, Lu et al., 2010) in 
vitro and has been used to inhibit HIF1α in tumour cells, indicating that 2-ME can 
inhibit hypoxia. The up-regulation of HIF1α expression results in increased 
expression of VEGF and the induction of angiogenesis so the effect of 2-ME 
treatment on the expression of HIF1α and VEGF was investigated to elucidate the 
mechanisms of angiogenesis inhibition by 2-ME . However, there was no difference 
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in the expression of HIF1α or VEGF protein following treatment with 2-ME, 
suggesting that the regulation of angiogenesis by 2-ME in the ovary involves the 
interaction of many factors and different pathways, which require further 
investigation. 
 
Treatment with 2-ME increases atresia via the stimulation of activated caspase-3, one 
of the main molecules involved in the induction of apoptosis, so it is likely that 2-ME 
also regulates the expression of other pro- or anti-apoptotic mediators. It was 
anticipated that 2-ME could have an effect on the expression of pERK and/or p38 
(LaVallee et al., 2003, Mooberry, 2003a, Mooberry, 2003b, Shimada et al., 2003, 
Lunn et al., 2002, Lin et al., 2007) as they are key factors involved in anti- and pro-
apoptotic pathways, respectively, that either lead to the inhibition or induction of the 
caspase cascade. The ERK/MAPK pathways play an important role in the regulation 
of apoptosis so the expression of pERK and p38 after treatment with 2-ME was 
quantified to clarify the mechanisms of apoptosis induction by 2-ME. This chapter 
has shown that there is a trend of decreasing pERK expression and that there is a 
significant increase in p38 expression. These results agree with other studies which 
have shown that 2-ME can induce apoptosis through the activation of p38 (Lunn et 
al., 2002), suggesting that 2-ME induces follicular apoptosis through the stimulation 
of pro-apoptotic pathways. However, it may also inhibit pro-survival mediators. 
 
Since 2-ME can inhibit cellular proliferation and induce apoptosis it has been 
suggested as a potential therapeutic agent for cancer treatment, especially in tumours 
of a reproductive nature (Lunn et al., 2002, Dahut et al., 2006). As a result 2-ME has 
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been used in several clinical trials but has been shown to have poor bioavailability 
and potency (Dahut et al., 2006, Adams et al., 2004). It will therefore be necessary to 
improve its pharmacokinetic properties before it can effectively be used in the clinic. 
It has also been suggested that 2-ME could be beneficial in the treatment of PCOS; 
however the studies that indicated this were performed in immortalised granulosa 
cells (Salih et al., 2008), making it difficult to apply these results to the clinical 
situation. Overall the investigations into the effects of 2-ME have suggested that it 
could have many clinical benefits but additional studies are required to improve its 
therapeutic potential. 
 
In conclusion, this chapter has demonstrated that 2-ME inhibits angiogenesis in the 
ovarian follicle and has a functional role in the induction of follicular atresia. It has 
been shown that 2-ME directly promotes apoptosis in primary granulosa cells, 
indicating an extravascular role for 2-ME during follicular development. 2-ME is a 
promising candidate for clinical use in the treatment of abnormal angiogenesis and 
further studies will hopefully confirm the potential of 2-ME as a therapeutic for 
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8 Chapter 8 General discussion 
This thesis has developed a novel in vitro angiogenesis assay for the study of 
follicular angiogenesis and it has been utilised to investigate the role of various pro- 
and anti-angiogenic factors in ovarian follicular angiogenesis in vitro in the rat and in 
vivo in the marmoset. The possibility of an extravascular role for these factors was 
also investigated using the in vitro assay and this chapter summarises the main 
findings of the thesis. The clinical implications of these findings and future research 
directions are also considered.  
 
8.1 The findings of the thesis 
The main findings of this thesis were: 
 Ovarian follicles can produce angiogenic outgrowths in in vitro culture 
 TSP-1 inhibits angiogenesis both in vitro and in vivo 
 TSP-1 induces follicular atresia both in vitro and in vivo 
 Ang-1 plays a role in regulating follicle health and survival 
 The receptor for Ang-1 has been shown to be expressed in rat granulosa cells 
 2-ME can inhibit angiogenesis and increase granulosa cell apoptosis 
 Factors involved in angiogenesis also have extravascular roles within the 
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Figure 8.1 Diagram showing the main expression of the various factors used in this 
thesis 
This diagram summarises the stages of follicular development when the main pro- or anti-
angiogenic factors discussed in this thesis are expressed (A) and also shows the action and 
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8.2 The in vitro follicle culture system as an angiogenesis 
model 
There are many in vitro assays currently available for the study of angiogenesis 
however they all have limitations. Furthermore, ovarian follicles are routinely 
cultured to investigate factors that affect follicle health and development and are 
relatively easy to handle and are widely available. Follicles grow well in in vitro 
culture and immature rat follicles develop in a short time frame indicating that an 
assay based on ovarian follicles could produce results quickly. The female 
reproductive system is unique as no other healthy adult tissues undergo spontaneous 
angiogenesis. Therefore in this thesis the natural angiogenic properties of ovarian 
follicles were utilised to provide a novel angiogenesis assay. 
 
Preantral and early antral follicles have undergone endothelial cell recruitment from 
the ovarian stroma and follicles at these stages can be easily isolated from immature 
rats. This thesis has demonstrated that isolated follicles can produce angiogenic 
outgrowths when cultured in the appropriate conditions and that these outgrowths are 
endothelial in nature and are surrounded by pericytes, suggesting that they are 
representative of the vessels that develop in vivo. The cultured follicles produced a 
dense network of blood vessels quickly, with blood vessels apparent after two days 
and a network of vessels established between 4-6 days of culture. The vessels could 
then be quickly and accurately quantified, allowing results to be determined in a 
short time period. Furthermore, the large numbers of preantral and early antral 
follicles present in the ovaries of immature rats allows several doses of a compound 
to be investigated in one experiment whilst keeping numbers high and the number of 
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animals used low. The evaluation of this culture system and its ease of use suggest 
that this is a valid method for the study of follicular angiogenesis and that it could be 
a useful tool for the investigation of angiogenesis. Additionally, as both 
physiological and pathological angiogenesis take place by very similar mechanisms 
and are regulated by many of the same factors it is likely that an angiogenesis model 
that allows detailed investigation of physiological angiogenesis and the regulation of 
the factors involved in it would be beneficial in improving the understanding of both 
physiological angiogenesis and pathological angiogenesis. The regulation of the 
factors involved in physiological angiogenesis is altered in pathological angiogenesis 
and improving the understanding of the importance of these factors in angiogenesis 
could help develop treatments for pathological angiogenesis. Furthermore, the 
angiogenesis utilised in the in vitro follicle culture assay occurs naturally so there is 
no need to induce disease to study the angiogenic process. Therefore, with all of 
these facts in mind, the in vitro follicle culture assay developed in this thesis is a 
good model for angiogenesis.  
 
8.2.1 Limitations of the model 
Although this angiogenesis assay has provided new insight into follicular 
angiogenesis, it does have its limitations. The use of EBM-2 medium is necessary for 
the development of angiogenic outgrowths yet it does not provide optimum 
conditions for follicle health. Traditionally follicles are cultured in media such as 
αMEM, McCoys or Waymouths, which allow the follicles to grow and develop 
during culture, but these media types do not allow the development of blood vessels. 
Therefore the conditions that would be optimal for follicle development are not ideal 
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for this assay. Substantial efforts were made during the course of this PhD to 
optimise the culture conditions to allow blood vessel development whilst still 
maintaining the health of the follicles, yet it was not possible to achieve optimal 
follicle health for long periods of time, alongside blood vessel development. 
   
8.3 The in vivo model of angiogenesis and follicle 
development 
The in vivo investigation of angiogenesis provides a more comprehensive look at the 
role of factors in regulating angiogenesis and also allows a whole animal view of the 
effects of compounds of interest. The marmoset model of ovarian angiogenesis is 
well established and has been described in great detail by our group (Fraser et al., 
2000, Fraser et al., 2006, Fraser and Duncan, 2009). This model has many 
advantages over other in vivo angiogenesis assays as it utilises and manipulates the 
natural angiogenic properties of the ovary and the angiogenesis that occurs is both 
natural and physiological. Additionally, the marmoset ovary contains numerous 
growing follicles at all stages of the cycle, allowing the effects on angiogenesis 
across the cycle to be seen in each ovary. 
 
The marmoset is commonly used in biomedical research, especially in reproductive 
research, due to their genetic similarity to humans, ease of handling, high 
reproduction rate (Torii et al., 1996) and their small size (approximately 350g) which 
makes them ideal for use in in vivo studies as this allows the use of small amounts of 
the compound of interest. The marmoset ovarian cycle lasts for approximately 28 
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days (Harding et al., 1982, Hearn, 1983) and it can be easily manipulated.  Our in-
house marmoset facility provides numerous healthy, cycling marmosets thus 
allowing terminal studies to be carried out so that tissues of interest can be isolated 
and collected for analysis by immunohistochemistry and in situ hybridisation. In 
addition, the ability to synchronise the ovarian cycle through the induction of 
luteolysis after injection of prostaglandin enables the study of precise stages in the 
ovarian cycle (Summers et al., 1985, Duncan et al., 1998, Gilchrist et al., 2001). The 
development of ovarian vasculature has been described in great detail in the 
marmoset (Wulff et al., 2001a, Wulff et al., 2002) so this, along with the other 
factors mentioned, makes the marmoset a good model for the in vivo investigation of 
angiogenesis. The studies in this thesis utilised the marmoset monkey as an 
experimental model in which to investigate the role of ABT-898 in regulating 
ovarian follicular angiogenesis and development in vivo.  
 
8.3.1 Limitations of the model 
Although the marmoset has a reproductive cycle and hormonal profile similar to that 
in the human, the model does have limitations. The marmoset is a multi-ovulatory 
species that has a longer luteal phase than that in humans and does not menstruate. 
Old World primates have a reproductive cycle that is more similar to humans than 
that of New World primates and they also menstruate. However, the invasiveness of 
in vivo studies severely limits the use of higher primates in research.  
 
In the in vivo studies carried out during this thesis, assays were performed to 
determine progesterone concentration but it would have been informative to evaluate 
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the function of the preovulatory follicles by determining changes in levels of plasma 
estradiol. However, no reliable assay for detecting changes in estradiol in the 
marmoset is available as detecting subtle differences in estradiol in marmosets may 
be confounded by high levels of circulating estrone (unpublished observations). 
Additionally, due to their small size, only a small volume of blood can be taken from 
the marmoset at each sampling interval, making it challenging to assay for multiple 
hormones. 
 
8.4 The importance of angiogenic factors in follicular 
development 
Angiogenesis plays an important role in follicular development as a blood supply is 
necessary for follicle maturation to occur. Angiogenesis must take place to allow the 
developing follicles to be supplied with gases, nutrients and hormones and a 
sufficient blood supply also allows endocrine, paracrine and autocrine regulation of 
follicular development to occur. Therefore it is an essential part of follicle 
development. Many of the receptors for factors that are involved in the regulation of 
angiogenesis are expressed within the ovary in non-vascular cells which has lead to 
the suggestion that they could have extravascular roles within the ovary. 
 
Although the main role of these factors is in regulating angiogenesis many of these 
factors, such as VEGF, TSP-1 and Ang-1, have been shown to act on non-vascular 
cells within the ovary. VEGF is the key factor involved in promoting angiogenesis 
and it has been demonstrated that VEGF has a crucial role in angiogenesis, which has 
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a role in ovarian function (Geva and Jaffe, 2000, Danforth et al., 2003, Zimmermann 
et al., 2003, Abramovich et al., 2006). Studies in the ovary have shown that when 
VEGF expression is suppressed follicles do not undergo follicle development and 
ovulation is blocked, showing the vital role VEGF has in both ovarian angiogenesis 
and ovarian function (Wulff et al., 2001a, Wulff et al., 2001b, Fraser et al., 2005a, 
Fraser et al., 2005b, Fraser et al., 2006, Taylor et al., 2007). It has also been shown 
that VEGF can have a cytoprotective effect within the ovary and that inhibition of 
VEGF results in increased apoptosis (Greenaway et al., 2004), indicating that VEGF 
has non-vascular effects within the ovary. Additionally, treatment with VEGF 
increases the activation of ERK1/2 whilst the inhibition of VEGF suppresses the 
stimulation of ERK1/2 (Doyle et al., 2010); supporting the suggestion that VEGF has 
non-vascular effects in the ovary in regulating granulosa cell function. 
 
The studies in this thesis have demonstrated that TSP-1, Ang-1 and 2-ME can all 
have extravascular actions within the ovary, in regulating cell survival mediators in 
granulosa cells. TSP-1 and 2-ME stimulate granulosa cell apoptosis through the up-
regulation of pro-apoptotic mediators including p38, indicating that anti-angiogenic 
factors could have a role in clearing follicles that are not selected for development 
from the ovary through the stimulation of similar pro-apoptotic pathways. The pro-
angiogenic factor Ang-1 stimulates the production of the pro-survival mediator 
pERK1/2 and reduces the expression of pro-apoptotic factors suggesting that it could 
improve follicle health and survival. Autocrine and paracrine signalling play an 
important role in regulating follicle development and several of the factors that 
regulate follicle development, such as activin and inhibin, are produced by the 
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granulosa cells themselves (Knight and Glister, 2006, Chedrese et al., 2009, Hillier, 
2009). These factors have also been shown to stimulate pro-survival mediators, 
including ERK1/2 signalling (Wang and Tsang, 2007), through autocrine signalling. 
Therefore it is likely that the regulation of granulosa cell survival observed after 
treatment with the factors used in this thesis is through autocrine signalling in the 
granulosa cells. 
 
Overall, this thesis has shown that a range of angiogenic factors have extravascular 
roles within the ovary and these effects involve the regulation of cell survival 
mediators. The discovery that angiogenic factors can have extravascular roles within 
the ovary suggests that they could have clinical applications outside of treating 
aberrant angiogenesis. Since factors such as Ang-1 may have a functional role in 
promoting follicular growth and survival, they could be novel factors for use in 
improving culture conditions for techniques such as in vitro maturation (IVM) 
protocols for the treatment of infertility.  
 
8.5 Clinical implications of the findings of the thesis 
Angiogenesis is a tightly regulated process and a disturbance in the balance of pro- 
and anti-angiogenic factors that regulate it can result in many clinical conditions. 
Excess angiogenesis is associated with tumour growth, aggravation of inflammatory 
disorders and reproductive pathologies such as PCOS and endometriosis. Therefore 
the elucidation of the regulation of angiogenesis is important for the development of 
new therapeutics for disorders associated with aberrant angiogenesis such as cancer, 
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coronary artery disease, PCOS and endometriosis (Folkman, 2001, Kerbel and 
Folkman, 2002, Carmeliet, 2004). In addition insufficient angiogenesis is involved in 
a number of clinical conditions including increased incidence of pre-eclampsia 
(Levine et al., 2004) and many age related diseases (Carmeliet, 2004).  
 
The detailed understanding of the factors involved in regulating angiogenesis is of 
great importance and although there are many assays available for angiogenesis 
research they all have limitations. The majority of existing in vitro assays are not 
representative of in vivo angiogenesis and the existing in vivo assays are often 
expensive and very technically demanding. Therefore, the development of an in vitro 
assay that would allow investigation into the roles of the factors involved in 
regulating angiogenesis and that would be more representative of angiogenesis in 
vivo would be of benefit. During the course of this thesis a novel in vitro assay has 
been developed for the investigation of follicular angiogenesis. The blood vessels 
that are produced in this assay develop from the endothelial cells present in the thecal 
layer of isolated preantral and early antral follicles. These blood vessels develop in 
three-dimensions around the follicle and are surrounded by supporting pericytes, as 
in vivo. These results suggest that the vessels that develop in this assay are 
representative of physiological follicular angiogenesis. Therefore, this assay could be 
beneficial in elucidating the role of factors involved in the regulation of follicular 
angiogenesis and could also be utilised to evaluate the effect of various compounds 
on follicular angiogenesis. 
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PCOS is the most common disorder in women of reproductive age (Franks, 1995) 
and is characterised by aberrant angiogenesis, hyperandrogenism and the 
accumulation of small anovulatory antral follicles with reduced follicular atresia 
(Franks et al., 2000, Agrawal et al., 2002). The existing treatments for PCOS are 
limited and are mainly aimed at controlling the symptoms of the disease. There are a 
few treatments, such as laser ablation, that results in a short period where ovarian 
cycles become ovulatory (Homburg, 2003, 2008) but there is currently no therapy 
that targets both the abnormal ovarian angiogenesis and the accumulated antral 
follicles. Treatment with TSP-1 and the thrombospondin mimetic ABT-898 inhibits 
follicular angiogenesis and also induces apoptosis of preantral and early antral 
follicles suggesting that it may be a potential treatment for PCOS as it could have a 
dual role in targeting the increased angiogenesis and inducing atresia of accumulated 
antral follicles without affecting preovulatory follicle development and ovulation.  
 
Targeting angiogenesis may be an effective treatment for PCOS as it is characterised 
by increased angiogenesis and decreased expression of anti-angiogenic factors. 
Additionally, angiogenesis is required for follicle growth and development to the 
antral stage and in PCOS follicles halt development and accumulate in the ovaries. 
Therefore the inhibition of angiogenesis could prevent the development of follicles to 
the antral stage, reducing the accumulation of non-growing antral follicles. It has also 
been shown that the common PCOS treatment metformin attenuates angiogenesis, 
suggesting that the inhibition of angiogenesis can be beneficial in the treatment of 
PCOS. Overall, the inhibition of angiogenesis in PCOS should have beneficial results 
on the reproductive effects of the disease and could lead to periods of ovulation and 
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fertility for women suffering from this condition. However, PCOS has many wide-
ranging effects and altering angiogenesis is unlikely to treat the wider effects of this 
condition.    
 
Tumour development is dependent on the stimulation of new blood vessel growth 
from the pre-existing vasculature (Folkman et al., 1971, McDougall et al., 2006) as 
this allows them to be supplied with nutrients and gases. Therefore, the development 
of anti-angiogenic agents is a focus of therapeutics for a number of angiogenesis-
related disorders. Anti-angiogenic agents deprive tumour cells of the nutrients, gases 
and survival factors that are required for their survival, resulting in the death of the 
tumour cells. There are many anti-angiogenic compounds under development 
(Kerbel and Folkman, 2002) that are undergoing various stages of clinical trials and 
have a variety of actions, including inhibiting the action of pro-angiogenic factors 
and inhibiting endothelial cell proliferation, migration and survival. Bevacizumab 
(Avastin
TM
), a humanised monoclonal antibody directed at VEGF, is the most 
advanced in clinical development (Ferrara, 2004). Bevacizumab was approved for 
use in metastatic cancer by the US Food and Drug Administration in 2004 (Huang et 
al., 2009) and has now been approved for use in a variety of cancers (Mancuso and 
Sternberg, 2006, Bossung and Harbeck, 2010, Chamberlain, 2010, Summers et al., 
2010). In addition Aflibercept (Regeneron
 
Pharmaceuticals), a recombinant chimeric 
protein comprising
 
portions of the extracellular domains of the human VEGFR1 and 
VEGFR2 expressed in sequence with the Fc portion of human Ig (Holash et al., 
2002), is currently in clinical trials and has shown promising results (Dixon et al., 
2009, Tew et al., 2009, Twardowski et al., 2010). 
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Therapeutics have been designed to mimic the anti-angiogenic activity of TSP-1 and 
they are usually designed to mimic the activity of the TSR region. The potency of a 
first-generation mimetic of TSP-1, ABT-510, was found to be insufficient in human 
clinical trials so a second generation mimetic of the anti-angiogenic activity of TSP-
1, ABT-898, has been developed. ABT-898 is thus expected to have greater efficacy 
than the other available TSP-1-mimetic peptides. ABT-898 has shown promising 
results in the in vitro and in vivo studies performed during the course of this PhD and 
will hopefully proceed to clinical trials after further investigations.  
 
There are many assisted reproduction techniques (ART) available for people with 
impaired fertility and the majority of them rely on the in vitro maturation of follicles. 
The health of the follicles during this process determines the success of ART so the 
discovery of novel factors that can improve the survival of follicles in vitro could be 
of benefit. The studies carried out during this thesis have shown that various 
angiogenic factors, such as Ang-1, can act on non-vascular cells within the ovary to 
improve follicle survival. Ang-1 has been shown to stimulate the expression of 
pERK and inhibit the expression of caspase-3 in granulosa cells, indicating that it 
plays a role in promoting cell survival. Many studies have indicated that Ang-1 may 
have a role in inhibiting apoptosis and the finding that Ang-1 can improve follicle 
and granulosa cell health in vitro suggests that it could be useful in improving 
conditions for in vitro follicle development culture systems. 
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8.6 Suggestions for further study 
During the course of this thesis a novel in vitro angiogenesis assay was developed to 
provide an assay that would allow the manipulation of follicular angiogenesis and 
would be representative of physiological angiogenesis. This assay could provide a 
method for mechanistic studies which would be a valuable tool in angiogenesis 
research and could be of benefit in elucidating the regulation of follicular 
angiogenesis. Additionally it could be used to investigate the effects of new 
compounds on follicular angiogenesis, allowing the screening of compounds of 
interest prior to investigation in vivo. This thesis has found that several angiogenic 
factors have extravascular roles within the ovary so the use of this in vitro 
angiogenesis assay would also enable the investigation into roles for these factors in 
follicle development and survival.  
 
The follicle culture system developed during this thesis could also be used to develop 
a directional model of growth. This could be done by using a transwell assay where 
endothelial cells are plated on one side of a porous membrane, and a solution 
containing the potential migratory factor is placed on the opposite side of the 
membrane from the cells. However, as the concentrations of the angiogenic factor 
can quickly normalise between the upper and lower chambers, it can be challenging 
to determine if the angiogenesis is due to directed migration or not. A more useful 
way of establishing a model of directed migration would be to use the under-agarose 
assay. In this assay a layer of agarose gel is prepared and then wells are punched into 
the gel, one contained the cells/follicles and the other containing the angiogenic 
factor (Hoying and Williams, 1996). The endothelial cells from the follicles then 
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migrate towards the angiogenic factor, allowing directed angiogenesis to be 
observed.  
 
TSP-1 has a functional role in the induction of follicular atresia as well as its anti-
angiogenic activity and as TSP-1 can inhibit angiogenesis and induce follicular 
atresia it could be a potential therapeutic for PCOS. PCOS is the most common 
endocrine disorder in women of reproductive age and is characterised by increased 
angiogenesis and decreased follicular atresia (Agrawal et al., 1998b, Franks et al., 
2000) so the use of TSP-1 as a therapeutic for this disorder is an exciting possibility. 
To establish whether TSP-1 could be of benefit in treating PCOS further studies 
should be carried out using a model of PCOS. There are several animal models of 
PCOS available (Beloosesky et al., 2004, Abbott DH et al., 2006, Dumesic et al., 
2007) and use of these models would enable investigation into the mechanisms of 
follicular development in PCOS and establish whether TSP-1 can inhibit follicular 
angiogenesis and induce follicular atresia in the PCOS ovary, as well as in normal 
ovaries. A successful outcome of these experiments would confirm the findings of 
this thesis and would strongly suggest that TSP-1 could be a useful treatment for 
PCOS.  
 
There is a prenatally androgenised rat model of PCOS available (McNeilly et al. 
unpublished data) that could be utilised to determine the potential of ABT-898 in 
treating PCOS. First the expression of TSP-1 mRNA and protein would be quantified 
in the rat model of PCOS as it is anticipated that TSP-1 expression will be decreased 
in the PCOS ovary. To investigate the potential of TSP-1 as a therapeutic for PCOS, 
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PCOS rats will be treated with a short course of ABT-898 and the effects on ovarian 
morphology, angiogenesis, follicular growth and cell death will be determined. It is 
anticipated that treatment will inhibit angiogenesis and promote atresia of 
accumulated antral follicles. A successful outcome will be followed by a study in 
which PCOS rats will be treated with TSP-1 peptide and vaginal smears taken to 
assess recovery of oestrous cyclicity followed by housing with males to confirm 
fertility. If successful, the sheep model of PCOS could be utilised to address selected 
questions and give the data greater relevance to the human. 
 
This thesis has found that Ang-1 up-regulates the expression of pro-survival 
mediators and inhibits the production of pro-apoptotic factors. To determine whether 
treatment with Ang-1 could be of benefit in IVM techniques further experiments 
should be conducted to assess the effect on the expression of factors that regulate 
follicle health and survival and also to determine whether Ang-1 can affect oocyte 
health. The culture of oocyte-granulosa cell cultures (OGCs) would determine the 
effect of Ang-1 treatment on oocyte health and qRT-PCR would enable the change in 
expression of factors such as pERK, p38, GDF-9 and BMP-15 to be determined. If 
Ang-1 was found to improve oocyte health and increase expression of factors 
indicative of follicle health it would support the hypothesis that Ang-1 could be of 
use in improving follicle survival in culture. 
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8.7 Conclusions 
A unique in vitro model has been developed to investigate the regulation of follicular 
angiogenesis in the rodent and to investigate the effects of various factors involved in 
the angiogenic cascade. Using this model, as well as an in vivo marmoset model, the 
studies reported in this thesis provide compelling evidence that TSP-1 both inhibits 
follicular angiogenesis and has an extravascular role inducing apoptosis within the 
ovary. This model has also been utilised to clarify the role of the angiopoietins in the 
ovary and have shown that, dependent on the dosage used, Ang-1 can both promote 
follicle survival and also induce follicular atresia. The potential to inhibit 
angiogenesis in the female reproductive tract and also to improve follicle survival 
and health has important implications for clinical practice, both in providing 
potential treatments for clinical conditions and in the improvement of in vitro   
culture techniques. 
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